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atg gcc tat tta tta aga gas gga sea cag aga tct act gga aac gag 48
Met Ala Tyr Lau Lau Arg Glu Gly Thr Gln Arg Ser Thr Gly Asn Glu
1	 5	 10	 15
gte, ate, eta aac aac ata get gta goo aaa eta tta ctg gas atg eta 96
Val Ile Lau Asn Asn Ile Ala Val Ala.Lys Ile Lau Lau Glu Met Leu
20	 25	 30
aag tca age eta ggt cot aag ggt tta gac sag atg tta gtt gag ggg 144
Lys Ser Ser Lau Gly Pro Lys Gly Lau Asp Lys Met Lau Val Glu Gly
35	 40	 45
caa gac att sea aia act aat gac ggt gcg aca ata gtt aaa aac atg 192
Gla Asp Ile Thr Ile Thr Asn Asp Gly Ala Thr Ile Val Lys Asn Met
;0	 55	 60
gas gtg cag cat cot act gca aaa tta ctc att gas ace get aaa act 240
Glu Val Gln His Pro Thr Ala Lys Lau Lau Ile Glu Thr Ala Lys Thr
65	 70	 75	 80
gtt gat acc gag gta gga gat ggg sea act tca gta gtc gtt ctt goo 288
Val Asp Thr Glu Val Gly Asp Gly Thr Thr Ser Val Val Val Lau Ala
85	 90	 95
ggg tta eta tta gas aaa get gag gat ttg ctg sat cag aag ate cat 336
Gly Lau Lau Lau Glu Lys Ala Glu Asp Lau Lau Asn Gln Lys Ile His
100	 105	 110
cca act gtc ata ata gas ggt tat agg aag get eta agt tca tca tta 384
Pro Thr Val Ile Ile Glu Gly Tyr Arg Lys Ala Lau Ser Ser Ser Lau
115	 120	 125
gas ttg tta ass agt att gca gat aag att agt cca gas gat agg sag 432




eta gtt cac gat eta gta tat act act eta tcg agt sag tte ttc tea 480
Ile Val His Asp Lau Val Tyr Thr Thr Lau Ser Ser Lys Phe Phe Ser
145	 150	 155	 160
sea gag cat act eta gag aag eta eta aat eta gtt att gaa get tca 528
Thr Glu His Thr Lau Glu Lye Ile Ile Asn Leu Val Ile Glu Ala Ser
165	 170	 175
ttg gcg gta ttg gat aaa aga gat gga acc tat gat ctg gat att aag 576
Leu Ala Val Leu Asp Lys Arg Asp Gly Thr Tyr Asp Leu Asp Ile Lys
180	 185	 190
sat eta aag att gta aaa gtc aat ggt ggg,gaa ttt gat gat agt gag 624
Asn Ile Lys Ile Val Lys Val Aen Gly Gly Glu Phe Asp Asp Ser Glu
195	 200	 205
ctt gta set ggg atc gtt gta gat aag gag coo acc aat gag set atg 672
Leu Val Asn Gly Ile Val Val Asp Lye Glu Pro Thr Asn Glu Asn Met
210	 215	 220
cog aaa agg gcg gas aac gtt aag gta atg tta get gac ttc cca tta 120




aaa ctt gas aaa acg gas att age atg sag ctg gga ata agt gac coo 768
Lys Leu Glu Lys Thr Glu Ile Ser Met Lys Leu Gly Ile"Ser Asp Pro
245	 250	 255
act cag eta aag gga tac ttg gat gas caa acg gca tat gtt aag caa 816
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atg gtg gat sag ata aag get atg ggc gtt aaa ttg ttt att aca caa 864
Met Val Asp Lys Ile Lys Ala Met Gly Val Lye Lau Phe Ile Thr Gln
275	 280	 285
aag gac att gat gaa gtc get tca tat tta atg gga aaa agt ggg ata 912
Lys Asp Ile Asp Glu Val Ala Ser Tyr . Leu Met Gly Lys Ser Gly Ile
290	 295	 300
ate, gcg tta aag aac gta aag agg agt gac ata gag tta ctg agt age 960
Ile Ala Lau Lys Ann Val Lys Arg Ser Asp Ile Glu Lou Lau Ser Arg
305	 310	 315	 320
get act ggt gcg aaa att gca agt agc atg aaa gac get sat gag agt 1008
Ala Thr Gly Ala Lys Ile Ala Ser Ser Met Lys Asp-Ala Asn Olu Ser
325	 330	 335
gat tta ggg gaa get aaa tta gtg gag gtt aga aat tta gga aag aac 1056
Asp Lau Gly Glu Ala Lys Lau Val Glu Val Arg Ann Lau Gly Lys Asn
340	 345	 350
aaa tac ctc . ttc att caa tct gat aaa get aaa gcg gtg act gta atc 1104
Lys Tyr Lau Phe Ile Gln Ser Asp Lys Ala Lys Ala Val Thr Val Ile
355	 360
	 365
ate. aag ggc tcg.aat aac atg gta act gat gaa gca gaa agg agt tta 1152
Ile Lys Gly Ser Asn Asn Met Val Thr Asp Glu Ala Glu Arg Ser Lou
370	 375	 380
sat gac gcc ttt aac tec ata aga aac ttg tta cta gaa ccc tat att 1200
Asn Asp Ala Phe Asn Ser Ile Arg Asn Lau Lau Lau Glu Pro Tyr Ile
385
	 390	 395	 400
gtg get ggt ggt ggt get gta gag gag gag ttg get aag agg tta agg 1248
Val Ala Gly Gly Gly Ala Val Glu Glu Olu Lou Ala Lys Arg Lau Arg
405	 410	 415
gag aac got gga aaa gtt ccc gga aag gag caa ttg gca ttt aat gca 1296




ttt gcg gat get ttg gag gag tac gtt tca ata cta tca gaa act get 1344
Phe Ala Asp Ala Lau Glu Glu Tyr Val Ser Ile Lau Ser Glu Thr Ala
435	 440
	 445
ggc atg gat ccc ate. agt gcg tta acc gaa ata aga cat aaa cat gca 1392
Gly Met Asp Pro Ile Ser Ala Lou Thr Glu Ile Arg His Lys His Ala
450	 455	 460
aac .ggg tta aag aat get ggg att gac ata gtt aag get aga att tac 1440
Asa Gly Lau Lys Asn Ala Gly Ile Asp Ile Val Lys Ala Arg Ile Tyr
465	 470	 475	 480
gat aac atg ctt gag ctt aaa gta atc gat tct cta aag gtt aag gaa 1488
Asp Asn Met Lau Glu Lau Lys Val Ile Asp Ser Lau Lye Val Lys Glu
485	 490	 495
caa gtt tta aag agc.gcc aca gaa gcc get act gcg att tta aag atc 1536
Gln Val Lou Lys Ser Ala Thr Olu Ala Ala Thr Ala Ile Lau Lys Ile
500	 505	 510
gac gac atg+ata gca gca get cct gca aag caa caa cct caa cca caa 1584
Asp Asp Not Ile Ala Ala Ala Pro Ala Lys Oln Gln Pro Gln Pro Gln
515	 520	 525
cag cca aat cca tac tta ggt to 1607
Oln Pro Ann Pro Tyr Lau Gly
530	 535
F'IG. 16B
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VERSATILE PLATFORM FOR	 et al., Nature 393: 152-155; Wang et al., 2002 Angew. Chem.
NANOTECHNOLOGY BASED ON CIRCULAR 	 Int. Ed. 41: 459-462), phage (Lee et al., 2002 Science 296:




Thin Solid Films 393: 12-18) havebeen used as templates and
5 in other nanoscale applications.
	
This application is a continuation-in-part of U.S. Ser. No.	 Various nanometer scale objects, including arrays of nano-
	
10/494,853, which is based on PCT/US02/35889, filed Nov. 	 particles formed by non-conventional methods are being
	
8, 2002, which claims priority of a provisional application,	 explored foruse as viable alternatives to standard lithographi-
	
U.S. Ser. No. 60/340,538, filed Nov. 8, 2001, the contents of 	 cally patterned devices. Individual nanoparticles, also known
all of which are hereby incorporated by reference in their io as quantum dots (QDs), have been shown to behave as iso-
entirety into this application. 	 lated device components such as single electron transistors
	
Throughout this application various publications are refer- 	 (Likharev, K. K., 1999 Proc. IEEE 87: 606-632; Thelander et
	
enced. The disclosures of these publications in their entireties 	 al., 2001 Appl. Phys. Lett. 79: 2106-2108). Theoreticians
	
are hereby incorporated by reference into this application in 	 have postulated that two-dimensional arrays of QDs with
order to more fully describe the state of the art to which this 15 nanoscale resolution could form the basis of future genera-
invention pertains. 	 tions of electronic and photonic devices. The function of these
	
The work described here was supported, at least in part, by 	 devices will be based on phenomena such as coulomb charg-
	
grants from: The National Aeronautics and Space Adminis- 	 ing, inter-dot quantum tunneling and other coherent proper-
	
tration. The United States government may, therefore, have	 ties derived from the electronic consequences of confinement
certain rights in the invention.
	
	 20 and nanoparticle surface area to volume ratios (Maier, S. A. et




B 65, 193408; Zrenner, A. et al., 2002 Nature 418: 612-614;
Berven et al., 2001 Adv. Mater. 13: 109-113).
	
The present invention relates to the field of bio-nanotech- 	 Traditional techniques for patterning ordered arrays of
nology. The present invention provides compositions and 25 materials onto inorganic substrates and manufacturing
	
methods for making chaperonin subunit polypeptides which 	 devices currently used are ion beam lithography and molecu-
	
are modified by relocating the N-terminal and C-terminal to	 lar beam epitaxy. These techniques possess inherent limita-
	
different positions. The modified chaperonin subunit	 tions due to the use of polymeric light masks for pattern
	
polypeptides can assemble as part of chaperonin structures, 	 formation, however, there is a theoretical limitation of pat-
and the relocated N- and C-terminal ends can be linked to or io terning that could ultimately limit the processes in the hun-
	
bind with organic or inorganic molecules. The assembled 	 dreds of nanometers.
	
chaperonin structures are useful for producing nanoscale fila- 	 While there are strong incentives to develop nanoscale
	
ments or two-dimensional crystals having functions pro- 	 architectures, these developments require alternate fabrica-
	
duced by the linked or bound organic or inorganic molecule. 	 tion methods and new insights into the behavior of materials
35 onnanometer scales (Nalwa, H. S., 2000 "Handbook of Mate-
BACKGROUND	 rials and Nanotechnology", Academic Press, San Diego).
Development of methods for ordering nanoscale materials
	
The controlled organization of inorganic materials into 	 through "bottom up" assembly will provide new tools for
	
multi-dimensional addressable arrays is the foundation for 	 creating nanostructured materials and devices that self-as-
both logic and memory devices, as well as other nonlinear 40 semble or self-repair. Synthetic and biological polymers have
	
optical and sensing devices (Zhirnov et al., 2001 Computer 	 gained attention because of their inherent ability to form
	
34: 34-43; Xia et al., 2000Adv. Mater. 12: 693-713). Many of 	 structures on the nanometer scale with little or no mechanical
	
these devices are currently fabricated using lithographic pat- 	 processing. Self-assembly and phase separation of these
	
terning processes that have progressively developed toward	 natural or synthetic polymers have been successfully used for
greater integration densities and smaller sizes. At submicron 45 nanoscale ordering of materials. Biopolymers form espe-
	
scales, however, conventional lithographic processes are	 cially well-defined structures and assemblies with highly spe-
	
approaching their practical and theoretical limits. At scales 	 cific chemical functionalities. Nucleic acids (7 Richter, et al.,
	
below 100 mu, ion and electron beam lithography becomes 	 2000 Advanced Materials 12:507-510; M G Warner and 7 E
	
prohibitively expensive and time consuming, and more 	 Hutchison 2003 Nature Materials 2:272-277; and K Keren, et
importantly, at these scales quantum effects fundamentally 5o al., 202 Science 297:72-75), proteins (K Douglas and N A
	
change the properties of devices (Sato et al., 1997 J. Appl. 	 Clark 1986 Appl Phys Lett 48:676-678; U B Sleytr, et al.,
Phys. 82: 696).	 1999 Angew Chem Int Edn 38:1034-1054; I Yamashita 2001
	
Nanoscale templates for constrained synthesis, in situ 	 Thin Solid Films 393:12-18; M Allen, et al., 2002 14:1562-
	
deposition, or direct patterning of nanometer scale inorganic 	 1565; R A McMillan, et al., 2002 Nature Materials 1:247-
arrays are being developed using both artificial and natural 55 252), virions and virus capsids (W Shenton, et al., 1999 Adv
	
materials. Artificial materials such as microphase separated	 Mater 11:253-256; S-W Lee, et al., 2002 Science 296:892-
	
block copolymers (Park et al., 2001 Appl. Phys. Lett. 79:	 895; Q Wang, et al., 2002 Angew Chem Int Ed Engl 41:459-
	
257-259) and hexagonally close-packed spheres (Hulteen et 	 462) have all been used to create nanostructured materials
	
al., 1995 J. Vac. Sci. Technol. A, 1553-1558) have been used 	 with unique properties.
for nanoscale fabrication. Natural materials such as DNA 60 A number of protein complexes have been developed as
	
(Richter et al., 2000 Adv. Mater. 12: 507-510; Keren et al., 	 nanoscale templates. These templates can be functionalized
	
2002 Science 297: 72-75), bacterial and archaeal surface 	 by genetic modification to add chemically reactive sites that
	
layer proteins (S-layer proteins) (Sleytr et al., 1999 Angew. 	 bind inorganic materials. For example, chaperonin com-
	
Chem. Int. Ed. 38: 1034-1054; Douglas et al., Appl. Phys. 	 plexes can be functionalized to bind soft metals. In nature,
Lett. 48: 676-678; Hall et al., 2001 CHEMPHYSCHEM 3: 65 chaperonins are protein complexes having two stacked rings
	
184-186), virus capsids (Shenton et al., 1999 Adv. Mater. 11: 	 each comprising 7, 8 or 9 HSP60 subunits. The HSP60 sub-
	





at different solvent-exposed sites, including the apical pore. 	 In one embodiment, the modified chaperonin polypeptide
The thiols of these cysteine residues provide binding sites for 	 comprises a Sulfolobus shibatae TF55 beta polypeptide com-
gold or zinc (PCT/US02/35889). The chaperonin complexes 	 prising the N-terminal and C-terminal ends relocated after
comprising these mutant HSP60 subunits bind gold or zinc	 any amino acid position in the range 149-158, in particular
and assemble into two-dimensional crystals. 	 5 relocated to position 153.
Protein complexes can also be modified to include peptide 	 In another embodiment, the modified chaperonin polypep-
sequences having desirable binding or catalytic functions. 	 tide comprises a Sulfolobus shibatae TF55 beta polypeptide
These protein complexes comprise subunits having inserted 	 comprising the N-terminal and C-terminal ends relocated
peptide sequences. However, the mutant subunits may fail to 	 after any amino acid position in the range 263-270, in par-
fold, assemble into complexes or organize into higher-order io ticular relocated to position 267.
structures. Furthermore, insertion as a loop may render the 	 In another embodiment, the modified chaperonin polypep-
peptide sequence inactive and fusion to one of the native	 tide comprises a Sulfolobus shibatae TF55 beta polypeptide
termini may not provide sufficient surface accessibility. To 	 comprising the N-terminal and C-terminal ends relocated
overcome this challenge, circular permutation has been used 	 after any amino acid position in the range 311-330, in par-
to join peptide sequences within a protein template. Circular 15 ticular relocated to position 316.
permutation is a reordering of the polypeptide chain such that 	 In another embodiment, the modified chaperonin polypep-
the original N- and C-terminal ends are joined and new ter- 	 tide comprises a Sulfolobus shibatae TF55 beta polypeptide
mini are created elsewhere in the protein. New peptide	 comprising the N-terminal and C-terminal ends relocated
sequences can be joined to either of the new termini without 	 after any amino acid position in the range 472-487, in par-
perturbing subunit assembly. Published studies of protein 20 ticular relocated to position 480.
circular permutation demonstrate that, for proteins in which 	 In yet another embodiment, the modified chaperonin
the native amino and carboxyl termini are near in space, many 	 polypeptide comprises a Sulfolobus shibatae TF55 beta
relocated positions for the new termini are viable (P T Beer- 	 polypeptide comprising the N-terminal and C-terminal ends
nink, et al., 2001 Protein Sci 10:528-537; U Heinemann and 	 relocated after any amino acid position in the range 494-508,
M Hahn 1995 Prog Biophys Mol Biol 64:121-143; M 25 in particular relocated to position 499.
Iwakura, et al., 2000 Nat Struct Biol 7:580-585). 	 The present invention also provides assembled chaperonin
The present invention provides chaperonin subunit 	 structures, comprising at least one of the modified chaperonin
polypeptides which are modified to relocate the native N-ter- 	 subunits of the invention.
minal and C-terminal ends from the central pore region to 	 The assembled chaperonin structures can have one or more
various new positions on the exterior of the folded modified 30 of 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, and 10-fold symmetry.
chaperonin polypeptide. The relocated N- and C-terminal 	 The present invention further provides: nucleic acid mol-
ends are joined with a peptide sequence that behaves as a 	 ecules encoding the modified chaperonin polypeptide of the
reporter. The modified chaperonin polypeptides fold into sub- 	 invention; vectors comprising these nucleic acid molecules;
units that self-assemble into double-ringed chaperonin struc- 	 and host cells carrying these vectors.
tures, and the chaperonin structures organize into higher 35	 The present invention provides in vivo methods for pro-
order structures such as two-dimensional crystals and fila- 	 ducing modified chaperonin polypeptides, comprising cultur-
ments. Additionally, the reporter peptide is functional. These 	 ing the host/vector systems under conditions suitable for the
chaperonin structures are useful forproducing ordered nanos-	 host to produce the modified chaperonin polypeptide.
cale materials and devices.	 The present invention also provides in vitro methods for
40 producing the assembled chaperonin structures of the inven-
SUMMARY	 tion, comprising reacting the modified chaperonin polypep-
tides under conditions suitable for self-assembly of the modi-
The present invention provides chaperonin polypeptides 	 fied chaperonin polypeptide into the assembled chaperonin
which are modified to include N-terminal and C-terminal 	 structures.
ends that are relocated from the central pore region to various 45	 The present invention provides chaperonin structures that
different positions in the polypeptide which are located on the	 organize into higher order structures such as nanofilaments or
exterior of the folded modified chaperonin polypeptide. 	 nanoarrays. These nanofilaments and nanoarrays can be used
The relocated N-terminal or C-terminal ends can be	 to produce nanodevices or nanocoatings.
covalently joined to, or bound with, a nucleic acid molecule,
a lipid, a carbohydrate, a second polypeptide, or a nanopar- 50	 BRIEF DESCRIPTION OF FIGURES
ticle.
In the modified chaperonin polypeptide, the naturally-oc- 	 FIG. 1 illustrates an end and side view of a model of an
curring N-terminal and C-terminal ends are joined together 	 HSP60 chaperonin at 2.3 Aresolution. The outlined region of
directly or with an intervening linker peptide sequence. In one 	 the side view shows a single subunit of HSP60.
embodiment, the intervening linker sequence comprises the 55	 FIGS. 2A-2R show the protein sequence alignment of S.
amino acid sequence Gly-Gly-Ser-Gly-Gly-Thr. 	 shibatae TF55 beta subunit (SEQ ID NO: 1), bacterial E. coli
The modified chaperonin polypeptide is based on a Group	 GroEL (SEQ ID NO:2), thermosome T. acidophilum beta
I or Group II chaperonin polypeptide.	 subunit (SEQ ID NO:3), cyanobacterial synechococcus
The Group I chaperonin polypeptides are from Escheri-
	HSP60 (SEQ ID NO:4), M. acetivorans HSP60-4 (SEQ ID
chia, Cyanobacteria, Mycobacteria, Coxiella, Rickettsia, 6o NO:5), M. tuberculosis HSP65 (SEQ ID NO:6), thermosome
Chlamydia, Thermotoga, chloroplast, mammalian mitochon- 	 A. pernix alpha subunit (SEQ ID NO:7), thermosome M.
dria, or yeast mitochondria. The Group II chaperonin	 mazei alpha subunit (SEQ ID NO:8), mitochondrial A.
polypeptides are from Sulfolobales, Methanopyrus, Pyrodic- 	 thaliana HSP60 (SEQ ID NO: 9), yeast TCPI alpha subunit
tium, Thermoplasma, Thermoplasma, Thermococus, Pyroco-
	(SEQ ID NO: 10), human mitochondrial HSP60 (SEQ ID
cus, Mathanococus, or yeast cytosol.	 65 NO: 11), mouse mitochondrial HSP60 (SEQ ID NO: 12),
In one embodiment, the modified chaperonin polypeptide 	 human TCPI alpha subunit (SEQ ID NO: 13), mouse TCPI
from Sulfolobus is an alpha, beta, or gamma polypeptide. 	 alpha subunit (SEQ ID NO: 14), and the consensus (SEQ ID
US 7,795,388 B2
5
NO: 15). Identical residues are enclosed in a dot-dashed box,
blocks of similar residues are enclosed in a solid box, and
conservative matches are enclosed in a dashed box.
FIG. 3 shows a structural alignment of the archaeal chap-
eronin (thermosome) and the bacterial chaperonin (GroEL),
indicating the structural similarities between group I and
group II chaperonins. The black areas of the structural align-
ment indicate where the features of the two chaperonin sub-
units overlap.
FIG. 4 shows the detailed structure of a Group II chapero-
nin subunit.
FIGS. 5A-D shows individual HSP60 (heat-shock protein)
chaperonins and filaments as observed in the electron micro-
scope.
FIGS. 6A and 6B show the organization of HSP60 rings
into 2-dimensional crystals on a metal grid coated with lipid
(6A) and filament bundles arranged on a bed of rings (visible
as spots in background) (613).
FIGS. 7A-E show the assembly of engineered HSP60s
(heat-shock proteins) into nanotemplates for the production
of nanoarrays comprising nanoscale materials such as nano-
particles.
FIGS. 8A-D show gold nanoparticles binding to engi-
neered chaperonins and chaperonin nanotemplates.
FIGS. 9A-D show semiconductor QD nanoarrays.
FIGS. 10A-D show the formation of a nanoarray of gold
nanoparticles. FIG. 10(D) shows XEDS spectra of bare car-
bon film (solid line) and the gold nanoparticle nanoarray
(dashed line) from the probed area outlined by a circle in FIG.
10(B), as indicated by the arrow.
FIGS. IIA-C show HAADF STEM imaging of a nanogold
array.
FIG. 12 shows a control experiment showing DIC (left) and
fluorescent (right) images of non-cys-mutated chaperonin
crystals after incubation with CdSe ZnS QDs.
FIG. 13 shows an Energy Filtered TEM thickness map of a
typical 2D protein crystal.
FIG. 14 illustrates steps in the formation of an ordered
nanoarray of nanoparticles on a substrate.
FIG. 15 shows the protein sequence alignment of S. shiba-
tae TF55 alpha subunit (SEQ ID NO: 39), beta subunit (SEQ
ID NO: 1) and gamma subunit (SEQ ID NO: 38).
FIGS. 16A and 16B show the DNA sequence (SEQ ID NO:
37) and amino-acid sequence for S. shibatae gamma subunit
(SEQ ID NO: 38).
FIGS. 17A-E show models of circular permutant proteins
at position: A)153, B) 267, Q 316, D) 480, and E) 499. The
left column shows ribbon representations of protein subunits.
The center column shows side views of surface representa-
tions of the assembled rings. The right column shows top
views of the surface representations of the assembled rings.
Amino termini are labeled in blue. Carboxyl termini are
labeled in red. The flexible linker sequences are labeled in
green. In the assembled rings, a single subunit is highlighted
in yellow.
FIG. 18 shows a native polyacrylamide gel electrophoresis
of wild-type chaperonin and circular permutants as unas-
sembled protein subunits and assembled double rings in the
presence and absence of ATP and magnesium ions.
FIGS. 19A-J shows transmission electron microscopy
(TEM) of assembled chaperonin double rings comprising
circular permutant chaperonin proteins (lacking fused
EYFP). Samples containing isolated double rings, shown in
panels A-E were prepared 1 hour after addition of ATP and
MgCl2 to the protein samples. Samples containing higher-
order structures, shown in panels F-J were prepared 24 hours
after addition of ATP and Mg2l to the protein samples. A)
6
Circular permutant at position 153 at 1 hour. F) Circular
permutant at position 153 at 24 hours. B) Circular permutant
at position 267 at 1 hour. G) Circular permutant at position
267 at 24 hours. C) Circular permutant at position 316 at 1
5 hour. H) Circular permutant at position 316 at 24 hours. D)
Circular permutant at position 480 at 1 hour. J) Circular
permutant at position 480 at 24 hours. E) Circular permutant
at position 499 at 1 hour. J) Circular permutant at position 499
at 24 hours.
io FIG. 20A-D shows circular permutant chaperonin proteins
at positions 267 and 480 joined with yellow fluorescent pro-
tein (EYFP). A) Fluorescence excitation (open symbols) and
emission (closed symbols) spectra for unmodified EYFP
(circles), 267 permutant-EYFP fusion protein (squares), 480
15 permutant-EYFP fusion protein (triangles). B) TEM showing
negatively stained rings formed by 480 permutant-EYFP
fusion protein. C) Fluorescence microscopy of a crystal
formed by the 267 permutant-EYFP fusion protein using
Leica filter cube 13 (excitation 470 mu, emission 515 mu). D)
20 TEM showing 2-dimensional crystal formed by 267 permu-
tant-EYFP fusion protein.
FIG. 21 shows the full (A) DNA (SEQ ID NO: 66) and (B)
amino acid (SEQ ID NO:67) sequence of a position 153
circular permutant chaperonin protein.
25 FIG. 22 shows the full (A) DNA (SEQ ID NO: 68) and (B)
amino acid (SEQ ID NO:69) sequence of a position 267
circular permutant chaperonin protein.
FIG. 23 shows the full (A) DNA (SEQ ID NO: 70) and (B)
amino acid (SEQ ID NO:71) sequence of a position 316
30 circular permutant chaperonin protein.
FIG. 24 shows the full (A) DNA (SEQ ID NO: 72) and (B)
amino acid (SEQ ID NO:73) sequence of a position 480
circular permutant chaperonin protein.
FIG. 25 shows the full (A) DNA (SEQ ID NO: 74) and (B)
35 amino acid (SEQ ID NO:75) sequence of a position 499
circular permutant chaperonin protein.
FIG. 26 shows the full (A) DNA (SEQ ID NO: 76) and (B)
amino acid (SEQ ID NO:77) sequence of a position 267
circular permutant chaperonin-EYFP fusion protein.
40 FIG. 27 shows the full (A) DNA (SEQ ID NO: 78) and (B)
amino acid (SEQ ID NO:79) sequence of a position 480
circular permutant chaperonin-EYFP fusion protein.
FIG. 28 shows the full (A) DNA (SEQ ID NO: 80) and (B)
amino acid (SEQ ID NO: 1) sequence ofwild-type TF55 alpha
45 subunit from Sulfolobus shibatae.
FIGS. 29A and 29B show the full (A) DNA (SEQ ID
NO: 81) and (B) amino acid (SEQ ID NO: 82) sequence of a
position 267 "dwarf' deletion circular permutant chaperonin
protein.
50 FIG. 30 shows the DNA sequence (SEQ ID NO:85) of
TF55 beta subunit from Sulfolobus shibatae.
FIG. 31 shows a different DNA sequence (SEQ ID NO: 86)
of TF55 beta subunit from Sulfolobus shibatae.
55 DETAILED DESCRIPTION OF THE INVENTION
Definitions
All scientific and technical terms used in this application
6o have meanings commonly used in the art unless otherwise
specified. As used in this application, the following words or
phrases have the meanings specified.
As used herein, the term "isolated" refers to a specific
nucleic acid or polypeptide, or a fragment thereof, in which
65 contaminants (i.e. substances that differ from the specific
nucleic acid or polypeptide molecule) have been separated
from the specific nucleic acid or polypeptide.
US 7,795,388 B2
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As used herein, the term "purified" refers to a specific
isolated nucleic acid or polypeptide, or a fragment thereof, in
which substantially all contaminants (i.e. substances that dif-
fer from the specific nucleic acid or polypeptide molecule)
have been separated from the specific nucleic acid or
polypeptide.
As used herein, the term "naturally-occurring" refers to a
nucleic acid or polypeptide molecule found in nature.
As used herein, the term "wild type" refers to a nucleic acid
or polypeptide molecule having the same nucleotide and/or
amino acid sequence as a naturally-occurring, non-mutant
molecule, respectively.
As used herein, the term "modified" refers to molecules
with amino acid or nucleotide sequences differing (mutated)
from a naturally-occurring i.e., wild-type, amino acid or
nucleotide, sequence. The modified molecules can retain the
same structural properties as a wild-type molecule.
As used herein, the term "derivative" means any modifica-
tion or alteration of a wild-type molecule. Derivatives
include, but are not limited to: a substitution, conservative or
non-conservative, in a amino acid and/or nucleotide sequence
including substitutions by other amino acids, nucleotides,
amino acid analogs or nucleotide analogs; a deletion of one or
more amino acids and/or nucleotides; an insertion of one or
more amino acids and/or nucleotides; and pre- and/or post-
translational modifications. A derivative molecule can share
sequence similarity and/or activity with its parent molecule.
As used herein, a first nucleotide or amino acid sequence is
said to have sequence "identity" to a second nucleotide or
amino acid sequence, respectively, when a comparison of the
first and the second sequences shows that they are exactly
alike.
As used herein, a first nucleotide or amino acid sequence is
said to be "similar" to a second sequence when a comparison
of the two sequences shows that they have few sequence
differences (i.e., the first and second sequences are nearly
identical). For example, two sequences are considered to be
similar to each other when the percentage of nucleotides or
amino acids that differ between the two sequences can be
between about 60% to 99.99%.
As used herein, the term "complementary" refers to nucleic
acid molecules having purine and pyrimidine nucleotide
bases which have the capacity to associate through hydrogen
bonding to form base pairs thereby mediating formation of
double stranded nucleic acid molecules. The following base
pairs are related by complementarity: guanine and cytosine;
adenine and thymine; and adenine and uracil. Complemen-
tary applies to all base pairs comprising two single-stranded
nucleic acid molecules, or to all base pairs comprising a
single-stranded nucleic acid molecule folded upon itself.
As used herein, the term "conservative" refers to substitut-
ing an amino acid residue for a different amino acid residue
that has similar chemical properties. A conservative amino
acid substitution includes: substituting any hydrophobic
(e.g., nonpolar) amino acid for any other hydrophobic amino
acid; or substituting any hydrophilic (polar, uncharged)
amino acid for any other hydrophilic amino acid; or substi-
tuting any positively charged amino acid for any other posi-
tively charge amino acid; or substituting any negatively
charge amino acid for any other negatively charged amino
acid (TE Creighton, "Proteins" WH Freeman and Company,
New York). The amino acid substitutions include, but are not
limited to, substituting any of isoleucine (I), valine (V), and
leucine (L) for any other of these hydrophobic amino acids;
aspartic acid (D) for glutamic acid (E) and vice versa;
glutamine (Q) for asparagine (N) and vice versa; and serine
(S) for threonine (T) and vice versa. Other substitutions can
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also be considered conservative, depending on the environ-
ment of the particular amino acid and its role in the three-
dimensional structure of the protein. For example, glycine
(G) and alanine (A), or glycine (G) and serine (S) can fre-
5 quently be interchangeable, as can alanine (A) and valine (V).
Methionine (M), which is relatively hydrophobic, can fre-
quently be interchanged with leucine and isoleucine, and
sometimes with valine. Lysine (K) and arginine (R) are fre-
quently interchangeable in locations in which the significant
i o feature of the amino acid residue is its charge and the differing
pK's of these two amino acid residues are not significant. Still
other changes can be considered conservative in particular
environments.
As used herein, the term "nonconservative" refers to sub-
15 stituting an amino acid residue for a different amino acid
residue that has different chemical properties. The noncon-
servative substitutions include, but are not limited to aspartic
acid (D) being replaced with glycine (G); asparagine (N)
being replaced with lysine (K); or alanine (A) being replaced
20 with arginine (R).
The single-letter codes for amino acid residues include the
following: A=alanine, R=arginine, N=asparagine,
D=aspartic acid, C—cysteine, Q—Glutamine, E—Glutamic
acid, G=glycine, H=histidine, I=isoleucine, L=leucine,
25 K=lysine, M=methionine, F —phenylalanine, P—proline,
S=serine, T=threonine, W=tryptophan, Y=tyrosine,
V=valine.
In order that the invention herein described can be more
30 fully understood, the following description is set forth.
The Modified Chaperonin Polypeptides
In its various aspects, the present invention provides: modi-
fied chaperonin polypeptides, and fragments and derivatives
thereof; assembled chaperonins comprising the modified
35 chaperonin polypeptides of the present invention; nucleic
acid molecules encoding the modified chaperonin polypep-
tides, or fragments and derivatives thereof; recombinant DNA
molecules; transformed host cells; host-vector systems;
methods for producing the modified chaperonin polypep-
40 tides; methods for using the modified chaperonin polypep-
tides including producing bio-nano scale devices and coat-
ings.
In nature, chaperonins are ubiquitous and essential subcel-
45 lular structures having 14, 16, or 18 heat shock protein sub-
units (e.g., HSP60), arranged as two stacked rings and mea-
suring approximately 16 to 18 mn tall by approximately 15 to
17 mn wide, depending on their species of origin (Hartl et al.,
2002 Science 295: 1852-8). Chaperonins have a central pore,
50 as well as apical, intermediate and equatorial domains. In a
wild-type HSP60 protein subunit, the naturally-occurring N-
and C-terminal ends occur in a region that forms part of the
central pore in the assembled chaperonin. FIG.1 illustrates an
end and side view of a chaperonin that comprises 16 subunits,
55 i.e., eight subunits per ring.
The present invention provides chaperonin subunit
polypeptides, and fragments or derivatives thereof, which are
modified to include N-terminal and C-terminal ends that are
relocated from their naturally-occurring positions to different
60 positions in the polypeptide.
In the modified chaperonin polypeptide, the N- and C-ter-
minal ends are relocated from the central pore region to a new
position on the exterior of the folded modified chaperonin
polypeptide. The positions of the relocated N- and C-terminal
65 ends are selected to circumvent the space constraints of the
central pore, thereby permitting j oining or binding other mol-





The modified chaperonin polypeptides of the present
invention are mutant chaperonin polypeptides. The modified
chaperonin polypeptides exhibit the same structural proper-
ties as naturally-occurring wild-type chaperonin subunit
polypeptides, which includes folding into a subunit structure
having the same or similar shape compared to a wild-type
chaperonin subunit polypeptide. The folded modified chap-
eronin subunit structure can self-assemble with other chap-
eronin subunit structures (folded wild-type and/or modified
subunit polypeptides) to form a double-ringed chaperonin
structure. The folded modified chaperonin subunit structure
can self-assemble in vivo or in vitro to form a double-ringed
chaperonin structure. The double-ringed chaperonin struc-
ture, comprising at least one modified polypeptide of the
present invention, can be organized into two-dimensional
crystals or filaments which are useful for producing nanode-
vices such as logic and memory devices, non-linear optical
devices, and sensing devices.
The present invention provides modified chaperonin
polypeptides, or fragments or derivatives thereof, derived or
isolated from any source whether natural, synthetic, semi-
synthetic, or recombinant.
The terms "modified chaperonin subunit polypeptides",
"modified chaperoninpolypeptides", and "modified polypep-
tides" refer to chaperonin subunit polypeptides which are
modified by relocating the N- and C-terminal ends. These
terms are used interchangeable herein.
Group I and II Chaperonin Polypeptides
The modified polypeptides can be produced using any
Group I or Group II chaperonin polypeptide. Chaperonins
have been classified into two groups, Group I and Group II,
based on sequence and structural comparisons. (See, e.g.,
Trent et al., 1991 Nature 354: 490-493; Horwich et al., 1993
Phil. Trans R. Soc. Lond. 339: 313-326).
Group I chaperonins are from bacteria and the bacterial-
derived organelles of Eukarya (mitochondria and chloro-
plasts), while Group II chaperonins are from Archaea and
eukaryotic cytosol. A description of the expression of endog-
enous, wild-type TF55 Sulfolobus shibatae, and a compari-
son of a Group I chaperonin (GroEL) to the Group II chap-
eronin TF55 is disclosed by Trent (U.S. Pat. No. 5,428,131).
Any of the Group I chaperonin subunit proteins canbe used
to produce the modified chaperonin polypeptides of the
present invention. Wild-type Group I chaperonins are com-
posed of seven subunits in each of the two rings of the double-
ring structure. The wild-type cpn60 subunit proteins, which
comprise about 550 to about 580 amino acid residues, have
been described by different names in different species,
including, but not limited to Escherichia coli GroEL protein,
Cyanobacterial goEL analogues, Mycobacterium tubercu-
losis and leprae 65 Kd antigen, Coxiella burnetti heat shock
protein B (gene htpB), Rickettsia tsutsugamushi major anti-
gen 58, Chlamydial 57 Kd hypersensitivity antigen (gene
hypB), Chloroplast RuBisCO subunit binding-protein alpha
and beta chains, Mammalian mitochondrial matrix protein PI
(mitonin or P60), and yeast HSP60 protein.
In one embodiment, e.g., when utilizing Group I chaper-
onins, chaperonin polypeptides, and/or mutant chaperonins
and/or mutant chaperonin polypeptides, a co-chaperonin can
be utilized in forming the higher order structures of the inven-
tion. As such, in one example of such an embodiment, a
composition or device of the invention further comprises a
co-chaperonin. Co-chaperonins are well known to those of
skill in the art (Harris et al., 1995 J. Structural Biol. 115:
68-77). In another, non-limiting example of such an embodi-
ment, a co-chaperonin can be utilized in producing nanofila-
ments. For example, the cpn60 in the bacterium E. coli
(GroEL) in nature is associated with a single ring structure
composed of 10 kDa proteins (co-chaperonin or cpn10)
called "GroES." As such, a GroES polypeptide represents an
5 exemplary, non-limiting species of co-chaperonin that can be
utilized in conjunction with Group I chaperonins, e.g., GroEL
or GroEL-derived chaperonins, chaperonin polypeptides,
and/or mutant chaperonins or chaperonin polypeptides. In
different embodiments of the invention, the compositions,
io e.g., nanotemplates or nanostructures, are formed from one or
more chaperonins with the co-chaperonin on one or both ends
of the chaperonin.
Any of the Group II chaperonins subunit proteins can be
used to produce the modified chaperonin polypeptides of the
15 present invention. Group II chaperonins are composed of
identical or diverse subunits arranged in rings of eight or nine
subunits, depending on the organism. In the yeast Saccharo-
myces cerevisiae, for example, there is evidence for eight
different subunits in each ring (Lin et al., 1997 Proc. Natl.
20 Acad. Sci. USA 94: 10780-10785). Among the Archaea some
thermophilic methanogens (e.g., Methanopyrus kandleri,
Methanococcus jannaschii, Methanococcus therm-
olithotrophicus) have chaperonins with identical subunits
(Furutani et al., 1998 J. Biol. Chem. 273: 28399-28407),
25 while in the mesophilic methanogen Methanosarcina ace-
tivorans there are five different subunits (Galagan et al., 2002
Genome Research 12: 532-542). Of the 50 archaeal chapero-
nin sequences in the databases most have >40% amino acid
sequence identity.
30 The majority of Group II chaperonins in Archaea have
eight subunits per ring and are referred to as "thermosomes"
(Klumpp, M., and Baumeister, W., 1998, FEBS Letters 430:
73-77), but the chaperonins in the thermoacidophilic Archaea
in the family Sulfolobales have nine subunits per ring (Trent
35 et al., 1991 Nature 354: 490-493; Marco et al., 1994 FEBS
341: 152-155). These Sulfolobus octadecameric chaperonins
are referred to as "rosettasomes" (Kagawa et al., 1995 J. Mol.
Biol. 253: 712-725) to distinguish them from thermosomes.
Other examples of thermosomes include chaperonins from
40 Pyrodictium occultum, Thermoplasma acidophilum and
Methanopyrus kandleri (Ellis et al., 1998 J. Struc. Biol. 123:
30-36). It has previously been reported that rosettasomes are
composed of two types of HSP60s known as TF55 alpha and
beta, that TF55 alpha and beta are among the most abundant
45 proteins in S. shibatae grown at optimal temperatures (75-83°
C.), and that their synthesis increases at heat-shock tempera-
tures (85-88° C.) (Kagawa et al., 1995 J. Mol. Biol. 253:
712-725). A third related subunit of S. shibatae, has also been
identified by sequence analyses (Archibald et al., 1999 Cur-
io rent Biology 9: 1053-1056). Sequence information from S.
solfataricus (Charlebois et al., 1998 Current Opinion in
Microbiology 1: 584-588) allowed TF55 alpha, beta, and
gamma expression to be predicted based on codon usage
(Karlin et al., 2001 J. Bacteriol. 183: 5025-5040). Chaper-
55 onins from eukaryotic cytosol are referred to as "TCPI,"
which identifies one of the proteins comprising the ring struc-
ture, "TriC" which means TCPI ring chaperonin, or "CCT"
which means chaperonin containing TCPL Any of these
chaperonins subunit proteins can be used to produce the
60 modified chaperonin polypeptides of the present invention.
Sources of gene sequences encoding chaperonin polypep-
tides include but are not limited to bacterial chaperonin genes
encoding such proteins as Gro ES/Gro EL; archaeal chapero-
nin genes encoding such proteins as TF55, TF56, alpha, beta,
65 gamma, and cpn60s; mammalian chaperonins such as Hsp60,
Hsp10, TCP-1, cpn60 and the homologues of these chapero-
nin genes in other species (7. G. Wall and A. Pluckthun,
US 7,795,388 B2
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Current Biology, 6:507-516 (1995); Hard, Nature, 381:571-
580 (1996)). Additionally, heterologous genomic or cDNA
libraries can be used as libraries to select or screen for chap-
eronins.
FIGS. 2A-2R show protein sequence alignments covering
a representative set of Groups I (bacteria) and Group II (ar-
chaea and eukarya) chaperonins. The protein sequence are
sequences for S. shibatae TF55 beta subunit (SEQ ID NO: 1),
bacterial E. coli GroEL (SEQ ID NO:2), thermosome T. aci-
dophilum beta subunit (SEQ ID NO:3), cyanobacterial syn-
echococcus HSP60 (SEQ ID NO:4), M. acetivorans HSP60-4
(SEQ ID NO:5), M. tuberculosis HSP65 (SEQ ID NO:6),
thermosome A. pernix alpha subunit (SEQ ID NO:7), ther-
mosome M. mazei alpha subunit (SEQ ID NO:8), mitochon-
drial A. thaliana HSP60 (SEQ ID NO: 9), yeast TCPI alpha
subunit (SEQ ID NO: 10), human mitochondrial HSP60 (SEQ
ID NO: 11), mouse mitochondrial HSP60 (SEQ ID NO: 12),
human TCPI alpha subunit (SEQ ID NO: 13), mouse TCPI
alpha subunit (SEQ ID NO: 14), and the consensus (SEQ ID
NO: 15). White letters on a black background, solid lines, and
dashed lines surround the regions of the sequence alignment
containing identical residues, a block of similar residues, and
conservative matches, respectively.
Folded Structure
While Group I chaperonin subunit proteins can have
greater than 50% sequence identity, sequence identity among
Group II chaperonin subunit proteins can be on the order of
less than 33%. Despite the sequence variations among the
cpn60 subunits from the different species, however, Group I
and Group II cpn60 subunits share significant structural simi-
larity. FIG. 3 shows a structural comparison between a sub-
unit of the archaeal (Thermoplasma acidophilum) thenno-
some and the bacterial (E. coli) GroEL chaperonins.
The alignment was performed using an algorithm based on
the iterative dynamic programming approach (Gerstein, M. &
Levitt, M., Protein Science 7: 445-456, 1998; and Gerrstein,
M. & Levitt, M, Proc. of ISMB-96, pp. 59-67, 1996).
For purposes of wild-type chaperonins and chaperonin
polypeptides, such three dimensional structural similarity
serves to illustrate that fact that any chaperonin or chaperonin
polypeptide routinely can be utilized as part of the composi-
tions and devices of the present invention, either alone or
combination. For purposes of modified chaperonins and
chaperonin polypeptides, as discussed in detail in the next
section, such sequence similarity serves to provide teaching
that allows for routine manipulation of sequences in produc-
ing the modified chaperonin polypeptides of the present
invention.
The two subunits exhibit very similar structures, in that
both possess an equitorial, an intermediate and an apical
region. Even though these two examples of cpn60 subunits
are farther apart by sequence than most cpn60 subunits, as
evidenced by the very little similarity in their sequence align-
ments (see FIGS. 2A-2R), the crystal structures for each
reveal that they share considerable structural identity most
all helical, sheet, and random coil regions correspond, as
shown in black in the center panel. Variations in structure are
tolerated in the apical domain, as evidenced by the loop of the
thermosome, while the equatorial domains adopt similar con-
served folding motifs.
It is noted that, while the chaperonins observed to date
comprise seven, eight or nine subunits per ring, the present
invention provides methods and compositions of exploiting
chaperonins with any number of subunits per ring (e.g., 7, 8,
9 or 10).
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Chaperonins from the different species can comprise only
a single type of subunit or they can have different types of
subunits (e.g., archeal chaperonins comprising alpha, beta,
gamma, etc.). These subunits are called alpha subunits, beta
5 subunits, or gamma subunits, due to some differences in the
protein sequences of the subunits of a given species. As is
known to one of ordinary skill in the art, in some species yet
more varieties of subunits exist. The structure of chaperonins
(Ellis et al., 1998, J. Struc. Biol. 123, 30-36) describes a
io chaperonin from Sulfolobus solfataricus with a 2:1 ratio of
alpha:beta subunit composition of the nine-membered ring
(rosettasomes). The present invention provides means of
assembling chaperonins from only a single type of wild-type
or modified chaperonin polypeptides, or from various propor-
15 tions of the different wild-type or modified chaperonin
polypeptides.
Ina specific embodiment, HSP60s (heat-shock proteins) in
organisms living at high temperatures, called "thermophiles,"
are the source of the wild-type and mutated chaperonin
20 polypeptides of the present invention. These proteins are
present in all organisms and are among the most abundant
proteins in extreme thermophiles, e.g., in one of the highest
temperature thermophiles Pyrodictium occultum, they report-
edly account for 73% of total protein (Phipps et al., 1991 The
25 EMBO Journal 10(7): 1711-1722).
Selecting the Position of Relocated Terminal Ends
Using the amino acid sequence and/or the predicted folded
structure of any Group I or II wild-type chaperonin subunit
30 polypeptide as a guide (FIGS. 2A-R and 15), one skilled in the
art can select the amino acid position to relocate the N- and
C-terminal ends. The new terminal end positions can be
selected based on the following criteria: the position is not
buried within the folded modified chaperonin polypeptide;
35 the new position is not near the subunit interface; and the new
position is not part of the regular secondary structure.
In one embodiment, the N-terminal and C-terminal ends
are relocated to any position on the exterior of the folded
polypeptide that occurs in the apical, intermediate or equato-
rial domain.
40 In another embodiment, any chaperonin subunit polypep-
tide can be modified by relocating the N- and C-terminal ends
to produce the modified polypeptides of the present invention,
including: TF55 alpha, beta or gamma subunits from Sulfolo-
bales shibatae. For example, the N- and C-terminal ends can
45 be relocated to any position 1-560 for TF55 alpha subunit,
position 1-552 for TF55 beta subunit, or position 1-535 for
TF55 gamma subunit (FIG. 15).
In another embodiment, using the amino acid sequence of
50 
wild-type TF55 beta subunit from Sulfolobus shibatae as a
guide, the N- and C-terminal ends are relocated to any amino
acid positions within or about a region having a consensus
sequence, a conserved folded structure, or non-conserved
sequence (FIG. 15). Many positions can be modified. In one
55 
embodiment, the N- and C-terminal ends can be relocated to
amino acid positions within or about the ranges: 149-158;
263-270; 311-330; 472-487; or 494-508. In yet another
embodiment, the N- and C-terminal ends are relocated to
amino acid positions 153, 267, 316, 480 or 499, based on
60 wild-type HSP60 beta subunit from Sulfolobus shibatae.
Linker Sequences
The modified chaperonin polypeptides also comprise the
naturally-occurring N- and C-terminal ends linked directly
together or linked with an intervening linker sequence. The
65 intervening linker does not interfere with the ability of the
modified chaperonin polypeptide to fold and assemble into
double-ringed chaperonin structures. In the modified chap-
US 7,795,388 B2
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eronin polypeptide, the intervening linker can maintain the
same or similar spatial organization or distance as that found
in a folded wild type chaperonin polypeptide. The intervening
linker can be a flexible or helical linker sequence (Arai, et al.,
2001 Protein Engineering 14:529-532; Waldo, et al., 1999 5
Nature Biotechnology 17:691-695). The intervening linker
sequence comprises between 1 to about 10 amino acid resi-
dues or derivatives thereof. The intervening linker sequence
comprises amino acid residues such as glycine, serine, ala-
nine and/or threonine, or derivatives thereof, in any combi- io
nation and in any order. In principle, the linker sequence can
include any amino acid residue, however, large and/or hydro-
phobic residues are more likely to cause problems. In one
embodiment, the linker sequence comprises the amino acid
sequence Gly-Gly-Ser-Gly-Gly-Thr (SEQ ID NO:64). In 15
another embodiment, the modified chaperonin polypeptide
comprises an additional linker sequence. For example, the
chaperonin-EYFP fusion protein which is modified at posi-
tion 267 comprises an additional linker comprising the
sequence Gly-Ser-Gly-Gly-Ser-Gly (SEQ ID NO:83) which 20
joins the yellow fluorescent protein to the chaperonin protein
(FIG. 26B). In another example, the chaperonin-EYFP fusion
protein which is modified at position 480 comprises an addi-
tional linker comprising the sequence Gly-Ser-Gly-Gly-Ser-
Gly-Ser-Gly (SEQ ID NO:84) which joins the yellow fluo- 25
rescent protein to the chaperonin protein (FIG. 27B).
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-continued
ASSSRSHFGQTD (SEQ ID NO: 19)
WAHAPQLASSST (SEQ ID NG:20)
ARYDLSIPSSES (SEQ ID NO: 21)
TPPRPIQYNHTS (SEQ ID NO: 22)
SSLQLPENSFPH (SEQ ID NO: 23)
GTLANQQIFLSS (SEQ ID NO: 24)
HGNPLPMTPFPG (SEQ ID NO: 25)
RLELAIPLQGSG (SEQ ID NO: 26)
Whaley et al. also describes amino-acid sequences that
bind silicon and not silicon dioxide. An example of an amino-
acid sequence that binds to ZnS(IO2) (Lee et al., 2002 Science
296: 892-895) is:
CNNPMHQNC	 (SEQ ID NO: 27)
Joined or Bound Molecules A list of partial amino-acid sequences from clones that
In one embodiment, the modified chaperonin polypeptides bind to Ag (Naik et al., 2002 Nature Materials 1: 169-172)
comprise relocated N- 	 and C-terminal ends that are 30 includes:
covalently joined with an organic molecule, or an inorganic
molecule or compound.
In a different embodiment, the modified chaperonin AYSSGAPPMPPF	 (SEQ ID NO: 28)
polypeptides comprise relocated N- and C-terminal ends that
bind non-covalently with an organic molecule, or an inor- 35
NPSSLFRYLPSD	 SEQ ID NO: 29)
ganic molecule or compound. SLATQPPRTPPV	 (SEQ ID NO: 30)
The organic molecule or inorganic molecule/compound is
joinedorboundto the modified polypeptide in suchawaythat A list of partial amino acid sequences from clones that bind
it does not disrupt the structure of the modified polypeptide. to An (Brown et al., 2000 J. Mol. Biol. 299, 725-735; Brown,
The modified polypeptide can fold into a structure that 40 S., 1997,Nature Biotechnol. 15, 269-272) includes:
resembles a wild-type folded chaperonin subunit polypep-
tide. The folded modified polypeptide can self-assemble into
a double-ringed chaperonin structure. The assembled chap- MHGKTQATSGTIQS	 (SEQ.	 ID. NO:	 31)
eronin structure can be organized into nanodevices or coat-
ings.	 45 ALVPTAHRLDGNMH	 (SEQ.	 ID. NO:	 32)
The organic molecule can be a second polypeptide mol- Further examples of peptide sequences that bind inorganic
ecule, including but not limited to a: protein; peptide frag-
ment; reporter molecule; metal-binding peptide; enzyme; molecules or compounds have been discovered using bacte-
hormone; growth factor; trophic factor; antibody; antigen; rial cell surface or phage display procedures, as reviewed by
receptor; toxin; fluorescent protein; or luminescent protein. 	 50 Sarikaya (2003 Nature Materials 2:577-7585).
The second polypeptide can be from any organism includ- A list of amino acid sequences from clones that bind to An
ing bacterial, viral, mammalian (e.g., bovine, porcine, (Sarikaya, et al., 2003 Nature Materials 2:577-585) includes:
murine, equine, canine, feline, monkey, ape, ovine or human),
piscine, avian or insect.
The second polypeptide includes metal-binding peptide 55 SKTSLGQSGASLQGSEKLTNG	 (SEQ ID NO: 40)
sequences that bind selectively to specific faces of gallium QATSEKLVRGMEGASLHPAKT	 (SEQ ID NO: 41)
arsenide, silicon or indium phosphide. An exemplary, non-
limiting list of partial amino-acid sequences from clones that A list of amino acid sequences from clones that bind to Pt
bind to different surfaces of GaAs and/or InP (Whaley et al., (Sarikaya, et al., 2003 Nature Materials 2:577-585) includes:2000 Nature 405: 665-668) includes: 	 60
DRTSTWR	 (SEQ ID NO: 42)
VTSPDSTTGAMA	 (SEQ ID NO: 16)
QSVTSTK	 (SEQ ID NO: 43)
AASPTQSMSQAP	 (SEQ ID NO: 17)
65	 SSSHLNK	 (SEQ ID NO: 44)
AQNPSDNNTHTH	 (SEQ ID NO: 18)
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	A list of amino acid sequences from clones that bind to Pd 	 A list of an amino acid sequences from clones that bind to
	
(Sarikaya, et al., 2003 Nature Materials 2:577-585) includes: 	 ZnS (Sarikaya, et al., 2003 Nature Materials 2:577-585)
includes:
SVTQNKY	 (SEQ ID NO: 45)
N
SPHPGPY	 (SEQ ID NO: 46)	 NPMHQN	 (SEQ ID NO: 63)
HAPTPML	 (SEQ ID NO:	 47) The second polypeptide includes a reporter molecule, such
as yellow fluorescent protein (EYFP) (SEQ M NO: 91), green
A list of amino acid sequences from clones that bind to 10 fluorescent protein (GFP), red fluorescent protein (RFP), DS
S'02 (Sarikaya, et al., 2003 Nature Materials 2:577-585) red from coral, auto-fluorescent proteins including blue fluo-
includes: rescent protein (BFP), cerulean fluorescent protein (CFP),
luciferase, glutathione-S-transferase (GST), horseradish per-
MSPHPHPRHHHT	 (SEQ ID NO: 48) oxidase (HRP), chloramphemcol acetyltransferase (CAT)
15 beta-galactosidase, beta-glucuronidase, and any derivatives
RGRRRRLSCRLL	 (SEQ ID NO: 49) of these reporter molecules (Labas, 2002 Proc NatlAcad Sci
USA 99:4256-4261; Shaner 2004 Nature Biotechnology
KPSHHHHHTGAN	 (SEQ ID NO: 50)
22:1567-1572; Patterson 2001 Cell Science 114: 837-838;
A list of amino acid sequences from clones that bind to Wei Wen Su 2005 Microbiol Cell Factories 4:12; Rizzo 2004
zeolites (Sarikaya, et al., 2003 Nature Materials 2:577-585) 20 Nature Biotechnology 22:445-449; Griesbeck 2001 Journal
includes: Biological Chemistry 276:29188-29194).
The second polypeptide includes an epitope tag, such as
VKTQATSREEPPRLPSKHRPG 	 ( SEQ ID NO: 51) histidine (His) tags, or V5 tags, FLAG tags, influenza hemag-
25 glutinin (HA) tags, Myc tags, VSV-G tags, or thioredoxin
MDHGKYRQKQATPG	 ( SEQ ID NO: 52) (Trx) tags. The tagged-fusion molecules are useful for facili-
A list of amino acid sequences from clones that bind to tating isolation and/or purification of the modified chaperonin
ZnO (Sarikaya, et al., 2003 Nature Materials 2:577-585) polypeptides (Marshak, D. R., et al., 1996 in: "Strategies for
includes: Protein Purification and Characterization" pp 396).
30	 The second polypeptide can include maltose binding pro-
tein (MBP), S-tag, Lex A DNA binding domain (DBD)
NTRMTARQHRSANHKSTQRA	 (SEQ ID NO: 53) fusions, GAL4 DNA binding domain fusions, and herpes
YDSRSMRPH	 (SEQ ID NO:	 54) simplex virus(HSV) BPI  protein.
35	 The second polypeptide can be engineered to include aA list of amino acid sequences from clones that bind to cleavage site located between the modified chaperonin
CaCO3 (Sarikaya, et al., 2003 Nature Materials 2:577-585) polypeptide and the second polypeptide so that the modified
includes: chaperonin polypeptide can be cleaved and purified away
from the second polypeptide. The cleavage site can include
40 recognition sequences for the following enzymes: enteroki-HTQNMRMYEPWF	 (SEQ ID NO: 55) nase,	 corin,	 MT-SP/matryptase, 	 trypsin,	 chymotrypsin,
DVFSSFNLKHMR	 (SEQ ID NO: 56) human airway trypsin-like protease (HAT), mast cell
tryptase, elastase, plasmin, kallikrein, TMPRSS2, MBL-as-
A list of amino acid sequences from clones that bind to sociated serine proteases (MASP-I and MASP-2), Stubble-
Cr203 (Sarikaya, et al., 2003 Nature Materials 2:577-585) stubbloid, furin, thrombin or factor Xa.
includes:
45
The organic molecule can be a nucleic acid molecule,
including but not limited to: DNA; RNA; DNA/RNAhybrids;
or derivatized nucleic acid molecules. The organic molecule
WRPKAATN	 (SEQ ID NO:	 57)
can be a lipid or a carbohydrate.
RIRHRLVGQ	 (SEQ ID NO:	 58) 50	 The inorganic molecule or compound is a nanoparticle
A list of an amino acid sequence from clones that bind to which includes: gallium arsenide; silicon; silicon dioxide;
Fe201 (Sarikaya, et al., 2003 Nature Materials 2:577-585) indium phosphide; ZnS; gold; silver; CdSe 	 ZnS; CdS;
includes: CdSe; InP; InGaAs; CuCl; InAs quantum dots; silicon nanoc-
rystals and nanopyramids; silver nanoparticles; magnetic
55 quantum dots (e.g., nanomagnets, such as CoCu, FeCu, NiFe/
RRTVKHHVN	 (SEQ ID NO: 59) Ag, and CoAg); transition metals (e.g., gold, silver, zinc,
cadmium, platinum, palladium, cobalt, mercury or nickel);
A list of amino acid sequences from clones that bind to alkali or alkaline earth metals (e.g., sodium, potassium, cal-
GaAs (Sarikaya, et al., 2003 Nature Materials 2:577-585) cium or cesium); group III elements (e.g., aluminum, gallium
includes: 60 or indium); group IV elements (e.g., silicon, germanium, tin
or lead); group V elements (e.g., phosphorous, arsenic, anti-
mony, or bismuth); or group VI elements (e.g., sulfur, sele-
AQNPSDNNTTH	 (SEQ ID NO: 60) nium or tellurium). The inorganic molecules or compounds
RLELAIPLQGSG	 (SEQ ID NO: 61) also include any given combination, such as 111-V compounds
65 like GaAs or A1GaAs. The inorganic molecules or com-
TPPRPIQYNHTS	 (SEQ ID NO: 62) pounds also include: a fullerene; a carbon nanotube; or a
dielectric, polymeric, or semiconducting nanoparticle.
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Amino Acid Analogs and Altered Polypeptides
The present invention further provides modified chapero-
nin polypeptides, or fragments or derivatives thereof, com-
prising amino acid analogs. The amino acid analogs can be
chemically synthesized, and include dextro or levo forms, or
peptidomimetics.
The modified chaperonin polypeptides can include any
combination of amino acids from natural and/or or non-natu-
ral sources. The amino acid residues can include L-amino
acids and/or D-amino acids. The amino acid residues can
include rare amino acids such as 4-hydroxyproline or
hydroxylysine. The amino acid can include organic acids or
amides. The amino acid can include derivatives of common
amino acids, such as amino acids having the C-terminal car-
boxylate esterified (e.g., benzyl, methyl or ethyl ester) or
amidated and/or having modifications of the N-terminal
amino group (e.g., acetylation or alkoxycarbonylation). The
amino acids can include side-chain modifications and/or sub-
stitutions (e.g., methylation, benzylation, t-butylation, tosy-
lation, alkoxycarbonylation, and the like). The amino acids
can include derivatives having an N-acetyl group such that the
amino group that represents the N-terminus of the linear
peptide prior to cyclization is acetylated, and/or a C-terminal
amide group (i.e., the carboxy terminus of the linear peptide
prior to cyclization is amidated). The amino acids can
include, but are not limited to, penicillamine, beta-beta-tet-
ramethylene cysteine, beta-beta-pentamethylene cysteine,
beta-mercaptopropionic acid, beta-beta-pentamethylene-
beta-mercaptopropionic acid, 2-mercaptobenzene, 2-mer-
captoaniline, 2-mercaptoproline, omithine, diaminobutyric
acid, alpha-aminoadipic acid, m-aminomethylbenzoic acid,
and alpha-beta-diaminopropionic acid.
The present invention also provides modified chaperonin
polypeptides which are altered, for example, by post-transla-
tional pathways or by chemical synthesis, including N- or
O-glycosylated amino acid residues. The N-terminal end of
the polypeptides can be altered to include acylated or alky-
lated residues. The C-terminal end of the polypeptides can be
altered to include esterified or amidated residues. The non-
terminal amino acid residues can be altered, including but not
limited to, alterations of the amino acids, arginine, aspartic
acid, asparagine, proline, glutamic acid, lysine, serine, threo-
nine, tyrosine, histidine, and cysteine.
Sequence Variants
The present invention provides modified chaperonin
polypeptides, or fragments or derivatives thereof, comprising
sequence variations of any naturally-occurring chaperonin
polypeptide (FIG. 2A-R, 15, 16, or 2813). As persons skilled
in the art understand, any number of amino acids can be
varied alone, or in combination with other amino acids and
yet the modified chaperonin polypeptides will retain their
functional activity (e.g., folding into a subunit structure that
self-assembles into a double-ringed chaperonin structure).
Sequence variants of the modified chaperonin polypeptides
include: amino acid substitutions, amino acid insertions,
amino acid deletions, mutant forms, allelic forms, and
homologs.
The sequence variants also includes chaperonin polypep-
tides from naturally-occurring or laboratory strains, where
the amino acid sequence of the chaperonin polypeptide dif-
fers from that of any of the Group I or II chaperonin polypep-
tides disclosed herein (see also FIGS. 2A-R, 15, 16 and
21-29)
Amino Acid Substitutions
The modified chaperonin polypeptides, or fragments or
derivatives thereof, can include amino acid substitutions,
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including conservative and/or non-conservative amino acid
substitutions. Guidance in determining which and how many
amino acid residues can be substituted in the modified chap-
eronin polypeptides can be found in the properties of a natu-
5 rally-occurring, chaperonin polypeptide. These properties
include the amino acid length, the physical length, the folded
conformation, or the ability to self-assemble into a chapero-
nin. These properties can be derived by prediction (e.g., based
on amino acid sequence) and/or experiment (e.g., based on
to X-ray crystallography or transmission electron microscopy
(TEM)). The substituted amino acids are selected so that the
properties of the variant, modified chaperonin polypeptides is
identical or similar to that of a naturally-occurring chaperonin
15 subunit polypeptides. In one embodiment, the modified chap-
eronin polypeptides comprise a cysteine substituted with
another amino acid. For example the cysteine at position 258
is substituted with alanine, as shown in FIG. 28B.
Mutant Forms
20 The present invention also provides modified chaperonin
polypeptides, or fragments or derivatives thereof, having a
mutation. The mutant variant has an amino sequence that
differs from that of the wild-type, naturally-occurring chap-
25 eronin polypeptide. The mutations include amino acid sub-
stitutions, deletions, insertions, additions, truncations, orpro-
cessing or cleavage errors of the protein. The mutant variants
can have the same or similar functional activity of a wild-type
chaperonin polypeptide.
30 In one embodiment, the modified chaperonin polypeptides
comprise deletions of up to 10, 20, 30, 40, 50, 60 or 70 amino
acids from the N- or C-terminal end. In another embodiment,
the modified chaperonin polypeptides comprise additional
deleted amino acids. For example, a "dwarf' modified chap-
35 eronin polypeptide (modified at position 267) comprises an
additional 52 amino acids deleted from the N-terminal end of
(e.g., FIG. 2913) compared to the 267 `non-dwarf' modified
polypeptide (FIG. 2213). These deletion variants retain the
ability to fold and assemble into double-ringed chaperonin
40 structures. FIG. 29A shows the corresponding DNA
sequence.
Designing Modified Chaperonin Polypeptides
The present invention provides methods for producing
45 modified chaperonin polypeptides through selective mutation
of the polypeptide, and then exploiting the ability of these
variants to self-assemble into higher-order structures under
various conditions for forming the compositions and devices,
e.g., nanotemplates, nanostructures, nanoarrays and nanode-
50 vices, of the invention.
The compositions and devices of the invention, e.g., the
nanotemplates, nanostructures, nanoarrays and nanodevices
of the invention, comprise, unless otherwise indicated, at least
one mutant chaperonin, which comprises at least one mutant
55 chaperonin polypeptide. Non-limiting examples of mutant
chaperonins and mutant chaperonin polypeptides that can be
utilized as part of the methods and compositions of the
present invention are described herein.
In referring to mutant chaperonins and mutant chaperonin
60 polypeptides, the term "mutant" refers to a difference relative
to what is considered a wild-type sequence. Representative,
non-limiting examples of wild-type chaperonin polypeptide
sequences are presented in FIGS. 2A-2R. Generally, a mutant
chaperonin sequence refers to a sequence that does not occur
65 in nature at a greater than 10% (±10%) allelic frequency, as
measured by standard methods and available data. For





polypeptide is one that is expressed by an allele that is present	 In general, the chaperonin subunits have many regions that
in the organism at no greater than 10% (±10%) allelic fre- 	 can accommodate relocated N- and C-terminal ends in each
quency.	 of their three domains-equatorial, intermediate, and apical
It is appreciated by those skilled in the art that the sequence 	 domains, as illustrated in FIG. 3. FIG. 4 shows the detailed
and three dimensional structural similarities between chaper- 5 structure of a Group II chaperonin subunit that can be used in
onins and chaperonin polypeptides from different organisms 	 selecting the relocated terminal positions.
can be used as a guide to utilize any chaperonin polypeptide	 Other modified chaperonin polypeptides have been previ-
to produce the modified chaperonin polypeptides and 	 ously described. These modified chaperonin polypeptides
assembled structures of the present invention. The sequence	 comprise mutations having single cysteine residues placed at
and three dimensional structural similarity of the subunits io various solvent-exposed sites on the polypeptide. The thiol
among the different types of chaperoning, which is illustrated 	 moiety of these cysteine residues provides binding sites for
by the sequence alignment depicted in FIGS. 2A-2R and the	 soft metals (see PCT/US02/35889). These mutations also
structural overlap as illustrated in a representative compari- 	 change the dimensions of the resulting chaperonin subunit,
son depicted in FIG. 3, provides the basis for the production	 such as length, inner pore diameter, outer diameter, and the
of the modified chaperonin polypeptides and assembled 15 like. The mutant chaperonin polypeptides described in PCT/
chaperonins of the invention.	 US02/35889 can be used as a guide to select the positions of
Further, the details of the structure of chaperonins can be 	 the relocated N- and C-terminal ends in the modified chap-
solved at atomic-resolution (2.3-2.8 A) (See, e.g., FIG. 1, and 	 eronin polypeptides of the present invention. The modified
Xu, Z. et al., 1997 Nature 388: 741-750; and Ditzel, L., J. 	 chaperonin polypeptides of the present invention can use any
Lowe, et al., 1998 Cell 93: 125-138). This provides detailed 20 of the mutant chaperonin polypeptides described in PCT/
information about the location of every atom of every amino	 US02/35889 as a basis, and relocate the N- and C-terminal
acid in the double ring structure (e.g., FIG. 4), and canbe used	 ends therein.
to routinely select positions for modification and can rou-	 The choice of mutation may also depend on the desired
tinely assess the properties of the modified chaperoning. 	 structure for the different applications of the present inven-
Utilizing the sequence and three dimensional structural 25 tion, including the formation of nanotemplates, nanostruc-
similarities among chaperonins and chaperonin polypeptides,	 tures, nanoarrays and nanodevices.
as well as the ability to solve at atomic-resolution the struc- 	 The choice of mutations to make depends on the desired
ture of particular chaperonins and chaperonin polypeptides, 	 structure of the resulting chaperonin, and can routinely be
the structure of the chaperonin polypeptides can be manipu-	 ascertained. In a specific embodiment, the mutated chapero-
lated to influence, for example, their folding, assembly, 3o nin polypeptide subunits include ones that assemble into
strength, and binding properties, as well as the assembly,	 higher order structures with less than seven subunits per ring
strength and binding properties of the resulting chaperoning. 	 or more than nine subunits per ring, such as six to 10 subunits
Such structural similarities can be utilized in a number of 	 per ring. Mutations can be made to the subunit sequence such
different ways in designing appropriate mutants. For 	 that the resulting subunit variants assemble into a structure
example, a mutant in one species that exhibits a desirable 35 with any number of subunits per ring. Mutations introduced
characteristic can be introduced into a corresponding position 	 that that change in number of subunits per ring can, for
in another chaperonin by utilizing the sequence similarity 	 example, be used to modify the diameter of a resulting ring
and/or the three dimensional structural similarity between the 	 nanostructure.
chaperoning. In one such embodiment, for example, the 	 Factors that affect the choice of which chaperonin polypep-
mutant S. shibatae sequences successfully utilized in the 40 tides to manipulate (e.g., from what species, which sub-
examples presented below can routinely be introduced into 	 unit(s), etc.), and what mutations are to be made to them,
other chaperonin polypeptides by these techniques. 	 include the desired dimensions, i.e., length, pore diameter,
Standard methods well known in the art which allow 	 and outer diameter, of the resulting chaperonin product, or
changing specific amino acids in chaperonin polypeptides, 	 introduction of a selective binding site anywhere on the
such as the method of site-directed mutagenesis, regions of 45 polypeptide. The subunits of both Group I and Group II
the subunits can be modified, and the resulting chaperonin	 chaperonins will tolerate a point mutation at almost any posi-
polypeptides can routinely be tested for their ability to pro- 	 tion. When sequence alignments are used in determining
duce chaperonins and, for example, nanotemplates, nano- 	 mutation positions, mutations at similar, non-identical resi-
structures, nanoarrays and nanodevices, e.g., their ability to 	 dues, as determined by sequence alignment, being preferred,
assemble into tubes and filaments or two-dimensional crys-  5o and non-conserved positions, as determined by sequence
tals can be tested. In one embodiment, for example, amino 	 alignment being more preferred. When three dimensional
acid tails can be attached to chaperonin polypeptide subunits 	 structural alignments are used in determining mutation posi-
that do not inhibit their ability to assemble into rings and	 tions, a structural alignment of chaperonin subunits, such as
tubes, and that allow the binding of various nanoscale mate- 	 that of FIG. 3, can serve as a guide in deciding where on the
rials, such as metals, at various locations of the chaperonins, 55 subunit to perform the mutation. The loops and turns from the
including inside the chaperonin structure. In one embodi- 	 two structures that do not directly superimpose can be choices
ment, one of the three HSP60 subunits (beta) from Sulfolobus	 of points to perform mutations, including deletions and inser-
shibatae, an organism that lives in geothermal hot-springs 	 tions. The amino acid sequence alignment of various chaper-
and grows at temperatures of up to 85° C./pH 2.0 is used to	 onins can also be used in determining the mutation positions.
form mutant chaperonins. The chaperonins in S. shibatae are 6o For example, FIG. 15 depicts sequence alignment of TF55
octadecameric with nine subunits per ring. FIG. 15 shows the	 alpha, beta and gamma subunits from S. shibatae. In the
protein sequence alignment of S. shibatae TF55 alpha subunit 	 modified chaperonin polypeptides of the present invention,
(SEQID NO: 39), beta subunit (SEQID NO: 1) and gamma 	 the N- and C-terminal ends can be relocated to any position
subunit (SEQ ID NO: 38). The beta subunit can be chosen for 	 1-560 for TF55 alpha subunit, position 1-552 for TF55 beta
a particular application based on such factors as its thenno- 65 subunit, or position 1-535 for TF55 gamma subunit (FIG. 15).
stability, which makes it easy to purify as a recombinant 	 In one embodiment, a choice of deletion of the amino acid
protein, and its propensity to form desirable structures.	 loop at the apical domain of a group II chaperonin is made
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through comparison of the structural alignment of FIG. 3, and
with the observation that the loopless group I chaperonin
subunit assembles into the double-ring structure of the chap-
eronin. In another embodiment, the N- or C-terminus is
removed. In yet another embodiment, the N- or C-terminus is
modified by inserting a sequence. The sequence can be
inserted for binding specificity, such as by introducing cys-
teine or tyrosine which can be modified chemically.
In one embodiment, the mutant chaperonin comprises one
more mutated chaperonin polypeptide sequences with one or
more point mutations. An exemplary point mutation in TF55-
beta from Sulfolobus shibatae results from residue 298 being
changed from cysteine to alanine and residue 270 changed
from glutamine to cysteine (see PCT/US02/35889). In
another embodiment, the mutant chaperonin comprises one
more mutated chaperonin polypeptide sequences with one or
more sequences deleted. An exemplary deletion in TF55-beta
results from Sulfolobus shibatae with residues 254 to 281
deleted (see PCT/US02/35889). In another embodiment, the
mutant chaperonin comprises one or more mutated chapero-
nin polypeptide sequences with one or more polypeptide
sequences inserted. An exemplary insertion in TF55-beta
results from Sulfolobus shibatae with peptides that possess
binding specificity inserted. As discussed above, correspond-
ing mutations can be routinely introduced into any other
chaperonin polypeptide.
In another embodiment, the peptides are designed to bind
nanoscale materials such as nanoparticles and quantum dots.
In yet another embodiment, the peptides are designed to bind
only to specific surfaces. Still other modifications can also be
made in the equatorial domains that include deletions, sub-
stitutions and additions to the N- and C-termini with little
effect on the formation of chaperonins or nanotemplates such
as filaments. For example, up to about 5, 10, 15, 20, 25, or 30
amino acids of the N- and/or C-terminus of the chaperonin
polypeptide can be modified, e.g., deleted. For example,
GroEL can be modified by removing up to about 27 amino
acids from the C-terminus without impairing its ability to
assemble into double rings.
Additional references that describe possible mutations of
specific residues of the polypeptides are contained in the
review article by Fenton (1997 Protein Science 6: 743-760).
The sequence alignment of FIGS. 2A-2R indicates that the
regions that have been manipulated in S. shibatae also exist in
other species. Whatever mutations have been successfully
made in one species may be successfully others species,
whether bacterial, other archea or eukarya. The correspond-
ing regions of the sequence alignments can therefore serve as
a guide in choice of manipulations to produce variants in
other species, combined with the knowledge of the region of
the chaperonin subunit that the given mutated sequence is
located. A successful mutation of the chaperonin polypeptide
from any given species is indicated if the mutated chaperonin
polypeptide retains its ability to assemble into the higher
order structures of the invention, including the nanotem-
plates, nanostructures, nanoarrays and nanodevices.
In a specific embodiment, guided by structural informa-
tion, the beta subunit of Sulfolobus shibatae is genetically
modified to add chemically reactive sites without destroying
its ability to assemble into chaperonins and 2D crystals.
While a detailed three-dimensional structure of S. shibatae
beta is not known, X-ray structures for homologous chapero-
nin subunits are known (See, e.g., Xu et al. And Diztel et al.,
supra.). Detailed transmission electron microscopic (TEM)
analyses of S. shibatae chaperonins have also been reported
(Trent et al., 1997 Proc. Nat. Acad. Sci 94: 5383-5388). Using
X-ray structures of homologous subunits and TEM analyses
of Sulfolobus chaperonins, a hypothetical three-dimensional
model for the beta chaperon can be produced, and used to
guide genetic manipulations (See, e.g., Peitsch, M. C., 1995
Bio/Technology 13: 658; Guex, N., Peitsch, M. C., 1997
5 Electrophoresis 18: 2714; Guex, N., Diemand, A., Peitsch, M.
C., 1999 TiBS 24: 364). At least two classes of beta mutants
can be created using site-directed mutagenesis, many of
which retain their ability to assemble into chaperonins that
form 2D crystals (FIGS. 7B and 7D).
10 The present invention provides at least five different modi-
fied chaperonin polypeptides which retain the ability to
assemble into chaperonin structures. These modified
polypeptides can be used as a guide to other modified chap-
eronin polypeptides.
15 In two classes of beta mutants of S. shibatae, the single
native cysteine residue in beta can be changed to a nonreac-
tive residue, for example, an alanine residue, e.g., to prevent
potential issues with folding and with assembly of mutant
subunits. A cysteine can then placed at different solvent-
20 exposed sites. The thiols of these cysteines can provide bind-
ing sites for soft metals including gold and zinc (see PCT/
US02/35889). In one class of beta mutants of S. shibatae, the
exposed cysteine is placed near the tip of a 28 amino acid loop
on the apical domain of beta, which in the assembled chap-
25 eronin protrudes into the central cavity. This mutant chapero-
nin has a ring of reactive thiols with a diameter of approxi-
mately 3 nm on both ends (FIG. 7A). In the other class of beta
mutants of S. shibatae, the protruding 28 amino acid loop was
removed and placed the exposed cysteine on the apical
30 domain itself. The mutant chaperonin assembled from this
subunit has a ring of reactive thiols with a diameter of
approximately 9 nm and an open pore into its central cavity
(FIGS. 7D, 7E).
The beta subunit of S. shibatae proves to have sufficient
35 structural plasticity in its apical domain to accommodate both
the amino acid substitutions and deletions can be made with-
out loss of its ability to form chaperonins and 2D crystals.
Under reducing conditions both classes of beta mutants
formed chaperonins that assembled into disk-shaped, hex-
40 agonally packed 2D crystals up to 20 µm in diameter (FIGS.
7B and 7D), the crystalline lattice ordering of which is con-
firmed by fast Fourier transformation (FFT) of the TEM
images FIG. 7D, inset).
With knowledge of the sequences of the group I or group II
45 chaperonin polypeptide, any number of mutations can be
judiciously placed at one or more areas of the apical, inter-
mediate and/or equatorial domains of the chaperonin
polypeptide. As evidenced by the sequence alignment of
FIGS. 2A-213, the regions that have been manipulated in S.
50 shibatae also exist in other species. Whatever mutations work
in one species can be made to work in others. These corre-
sponding regions of the sequence alignments can therefore
serve as a guide in choice of manipulations to produce vari-
ants in other species. Thus, the many different varieties of
55 binding sites that can be placed at different locations on a
chaperonin can be exploited in the formation of the nanotem-
plates, nanostructures, nanoarrays and nanodevices of the
present invention.
60 Nucleic Acid Molecules
The present invention provides various isolated nucleic
acid molecules, or fragments or derivatives thereof, compris-
ing polynucleotide sequences encoding the modified chap-
eronin subunit polypeptides of the present invention. The
65 nucleic acid molecules of the present invention are also
termed "nucleic acid molecules encoding the modified
polypeptides" or "nucleic acid molecules of the present
US 7,795,388 B2
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invention". For example, the polynucleotide sequence of a
nucleic acid molecule encoding the modified chaperonin sub-
unit polypeptide is shown in FIGS. 21A, 22A, 23A, 24A,
25A, 26A, 27A and 29A.
The present invention further provides related polynucle-
otide molecules, such as complementary modified chapero-
nin subunit polypeptides, or a part thereof, and those that
hybridize to the nucleic acid molecules of the invention.
The polynucleotide sequences encoding the modified
chaperonin subunit polypeptides, are preferably in isolated
form, and include, but are not limited to, DNA, RNA, DNA/
RNA hybrids, and related molecules, and fragments thereof.
Specifically contemplated are genomic DNA, cDNA,
ribozymes, and antisense RNA or DNA molecules, as well as
nucleic acids molecules based on an alternative backbone or
including alternative bases, whether derived from natural
sources or synthesized.
In accordance with the practice of the invention, the nucleic
acid molecules of the invention can be isolated full-length or
partial length molecules. The nucleotide sequence of the
invention can encode all or portions of the modified chapero-
nin subunit polypeptides of the invention.
Isolated Nucleic Acid Molecules
The nucleic acid molecules of the invention are preferably
in isolated form, where the nucleic acid molecules are sub-
stantially separated from contaminant nucleic acid molecules
having sequences other than modified chaperonin subunit
sequences. A skilled artisan can readily employ nucleic acid
isolation procedures to obtain isolated, modified chaperonin
subunit sequences (Sambrook et al., in: "Molecular Cloning"
(1989)). The present invention also provides for isolated
modified chaperonin subunit sequences generated by recom-
binant DNA technology or chemical synthesis methods. The
present invention also provides nucleotide sequences isolated
from various organisms including bacterial, viral, mamma-
lian (e.g., bovine, porcine, murine, equine, canine, feline,
monkey, ape, ovine or human), piscine, avian or insect.
The isolated nucleic acid molecules include DNA, RNA,
DNA/RNA hybrids, and complementary sequences, or a frag-
ment or derivative thereof, and those which hybridize to the
nucleic acid molecules encoding the modified chaperonin
subunit polypeptides. The preferred nucleic acid molecules
have nucleotide sequences identical to or similar to the nucle-
otide sequences disclosed herein. Specifically contemplated
are genomic DNA, RNA e.g., small interfering RNA, cDNA,
ribozymes and antisense molecules.
Linker Sequences
The present invention provides nucleic acid molecules
encoding the modified polypeptides having the naturally-
occurring N- and C-terminal ends linked directly together or
linked with an intervening linker sequence. The nucleic acid
molecule can encode the intervening linker sequence com-
prising 1 to about 10 amino acid residues. The nucleic acid
molecules encode a flexible or helical linker peptide. The
intervening linker sequence comprises amino acid residues
such as glycine, serine, alanine, and/or threonine, or deriva-
tives thereof. In one embodiment, the nucleic acid molecule
encodes a linker sequence comprising the amino acid
sequence Gly-Gly-Ser-Gly-Gly-Thr (SEQ ID NO:64). In
another embodiment, the nucleic acid molecule comprises
the nucleotide sequence GGTGGTTCTGGTGGTACC (SEQ
ID NO: 65) shown as part of the sequences in FIGS. 21A, 22A,
23A, 24A, 25A 26A, 27A and 29A.
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The Second Polypeptide Sequences
The present invention provides nucleic acid molecules
encoding the modified polypeptides joined with a second
polypeptide sequence. The modified chaperonin subunit
5 sequence is operatively joined, in-frame, to the second
polypeptide sequence.
The nucleotide sequence encoding the second polypeptide
can encode a: protein; peptide fragment; reporter molecule;
metal-binding peptide; enzyme; hormone; growth factor;
to trophic factor; antibody; receptor; toxin; fluorescent protein;
luminescent protein; or metal-binding peptide. These second
polypeptides are described above.
Sequence Identity and Similarity
15 The present invention provides isolated nucleic acid mol-
ecules having a polynucleotide sequence identical or similar
to the modified chaperonin subunit sequences disclosed
herein.
One embodiment of the invention provides nucleic acid
20 molecules that exhibit sequence identity or similarity with the
modified chaperonin subunit nucleotide sequences, such as
molecules that have at least 60% to 99.9% sequence similarity
and up to 100% sequence identity with the sequences of the
invention as shown in FIG. 21A, 22A, 23A, 24A, 25A, 26A,
25 27A, or 29A. Another embodiment provides nucleic acid
molecules that exhibitbetween about 75% to 99.9% sequence
similarity, and another embodiment provides molecules that
have between about 86% to 99.9% sequence similarity. Yet
another embodiment provides molecules that have 100%
30 sequence identity with the modified chaperonin subunit
sequences of the invention as shown in FIG. 21A, 22A, 23A,
24A, 25A, 26A, 27A, or 29A.
Complementary Nucleotide Sequences
The present invention also provides nucleic acid molecules
35 that are complementary to the sequences as described in FIG.
21A, 22A, 23A, 24A, 25A, 26A, 27A, or 29A. Complemen-
tarity can be full or partial. A nucleotide sequence that is fully
complementary is complementary to the entire modified
chaperonin subunit sequence as described in any one of FIG.
40 21A, 22A, 23A, 24A, 25A, 26A, 27A, or 29A. A nucleotide
sequence that is partially complementary is complementary
to only a portion of sequences as described in any one of FIG.
21A, 22A, 23A, 24A, 25A, 26A, 27A, or 29A. The comple-
mentary molecules include anti-sense nucleic acid mol-
45 ecules.
Hybridizing Nucleic Acid Molecules
The present invention further provides nucleic acid mol-
ecules having polynucleotide sequences that selectively
5o hybridize to the nucleotide sequence of the invention as
shown in any one of FIG. 21A, 22A, 23A, 24A, 25A, 26A,
27A, or 29A. The nucleic acid molecules that hybridize can
hybridize under high stringency hybridization conditions.
Typically, hybridization under standard high stringency con-
55 ditions will occur between two complementary nucleic acid
molecules that differ in sequence complementarity by about
70% to about 100%. It is readily apparent to one skilled in the
art that the high stringency hybridization between nucleic
acid molecules depends upon, for example, the degree of
60 identity, the stringency of hybridization, and the length of
hybridizing strands. The methods and formulas for conduct-
ing high stringency hybridizations are well known in the art
(Sambrook, et al., in: "Molecular Cloning" (1989)).
In general, stringent hybridization conditions are those
65 that: (1) employ low ionic strength and high temperature for
washing, for example, 0.015M NaCl/0.0015M sodium cit-





ization a denaturing agent such as formamide, for example,
50% (vol/vol) formamide with 0.1% bovine serum albumin/
0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium
phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM
sodium citrate at 42 degrees C.	 5
Another example of stringent conditions include the use of
50% formamide, 5xSSC (0.75M NaCl, 0.075 M sodium cit-
rate), 50 mM sodium phosphate (pH 6.8), 0.1 % sodium pyro-
phosphate, 5xDenhardt's solution, sonicated salmon sperm
DNA (50 mg/ml), 0.1% SDS, and 10% dextran sulfate at 42 to
degrees C., with washes at 42 degrees C. in 0.2xSSC and
0.1% SDS. A skilled artisan can readily determine and vary
the stringency conditions appropriately to obtain a clear and
detectable hybridization signal.
Nucleic Acid Fragments	 15
The present invention further provides nucleic acid mol-
ecules having fragments of the modified chaperonin subunit
sequences of the invention, such as a portion of the sequences
shown in any one of FIGS. 21A, 22A, 23A, 24A, 25A, 26A, 20
27A, or 29A. The size of the fragment will be determined by
its intended use. For example, if the fragment is chosen to
encode a full-length modified chaperonin subunit polypep-
tide, then the skilled artisan shall select the polynucleotide
fragment that is large enough to encode this polypeptide. If
the fragment is to be used as a nucleic acid probe or PCR 25
primer, then the fragment length is chosen to obtain a rela-
tively small number of false positives during a probing or
priming procedure.
The nucleic acid molecules, fragments thereof, and probes
and primers of the present invention are useful for a variety of so
molecular biology techniques including, for example, hybrid-
ization screens of libraries, or detection and quantification of
mRNA transcripts as a means for analysis of gene transcrip-
tion and/or expression. The probes and primers can be DNA, 35
RNA or derivatives of DNA or RNA molecules. A probe or
primer length of at least 15 base pairs is suggested by theo-
retical and practical considerations (Wallace, B. and Miyada,
G. 1987 in: "Oligonucleotide Probes for the Screening of
Recombinant DNA Libraries" in: Methods in Enzymology
152:432-442, Academic Press). 	 40
Fragments of the modified chaperonin nucleotide
sequences that are particularly useful as selective hybridiza-
tion probes or PCR primers can be readily identified from the
modified chaperonin nucleotide sequences, using art-known 45
methods. For example, sets of PCR primers that bind and/or
detect a portion of nucleic acid molecule encoding the modi-
fied chaperonin subunit polypeptides can be made by PCR
methods (described in U.S. Pat. No. 4,965,188). The probes
and primers of this invention can be prepared by methods well 
50known to those skilled in the art (Sambrook, et al. supra). The
probes and primers can be synthesized by chemical synthesis
methods (ed: Gait, M. J. 1984 in: "Oligonucleotide Synthe-
sis", IRL Press, Oxford, England).
One embodiment of the present invention provides nucleic 
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acid primers that are complementary to any of the sequences
shown in FIGS. 21A, 22A, 23A, 24A, 25A, 26A, 27A, or
29A, which allow specific amplification of nucleic acid mol-
ecules of the invention or of any specific portions thereof.
Alternatively, a fragment of the modified chaperonin sub- 60
unit molecule sequence can be used to construct a recombi-
nant fusion gene having the modified chaperonin subunit
sequence fused to a different sequence.
Codon Usage Variants
The present invention provides isolated codon-usage vari- 65
ants that differ from the disclosed modified chaperonin sub-
unit nucleotide sequences, yet do not alter the predicted
polypeptide sequence or biological activity of the encoded
modified chaperonin subunit polypeptide. For example, a
number of amino acids are designated by more than one
triplet codon. Codons that specify the same amino acid can
occur due to degeneracy in the genetic code. Examples
include nucleotide codons CGT, CGG, CGC, and CGA
encoding the amino acid, arginine (R); or codons GAT, and
GAC encoding the amino acid, aspartic acid (D). Thus, a
protein can be encoded by one or more nucleic acid molecules
that differ in their specific nucleotide sequence, but still
encode protein molecules having identical sequences. The




Alanine Ala A GCU, GCC, GCA, GCG
Cysteine Cys C UGU, UGC
AsparticAcid Asp D GAU, GAC
Glutamic Acid Glu E GAA, GAG
Phenylalanine Phe F UUU, UUC
Glycine Gly G GGU, GGC, GGA, GGG
Histidine His H CAU, CAC
Isoleucine Ile I AUU, AUC, AUA
Lysine Lys K AAA, AAG
Leucine Leu L UUA, UUG, CUU, CUC,
CUA, CUG
Methionine Met M AUG
Asparagine Asn N AAU, AAC
Proline Pro P CCU, CCC, CCA, CCG
Glutamine Gln Q CAA, CAG
Arginine Arg R CGU, CGC, CGA, CGG,
AGA,AGG
Serine Ser S UCU, UCC, UCA, UCG,
AGU,AGC
Threonine Thr T ACU, ACC, ACA, ACG
Valine Val V GUU, GUC, GUA, GUG
Tryptophan Trp w UGG
Tyrosine Tyr Y UAU, UAC
The codon-usage variants can be generated by recombi-
nant DNA technology. Codons can be selected to optimize the
level of production of the RNA transcripts encoding the modi-
fied chaperonin subunit polypeptides in a particular prokary-
otic or eukaryotic expression host. Codons can be selected to
extend the half-life or increased stability of the transcript
encoding the modified chaperonin subunit polypeptide. The
present invention provides selecting every possible triplet
codon to generate every possible combination of nucleotide
sequences that encode the modified chaperonin subunit
polypeptides of the present invention. This particular embodi-
ment provides isolated nucleotide sequences that vary from
the sequences as described in described in any one of FIGS.
21A, 22A, 23A, 24A, 25A, 26A, 27A, or 29A, such that each
variant nucleotide sequence encodes a molecule having
sequence identity with the amino acid sequence described in
FIGS. 21B, 22B, 23B, 24B, 25B, 26B, 27B, or 29B.
Variant Nucleotide Sequences
The present invention provides nucleic acid molecules
comprising polynucleotide sequences encoding variant forms
of any of the modified chaperonin subunit polypeptides hav-
ing the same or similar structure to a naturally-occurring,
wild-type chaperonin subunit polypeptide.
The variant nucleotide sequences of the present invention
include conservative or non-conservative amino acid substi-
tutions. The variant nucleotide sequences include mutations
such as amino acid substitutions, deletions, insertions, addi-
tions, truncations, or processing or cleavage errors of the
protein. The variant nucleotide sequences include allelic or
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homolog variants of the naturally-occurring modified chap-
eronin subunit polypeptides. In one embodiment, the variant
nucleic acid molecule, which encodes a modified chaperonin
polypeptide, comprises silent mutations where the nucleotide
sequence in certain regions differs from that of a wild type
sequence but still encodes the same amino acids. The silent
mutations can be useful for suppressing Shine-Dalgarno
sequences when expressed in bacteria.
Derivative Nucleic Acid Molecules
The nucleic acid molecules of the invention also include
derivative nucleic acid molecules which differ from DNA or
RNA molecules, and anti-sense molecules.
Derivative molecules include peptide nucleic acids
(PNAs), and non-nucleic acid molecules including phospho-
rothioate, pho sphotri ester, phosphoramidate, and meth-
ylphosphonate molecules, that bind to single-stranded DNA
or RNA in a base pair-dependent manner (P C Zamecnik, et
al., 1978 Proc. Natl. Acad. Sci. 75:280284; P C Goodchild, et
al., 1986 Proc. Natl. Acad. Sci. 83:4143-4146). Peptide
nucleic acid molecules comprise a nucleic acid oligomer to
which an amino acid residue, such as lysine, and an amino
group have been added. These small molecules, also desig-
nated anti-gene agents, stop transcript elongation by binding
to their complementary (template) strand of nucleic acid (P E
Nielsen, et al., 1993 Anticancer Drug Des 8:53-63). Reviews
of methods for synthesis of DNA, RNA, and their analogues
can be found in: Oligonucleotides and Analogues, eds. F
Eckstein, 1991, IRL Press, New York; Oligonucleotide Syn-
thesis, ed. M J Gait, 1984, IRL Press, Oxford, England. Addi-
tionally, methods for antisense RNA technology are
described in U.S. Pat. Nos. 5,194,428 and 5,110,802. A
skilled artisan can readily obtain these classes of derivative
nucleic acid molecules using the herein described modified
chaperonin polynucleotide sequences, see for example
"Innovative and Perspectives in Solid Phase Synthesis"
(1992) Egholm, et al. pp 325-328 or U.S. Pat. No. 5,539,082.
Labeled Nucleic Acid Molecules
The present invention provides nucleic acid molecules of
the invention linked or labeled with a detectable marker.
Examples of a detectable marker include, but are not limited
to, a radioisotope, a fluorescent compound, a bioluminescent
compound, a chemiluminescent compound, a metal chelator
or an enzyme. Technologies for generating labeled nucleic
acid molecules are well known (Sambrook et al., in Molecular
Cloning (1989)).
Recombinant Nucleic Acid Molecules
The present invention provides recombinant nucleic acid
molecules (e.g., DNA or RNA) comprising nucleotide
sequences encoding the modified chaperonin subunit
polypeptides, or a fragment or derivative thereof, as described
herein. As used herein, a recombinant nucleic acid molecule
has been subjected to molecular manipulation in vitro. Meth-
ods for generating recombinant nucleic acid molecules are
well known in the art (Sambrook et al., Molecular Cloning
(1989)). In one embodiment, the recombinant DNA mol-
ecules of the present invention are operably linked to one or
more expression control sequences and/or vector sequences.
Vectors
The recombinant nucleic acid molecules of the present
invention each comprise the polynucleotide sequence, or
fragments or derivatives thereof, encoding the modified chap-
eronin subunit polypeptides joined to a vector to generate a
recombinant vector molecule.
The term vector includes, but is not limited to, plasmids,
cosmids, BACs, YACs, PACs and phagemids. The vector can
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be an autonomously replicating vector comprising a replicon
that directs the replication of the rDNA within the appropriate
host cell. Alternatively, the vector directs integration of the
recombinant vector into the host cell. Various viral vectors
5 can also be used, such as, for example, a number of well
known retroviral and adenoviral vectors (Berkner 1988 Bio-
techniques 6:616-629).
The vectors of the invention permit expression of the modi-
fied chaperonin subunit polypeptides, or fragments or deriva-
io tives thereof, in prokaryotic or eukaryotic host cells. The
vectors can be expression vectors, comprising an expression
control element, such as a promoter sequence, which enables
transcription of the inserted modified chaperonin subunit
nucleotide sequence and can be used for regulating the
15 expression (e.g., transcription and/or translation) of a linked
modified chaperonin subunit nucleotide sequence in an
appropriate host cell.
The expression control elements can be of various origins,
including naturally-occurring and synthetic. The naturally-
20 occurring elements can be cellular or viral in origin. Expres-
sion control elements are known in the art and include, but are
not limited to, inducible promoters, constitutive promoters,
secretion signals, enhancers, transcription terminators, and
other transcriptional regulatory elements.
25 Other expression control elements that are involved in
translation are known in the art, and include the Shine-Dal-
garno sequence (e.g., prokaryotic host cells), and initiation
and termination codons. Exogenous transcriptional elements
and initiation codons can be of various origins, both natural
3o and synthetic.
The promoters can be inducible which are regulated by
environmental stress (e.g., heat, oxidizing conditions, ortoxic
compounds), environmental stimuli or the growth medium of
the cells (IPTG), including those from the genes for heat
35 shock proteins (e.g., hsp60), alcohol dehydrogenase 2, isocy-
tochrome C, acid phosphatase, enzymes associated with
nitrogen catabolism, and enzymes responsible for maltose
and galactose utilization.
The promoters can be constitutive including yeast beta-
40 factor, alcohol oxidase, cytomegalovirus, and PGH. For
reviews, seeAusubel et al (1987 Current Protocols in Molecu-
lar Biology, John Wiley & Sons, New York N.Y.) and Grant et
al (1987 Methods in Enzymology 153:516-544).
The promoter can be plac (with a laci q on the vector to
45 reduce background expression), which can be regulated by
the addition of isopropylthiogalactoside (IPTG), anotherpro-
moter pT7(D10, which is specific to T7 RNA polymerase and
is not recognized by E. coli RNA polymerase. T7 RNA poly-
merase, which is resistant to rifamycin, is encoded on the
5o defective lambda DE lysogen in the E. coli BL21 chromo-
some. T7 polymerase in BL2I (DE3) is super-repressed by the
laciq gene in the plasmid and is induced and regulated by
IPTG.
The efficiency of transcription can be augmented by the
55 inclusion of enhancers appropriate to the cell system in use
(Scharf, D., et al, 1994 Results Probl. Cell. Differ. 20:125-62;
Bittner, et al., 1987 Methods in Enzymol.153:516-544). Viral
promoters include SV40 early promoter or the promoter
included within the LTR of a retroviral vector. Other viral
60 promoters include the cytomegalovirus promoter (M Boshart,
et al., 1985 Cell 41:521-530).
Commonly used eukaryotic control sequences for use in
expression vectors include promoters and control sequences
compatible with mammalian cells such as, for example, CMV
65 promoter and avian sarcoma virus (ASV) (7cLN vector).
Other commonly used promoters include the early and late
promoters from Simian Virus 40 (SV40) (Fiers, et al., 1973
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Nature 273:113), or other viral promoters such as those
derived from polyoma, Adenovirus 2, and bovine papilloma
virus. An inducible promoter, such as hMTII (Karin, et al.,
1982 Nature 299:797-802) can also be used.
Transcriptional control sequences foryeastvectors include
promoters for the synthesis of glycolytic enzymes (Hess et
al., 1968) J Adv Enzyme Reg. 7:149; Holland et al., 1978
Biochemistry 17:4900). Additional promoters known in the
art include the CMV promoter provided in the CDM8 vector
(Toyama and Okayama 1990 FEBS 268:217-221); the pro-
moter for 3-phosphoglycerate kinase (Hitzeman et al., 1980)
Biol Chem 255:2073), and those for other glycolytic
enzymes.
Specific translation initiation signals can also be required
for efficient translation of a modified chaperonin subunit
polypeptide. These signals include the ATG-initiation codon
and adjacent sequences. The ATG-initiation sequences or
upstream sequences of a naturally-occurring modified chap-
eronin subunit polypeptides can be inserted into the appro-
priate expression vector. Alternatively, a synthetic ATG-ini-
tiation codon and other sequences can be used. The ATG-
initiation codon must be in the correct reading-frame to
ensure translation of the insert sequence.
The expression control elements can be placed at the 3' end
of the coding sequences.
These sequences can act to stabilize messenger RNA. Such
terminators are found in the 3' untranslated region following
the coding sequences in several yeast-derived and mamma-
lian genes.
The expression vector can include at least one selectable
marker gene encoding a gene product that confers drug resis-
tance such as resistance to kanamycin, ampicillin, chloram-
phenicol or tetracycline.
The expression vector can include any marker gene. These
include, but are not limited to, the herpes simplex virus thy-
midine kinase (M Wigler et al., 1977 Cell 11:223-32) and
adenine phosphoribosyltransferase (I Lowy et al., 1980 Cell
22:817-23) genes which can be employed in tk-minus or
aprt-minus cells, respectively. Also, antimetabolite, antibiotic
or herbicide resistance can be used as the basis for selection;
for example, dhfr which confers resistance to methotrexate
(M Wigler et al., 1980 Proc Natl Acad Sci 77:3567-70); npt,
which confers resistance to the aminoglycosides neomycin
and G-418 (F Colbere-Garapin et al., 1981 J. Mol. Biol.
150:1-14) and als or pat, which confer resistance to chlorsul-
furon and phosphinotricin acetyltransferase, respectively (L
E Murry, in: McGraw Yearbook of Science and Technology
(1992) McGraw Hill NewYorkN.Y., pp 191-196). Additional
selectable genes have been described, for example, trpB,
which allows cells to utilize indole in place of tryptophan, or
hisD, which allows cells to utilize histinol in place of histidine
(Hartman, and Mulligan 1988 Proc. Natl. Acad. Sci. 85:8047-
51). Recently, the use of visible markers has gained popular-
ity with such markers as anthocyanins, P-glucuronidase and
its substrate, GUS, and luciferase and its substrate, luciferin,
being widely used not only to identify transformants, but also
to quantify the amount of transient or stable protein expres-
sion attributable to a specific vector system (CA Rhodes et al.,
1995 Methods Mol. Biol. 55:121-131).
The vector also comprises multiple endonuclease restric-
tion sites that enable convenient insertion of exogenous DNA
sequences. Methods for generating a recombinant expression
vector encoding the modified chaperonin subunit polypep-
tides are well known in the art (T Maniatis, et al., 1989
Molecular Cloning, A Laboratory Manual, Cold Spring Har-
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bor Laboratory, Cold Spring Harbor; N.Y.; F Ausubel, et al.
1989 Current Protocols in Molecular Biology, John Wiley &
Sons, New York MY.).
The expression vectors can include expression control ele-
5 ments for expression in bacterial host cells. These expression
control elements can be induced by environmental conditions
such as heat-shock, or by addition of agents such as isopro-
pyl-p-D-thiogalactopyranoside (e.g., IPTG) (N Yamaguchi,
et al. 2002 The J of Biol Chem 277:6806-6812). Prokaryotic
io cell expression vectors are well known in the art and are
available from several commercial sources. For example,
pET19b (Novagen, Madison, Wis.), Superlinker vectors
pSE280 and pSE380 (Invitrogen, San Diego, Calif.), pGEX
vector (Promega, Madison, Wis.), pTrcHisB vector (Invitro-
15 gen), pET vector (e.g., pET-21, Novagen Corp.), BLUE-
SCRIPT phagemid (Stratagene, LaJolla, Calif.), pSPORT
(Gibco BRL, Rockville, Md.), orptrp-lac hybrids can be used
to express the modified chaperonin subunit polypeptides in
bacterial host cells.
20 The expression vectors used for generating modified chap-
eronin subunit polypeptides can be compatible with eukary-
otic host cells. The vectors can be compatible with vertebrate
cells. These vectors can include expression control elements
such as promoters and/or enhancers from mammalian genes
25 or mammalian viruses. Other expression vectors can include
tissue-specific or cell-specific promoters and/or enhancers
from mammalian genes or mammalian viruses.
The expression vectors can be compatible with other
eukaryotic host cells, including insect, plant, or yeast cells.
3o The expression vectors can include expression control ele-
ments, such as the baculovirus polyhedrin promoter for
expression in insect cells. The promoters and/or enhancers
derived from plant cells (e.g., heat shock, RUBISCO, storage
protein genes), viral promoters or leader sequences or from
35 plant viruses can also be used.
Eukaryotic cell expression vectors are well known in the
art and are available from several commercial sources,
including PSVL and pKSV-10 (Pharmacia), pBPV-1/pML2d
(International Biotechnologies, Inc.), pTDTI (ATCC,
40 #31255), and similar eukaryotic expression vectors.
Examples of expression vectors for eukaryotic host cells
include, but are not limited to, vectors for mammalian host
cells including: BPV-1; pHyg; pRSV; pSV2; pTK2 (Mania-
tis); pIRES (Clontech); pRc/CMV2; pRc/RSV; pSFVI (Life
45 Technologies); pVPakc Vectors; pCMV vectors; pSG5 vec-
tors (Stratagene); retroviral vectors (e.g., pFB vectors (Strat-
agene)); pCDNA-3 (Invitrogen) or modified forms thereof,
adenoviral vectors; Adeno-associated virus vectors; bacu-
lovirus vectors. Other expression vectors for eukaryotic host
50 cells include pESC vectors (Stratagene) for yeast and pFast-
Bac for expression in insect cells (Gibco/BRL, Rockville,
Md.).
Host-Vector Systems
The present invention further provides a host-vector sys-
55 tem comprising a vector comprising a modified chaperonin
subunit nucleotide sequence, or a fragment or derivative
thereof, introduced into a suitable host cell.
The host-vector system can be used to transcribe and/or
60 express (e.g., produce) the modified chaperonin subunit
polypeptides of the invention. The host cell can be either
prokaryotic or eukaryotic.
Prokaryotic Host Cells
Examples of suitable prokaryotic host cells include bacte-
65 ria strains from genera such as Escherichia, Bacillus,
Pseudomonas, Streptococcus, and Streptomyces. In one
embodiment, E. coli strain BL21(DE3) and BL21(DE3/
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pLysS) (Novagen, Madison, Wis.), although other compat-
iblerecA strains, such as HMS174(DE3) and HMS174(DE3/
pLysS) can be used.
Inbacterial systems, a number of expression vectors canbe
selected depending upon the use intended for the modified
chaperonin subunit polypeptides. For example, when large
quantities of the modified chaperonin subunit polypeptides
are desired, vectors that direct high level expression of fusion
proteins that are soluble and readily purified can be desirable.
Such vectors include, but are not limited to, the multifunc-
tional E. coli cloning and expression vectors such as BLUE-
SCRIPT (Stratagene), in which the modified chaperonin sub-
unit nucleotide sequence can be ligated into the vector
in-frame with sequences for the amino-terminal Met and the
subsequent 7 residues of galactosidase so that a hybridprotein
is produced. Other vectors include the pET19b (Novagen),
pIN vectors (Van Heeke & Schuster 1989 J Biol Chem 264:
5503-5509), and the like. The pGEX vectors (Promega,
Madison Wis.) can also be used to express foreignproteins as
fusion proteins with glutathione S-transferase (GST). In gen-
eral, such fusion proteins are soluble and can easily be puri-
fied from lysed cells by adsorption to glutathione-agarose
beads followed by elution in the presence of free glutathione.
Proteins made in such systems are designed to include hep-
arin, thrombin or factor Xa protease cleavage sites so that the
cloned protein of interest can be released from the GST moi-
ety at will.
The methods for introducing the modified chaperonin sub-
unit nucleotide sequences into the host cells are well-known
methods that depend on the type of vector used and host
system employed. For example, prokaryotic host cells are
typically introduced (e.g., transformed) with nucleic acid
molecules by electroporation or salt treatment methods (Co-
hen et al., 1972 Proc Acad Sci USA 69:2110; Maniatis, T., et
al., 1989 in: Molecular Cloning, A Laboratory Manual, Cold
Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
Eukaryotic Host Cells
Examples of suitable eukaryotic host cells include insect
cells, yeast cells, plant cells, or animal cells such as mamma-
lian cells.
An expression system that can be used to express modified
chaperonin subunit polypeptides is an insect system. In one
such system, Autographa californica nuclear polyhedrosis
virus (AcNPV) can be used as a vector to express foreign
genes in Spodoptera frugiperda insect cells or in Trichoplusia
larvae. The sequence encoding a modified chaperonin sub-
unit polypeptides can be cloned into a nonessential region of
the virus, such as the polyhedrin gene, and placed under
control of the polyhedrin promoter. Successful insertion of a
modified chaperonin subunit sequence will render the poly-
hedrin gene inactive and produce recombinant virus lacking
coat protein. The recombinant viruses can then used to infect
S. frugiperda cells or Trichoplusia larvae in which the modi-
fied chaperonin subunit polypeptides can be expressed
(Smith et al 1983 J Virol 46:584; E K Engelhard, et al, 1994
Proc Nat Acad Sci 91:3224-3227).
In mammalian host cells, a number of viral-based expres-
sion systems can be utilized. In cases where an adenovirus is
used as an expression vector, a modified chaperonin subunit
nucleotide sequence can be ligated into an adenovirus tran-
scription/translation vector having the late promoter and tri-
partite leader sequence. Insertion in a nonessential El or E3
region of the viral genome results in a viable virus capable of
expressing a modified chaperonin subunit polypeptides in
infected host cells (Logan and Shenk 1984 Proc Natl Acad Sci
81:3655-59). In addition, transcription enhancers, such as the
32
rous sarcoma virus (RSV) enhancer, can be used to increase
expression in mammalian host cells.
In yeast, Saccharomyces cerevisiae, a number of vectors
including constitutive or inducible promoters such as beta-
s factor, alcohol oxidase and PGH can beused. Forreviews, see
Ausubel et al (Current Protocols in Molecular Biology, John
Wiley & Sons, New york N.Y.) and Grant et al (1987 Methods
in Enzymology 153:516-544).
In cases where plant expression vectors are used, the
io expression of a sequence encoding a modified chaperonin
subunit polypeptides can be driven by any of a number of
promoters. For example, viral promoters such as the 35S and
19S promoters of CaMV (Brisson, et al., 1984 Nature 310:
511-514) can be used alone or in combination with the omega
15 leader sequence from TMV (Takamatsu, et al., 1987 EMBO J
6:307-311). Alternatively, plant promoters such as the small
subunit of RUBISCO (Coruzzi et al 1984 EMBO J 3:1671-
1680; Broglie et al 1984 Science 224:838-843); or heat shock
promoters (J Winter and R M Sinibaldi 1991 Results Probl
20 Cell Differ. 17:85-105) can be used.
In addition, a host cell strain can be chosen for its ability to
modulate the expression of the inserted modified chaperonin
subunit nucleotide sequences or to process the expressed
protein in the desired fashion. Such modifications of the
25 expressed modified chaperonin subunit polypeptides include,
but are not limited to, acetylation, carboxylation, glycosyla-
tion, phosphorylation, lipidation and acylation. Post-transla-
tional processing which cleaves a precursor form of the pro-
tein (e.g., a pre-pro protein) can also be important for correct
30 insertion, folding and/or function. Different host cells such as
CHO, HeLa, MDCK, 293, WI38, etc. have specific cellular
machinery and characteristic mechanisms for such post-
translational activities and can be chosen to ensure the correct
modification and processing of the introduced, foreign pro-
35 tein.
The methods for introducing the modified chaperonin sub-
unit nucleotide sequences into eukaryote host cells are well-
known methods that depend on the type of vector used and
host system employed. For example, in vertebrate cells, the
4o nucleic acid sequences are introduced with vectors using
various methods, including calcium phosphate-mediated
DNA transfection (Graham and Van der Eb 1973 Virology
52:456-467; M Wigler, et al 1977 Cell 11:223-232) or other
cationic-mediated transfection methods, electroporation (E
45 Neuman, et al 1982 EMBO J 1:841-845), microinjection (W
F Anderson, et al 1980 Proc Natl Acad Sci USA 77:5399-
5403; M R Cappechi 1980 Cell 22:479-488; A Graessman, et
al 1979 J Virology 32:989-994), or lipid methods including
encapsulation of DNA in lipid vesicles (M Schaefer-Ridder
50 1982 Science 215:166-168). Other methods include the par-
ticle gun method. Still other methods include using an aden-
ovirus transcription/translation vector comprising the late
promoter and tripartite leader sequence. A nucleic acid
sequence can be inserted in a nonessential El or E3 region of
55 the adenoviral genome to create a viable virus capable of
expressing the protein encoded by the nucleic acid sequence
(Logan and Shenk 1984 Proc Natl Acad Sci 81:3655-59).
Alternatively, retroviral transfer methods can be used (E
Gibloa, et al 1986 BioTechniques 4:504-512).
60 Plant cells can be introduced by direct DNA transformation
or pathogen-mediated transfection. For reviews of such tech-
niques, see Hobbs, S. in: "McGraw Yearbook of Science and
Technology" (1992) McGraw Hill New York N.Y., pp 191-
196; or Weissbach and Weissbach (1988) in: "Methods for
65 Plant Molecular Biology", Academic Press, New York N.Y.,
pp 421-463. Alternatively, plant cells can be introduced via a
particle-gun method using metal particles.
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Selection of Transformed Cells
The host cells introduced with the modified chaperonin
subunit nucleotide sequences can be identified by techniques
well known in the art. The cells can be selected, lysed and
their DNA content examined for the presence of the intro-
duced sequences using a DNA gel blot method or similar
method (Southern 1975 7 Mol Biol 98:503; Berent et al., 1985
Biotech 3:208). Alternatively, the proteins produced from the
cells of the invention can be assayed via a biochemical assay
or immunological method.
Any number of selection systems can be used to recover the
introduced (e.g, transformed or transfected) cells. The intro-
duced cells can be selected based on expression of herpes
simplex virus thymidine kinase (Wigler, M., et al., 1977 Cell
11:223-32), or adenine phosphoribosyltransferase (Lowy, I.
et al., 1980 Cell 22:817-23) genes which can be employed in
tk-minus or aprt-minus cells, respectively. Also, antimetabo-
lite, antibiotic or herbicide resistance can be used as a basis
for selection; for example, dhfr which confers resistance to
methotrexate (Wigler, M., et al., 1980 Proc Natl Acad Sci
77:3567-70); npt, which confers resistance to the aminogly-
cosides neomycin and G-418 (Colbere-Garapin, F., et al.,
1981 J. Mol. Biol. 150:1-14) and als or pat, which confer
resistance to chlorsulfuron and phosphinotricin acetyltrans-
ferase, respectively. Additional selectable genes have been
described, for example, trpB, which allows cells to utilize
indole in place of tryptophan, or hisD, which allows cells to
utilize histinol in place of histidine (S C Hartman and R C
Mulligan 1988 Proc. Natl. Acad. Sci. 85:8047-51). Recently,
the use of visible markers has gained popularity with such
markers as anthocyanins, beta-glucuronidase and its sub-
strate, GUS, and luciferase and its substrate, luciferin, being
widely used not only to identify transformants, but also to
quantify the amount of transient or stable protein expression
attributable to a specific vector system (C Rhodes, et al., 1995
Methods Mol. Biol. 55:121-131).
Producing Modified Polypeptides
The present invention provides methods for producing the
modified chaperonin subunit polypeptides. The modified
polypeptides of the invention, or fragments or derivatives
thereof, can be produced as recombinant molecules produced
in prokaryote or eukaryote host cells, or generated as syn-
thetic molecules.
The modified polypeptides can be produced using standard
recombinant technology techniques. For example, expression
vectors comprising nucleotide sequences encoding the modi-
fied chaperonin subunit polypeptides can be introduced into a
prokaryote or eukaryote host cell (i.e., a host-vector system),
the host-vector system can be cultured under conditions suit-
able for the host cell to produce the modified polypeptides,
and the polypeptides so produced can be isolated. The iso-
lated modified polypeptides can be enriched to further sepa-
rate the modified polypeptides away from other non-desirable
polypeptides or cellular fractions. The isolated modified
polypeptides can be purified to produce a sample of modified
polypeptides having very little or no contaminating non-de-
sirable polypeptide or cellular fractions.
In one embodiment, the host-vector system can be cultured
at non-heat stress temperatures (e.g., 75 degrees C.). In
another embodiment, the host-vector system can be cultured
at heat stress temperatures (e.g., 86 degrees C.).
In a non-limiting example, a sequence encoding a thermo-
stable chaperonin, e.g. a thermostable HSP60, can be trans-
ferred into E. coli and grown at temperatures standard for the
cell. The expressed polypeptide can then be easily purified
from E. coli proteins by heating and centrifugation. The ther-
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molabile E. coli proteins precipitate leaving the thermostable
polypeptide greater than 90% pure after a centrifugation.
In an embodiment where the chaperonin polypeptides are
thermostable extremophiles, the cell extracts can be heated
5 for easier purification of the chaperonin subunits. For
example, the purification of the chaperonin beta subunit of
Sulfolobusshibatae expressed inE. coli involves heating total
cell extracts to 85° C. for 30 minutes, which precipitates most
E. coli proteins, but the thermostable beta remains soluble.
10 Therefore, heating and centrifuging cell extracts separates the
beta subunit from most E. coli proteins, which simplifies
further purification using ion exchange chromatography (Ka-
gawa, H. K. et al., 1995 The 60 kDa heat shock proteins in the
hyperthermophilic archaeon Sulfolobus shibatae. 7 Mol Biol
15 253:712-25).
In one non-limiting example, a purification procedure
comprises, either alone or in combination: 1) chromatogra-
phy on molecular sieve, ion-exchange, and/or hydrophobic
matrices; 2) preparative ultracentrifugation; and 3) affinity
20 chromatography.
Assembled Chaperonin Structures
The present invention provides assembled chaperonin
structures comprising at least one of the modified chaperonin
25 polypeptides of the invention from Group I or Group II sub-
unit polypeptides, or any combination and any proportion of
Group I and II. The chaperonin structures comprise at least
one of the modified chaperonin polypeptides from alpha,
beta, or gamma subunits, or any combination or in any pro-
30 portion thereof. The chaperonin structures comprise at least
one modified chaperonin polypeptide from one organism, or
from different organisms (chimeric chaperonin structure).
The chaperonin structures comprise at least one modified
polypeptide which are based on HSP60, TCP-1, thermal fac-
35 for 55 (TF55), thermal factor 56 (TF56), or GroEL subunits.
The choice of subunits can be made depending on factors
such as operating conditions. For example, if the subunits or
chaperonin structures are to experience high operating tem-
peratures, then one skilled in the art could select a modified
40 polypeptide from extremophiles. The chaperonin structures
comprise 7, 8, 9 or 10 subunits per ring. The chaperonin
structures can have 2-, 3-, 4-, 5-, 6-, 7-, 8- 9-, or 10-fold
symmetry. The chaperonin structures comprise at least on of
the modified chaperonin polypeptides and a co-chaperonin
45 (e.g., GroEL and GroES).
Production In Vivo
The present invention provides methods for producing the
double-ringed chaperonin structures in vivo, comprising: cul-
turing a host cell carrying an expression vector (host-vector
50 system) under conditions suitable for the cell to produce the
modified chaperonin polypeptide in the cell and permitting
self-assembly of the chaperonin structure in the cell; and
isolating the assembled chaperonin structure from the cell.
In one embodiment, the host cell co-expresses the modified
55 chaperonin polypeptide (e.g., GroEL) and a co-chaperonin
polypeptide (e.g., GroES) so as to self-assemble in the cell the
chaperonin structure comprising the modified chaperonin
polypeptide and the co-chaperonin.
60 Production In Vitro
The present invention provides methods for producing the
double-ringed chaperonin structures in vitro. In one embodi-
ment, the methods comprise: reacting isolated modified chap-
eronin polypeptides under conditions suitable to permit self-
65 assembly of the modified chaperonin polypeptides to form
the chaperonin structures. In another embodiment, the meth-
ods comprise: reacting isolated modified chaperonin
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polypeptides with wild-type chaperonin polypeptides under
conditions suitable to permit self-assembly of the modified
chaperonin polypeptides and the wild-type chaperonin
polypeptides to form the chaperonin structures.
The assembly reaction can be performed using modified 5
and/or wild-type chaperonin polypeptides that are enriched or
purified. Alternatively, the assembly reaction can be per-
formed using modified and/or wild-type chaperonin polypep-
tides from crude cell extracts. The assembly reaction can be
allowed to proceed prior to purification of the assembled 10
chaperonin structures.
The conditions suitable to permit self-assembly of the
modified chaperoninpolypeptides (withmodified chaperonin
polypeptides or with wild-type chaperonin polypeptides)
includes Mg2l, in the presence ofATP, ADP, AMP-PNP, GTP 15
or ATPyS. The temperature or pH for formation will depend
on the type and thermostability of the modified or wild-type
chaperonin polypeptides or the chaperonin structures. For
example, for the thermostable chaperonin beta subunit of S.
shibatae, the temperature canbe4°C.-85°C.,while it may be 20
lower for other types of polypeptides (e.g., less than 40° C.).
For a given modified chaperonin polypeptide, optimal condi-
tions for self-assembly (i.e., concentration and proportion of
Mg2l to ATP, ADP, AMP-PNP, GTP or ATPyS) are easily
determined by routine experimentation, such as by changing 25
each variable individually and monitoring formation of the
appropriate products. For formation of the chaperonins any of
Mg2l, ATP, ADP, AMP-PNP, GTP orATPyS can be present in
an amount ranging from 1 mM, up to 10 mM, 20 mM, 30 mM
or higher. For example, filaments can be formed in 5 mM 30
HEPES buffer with 25 mM MgCl2 and 1 mM ATP (total
volume 300 µl) (Yoai et al., 1998 Archives of Biochemistry
and Biophysics 356:55-62). While it has been shown that the
formation of chaperonins from alpha and beta subunits of S.
shibatae does not depend on the presence of K', formation of 35
the higher order structures from the subunits of other organ-
isms may require the presence of K'.
In another embodiment, the chaperonin are formed in the
absence of introduction of any of Mgt+, ATP, ADP, AMP-
PNP, GTP or ATPyS. At sufficiently high concentrations of 40
the chaperonins, e.g., at concentrations of 2-5 mg/ml, or up to
30 mg/ml or more, some of the higher order structures can
spontaneously assemble (Quaite-Randall et al., 1995, J. Biol.
Chem. 270, 28818-28823). The concentration of the chaper-
onins or chaperonin polypeptides indifferent embodiments is 45
0.1 mg/ml, 0.5 mg/ml, 1 mg/ml, 2, mg/ml, 5 mg/ml, 10
mg/ml, 20 mg/ml, 30 mg/ml, 50 mg/ml or higher.
Higher Order Structures
The present invention provides higher order structures 50
comprising the modified chaperonin polypeptides of the
invention. The higher order structures include rings, tubes,
filaments, and sheets (2-D crystals). The nanorings can have
rectangular, pentagonal, hexagonal or heptagonal architec-
tural arrangements of chaperonins. 	 55
The present invention also provides methods for producing
the higher order structures. In one embodiment, the methods
comprise: reacting isolated modified chaperonin polypep-
tides under conditions suitable to permit self-assembly of the
modified chaperonin polypeptides to form assembled chap-
eronin structures which can form the higher order structures.
In another embodiment, the methods comprise: reacting iso-
lated modified chaperonin polypeptides with wild-type chap-
eronin polypeptides under conditions suitable to permit self-
assembly of the modified chaperonin polypeptides and the
wild-type chaperonin polypeptides to form assembled chap-
eronin structures which can form the higher order structures.
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The conditions suitable to permit formation of the higher
order structures include: the presence or absence of ATP,
ADP, AMP-PNP, GTP or ATPyS in the reaction; and/or the
concentration of the modified and/or wild-type chaperonin
polypeptides. The presence of ATP induces the formation of
an extensive network of filaments, while using ADP, AMP-
PNP, GTP or ATPyS induces the formation of shorter fila-
ments. For example, with respect to reactions comprising
mutant and/or mutant and wild-type TF55 a and R subunits of
S. shibatae, chaperonin structures can be formed at concen-
trations of approximately 0.1 mg/ml, while filaments are
formed at approximately 0.5 mg/ml. Longer aligned fila-
ments can be formed at concentrations of approximately 1.0
mg/ml. Other conditions are known for forming structures
like filaments of differing average lengths or two-dimen-
sional arrays (Yaoi et al., 1998 Archives of Biochemistry and
Biophysics 356: 55-62; and Trent et al., 1997 Proc. Natl.
Acad. Sci 94: 5383-5388). Thus, the length of filaments can
be controlled through manipulation and choice of reaction
conditions, with certain concentrations necessary for particu-
lar structures being routinely attainable.
The architectural symmetry of the chaperonin structures
and higher order structures can be dictated by varying the
reaction conditions, or through directed binding or arrange-
ment of the chaperonins relative to each other. The architec-
tural symmetry includes 1, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- or
10-fold symmetry. For example, nanofilaments having one-
dimensional architectural symmetry can be formed using cer-
tain mutant chaperonin polypeptides in the presence of Mg21
and nucleotides. These nanofilaments can cluster to form
bundles of filaments that are microns in length and with
bundle diameters of up to microns in thickness.
FIG. 5 shows that in the electron microscope individual
HSP60s in the double-rings appear as black "blobs" (A, end
view) or alternating dark and light bands (B, side view). These
double-rings self-assemble into chains or porous tubes (C)
and the tubes associate into filaments (D). FIG. 6 shows the
organization of HSP60 rings into 2-dimensional crystals on a
metal grid coated with lipid (A) and filament bundles
arranged on a bed of rings (visible as spots in background)
(B). In general, the choice of proportion of ATP to Mg2l
affects the formation of higher order structures, such as fila-
ments or arrays. The higher order structures can have long
range two- or three-dimensional ordering as in an array with
trigonal or hexagonal close packed architectural arrangement
of the chaperonins through self-assembly (FIG. 6).
The various architectural symmetries can also be dictated
through directed arrangement of the chaperonins onto a sub-
strate either through a masking technique or by directed bind-
ing (Whaley et al., 2000 Nature 405: 665-668, which
describes peptides that bind to selectively to specific faces
gallium arsenide, silicon or indium phosphide). An exem-
plary, non-limiting list of partial amino-acid sequences from
clones that bind to different surfaces of GaAs and/or InP
(Whaley et al., 2000 Nature 405: 665-668) includes:
AQNPSDNNTHTH	 (SEQ ID NO: 18)
ASSSRSHFGQTD	 (SEQ ID NO: 19)
VTSPDSTTGAMA	 (SEQ ID NO: 16)
60	 AASPTQSMSQAP	 (SEQ ID NO: 17)
WAHAPQLASSST	 (SEQ ID NO: 20)
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TPPRPIQYNHTS (SEQ ID NO: 22)
SSLQLPENSFPH (SEQ ID NO: 23)
GTLANQQIFLSS (SEQ ID NO: 24)
HGNPLPMTPFPG (SEQ ID NO: 25)
RLELAIPLQGSG (SEQ ID NO: 26)
Whaley et al. also describes amino-acid sequences that
bind silicon and not silicon dioxide. An example of an amino-
acid sequence that binds to ZnS(IO2) (Lee et al., 2002 Science
296: 892-895) is:
CNNPMHQNC	 (SEQ ID NO: 27)
A list of partial amino-acid sequences from clones that
bind to Ag (Naik et al., 2002 Nature Materials 1: 169-172)
includes:
AYSSGAPPMPPF	 (SEQ ID NO: 28)
NPSSLFYRLPSD	 (SEQ ID NO: 29)
SLATQPPRTPPV	 (SEQ ID NO: 30)
A list of partial amino-acid sequences from clones that
bind to An (Brown et al., 2000 J. Mol. Biol. 299: 725-735;
Brown, S, 1997 Nature Biotechnol. 15: 269-272) includes:
MHGKTQATSGTIQS	 (SEQ ID NO: 31)
ALVPTAHRLDGNMH	 (SEQ ID NO: 32)
Another advantage is that HSP60 nanotemplate structures
such as rings, tubes, and filaments (to be described in detail
below) bind to DNA and RNA using the method of"gel shift,"
to proteins by the method of autoradiography, and to lipo-
somes and lipid monolayers.
Nanostructures, Nanoarrays, Nanodevices
The modified polypeptides can self-assemble into chapero-
nin structures which can be used as the basis for producing
nanotemplates, nanostructures, nanoarrays and nanodevices.
The term "nanotemplate" as used herein, unless otherwise
indicated, refers to a composition comprising at least one
modified chaperonin polypeptide
The term "nano structure" as used herein, unless otherwise
indicated, refers to a composition comprising at least one
modified chaperonin polypeptide and one or more nanoscale
materials, such as nanoparticles and/or quantum dots.
The term "nanoarray" as used herein, unless otherwise
indicated, refers an ordered arrangement of at least one modi-
fied chaperonin polypeptide and/or nanostructures.
The term "nanodevice" as used herein, unless otherwise
indicated, refers to a device comprising at least one modified
chaperonin polypeptide, at least one nanostructure, and/or at
least one nanoarray. Exemplary devices include, but are not
limited to, electronic, semiconductor, mechanical, nanoelec-
tromechanical, magnetic, photonic, optical, optoelectronic or
biomedical devices.
The term "nanounit" as used herein, unless otherwise indi-
cated, refers any of the components or "basic building blocks"
of a nanostructure, including, for example: a nanscale object,
such as a nanoparticle or a quantum dot; a modified chapero-
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nin polypeptide; and a wild-type chaperonin; a wild-type
chaperonin polypeptide; a mutant chaperonin; or a chapero-
nin polypeptide.
In a specific embodiment, the nanotemplate can comprise a
5 chaperonin structure comprising at least one modified chap-
eronin polypeptide, which serve as "spacers" in the nanotem-
plates. The spacer chaperonins can be confined to specific
regions of the nanotemplate, and would not present specific
binding sites for any of polypeptides, nanoscale materials or
io linker molecules. The spacers can therefore serve a similar
function as a mask in semiconductor fabrication.
The generation of several different mutations of a given
subunit can result in differences in dimension of the resulting
chaperonins that comprise the nanotemplate. For example, a
15 variant produced through the removal of a 28 amino acid loop
at the apical end from of the R subunit of S. shibatae resulted
in a chaperonin with an expanded internal pore diameter of
from 2.5 mir to 9 rim (see FIGS. 713-D). This can be exploited
in forming a nanotemplate with different mixtures of chap-
20 eronin subunit variants to present pores with different pore
diameters for the binding of nanosale objects such as nano-
particles and/or quantum dots.
The chaperonins and/or nanotemplates can differ accord-
ing to the types of subunits and also the combinations of types
25 of subunits used in formation. For example, in vitro alpha and
beta subunits of S. shibatae form homo-oligomeric rosetta-
somes, while mixtures of alpha, beta, and gamma form het-
ero-oligomeric rosettasomes. It has also been found that beta
homo-oligomeric rosettasomes and all hetero-oligomeric
3o rosettasomes of S. shibatae associate into filaments. FIG. 15
shows the protein sequence alignment of S. shibatae TF55
alpha subunit (SEQ ID NO: 39), beta subunit (SEQ ID NO: 1)
and gamma subunit (SEQ ID NO: 38). In vivo rosettasomes
are hetero-oligomeric with an average subunit-ratio of 1 a: l R:
35 0.1 y in cultures grown at 75' C., a ratio of 1 a:3 R: ly in cultures
grown at 60° C., and a ratio of 2u 3p:0y after 86° C. heat
shock. Additionally, it has been observed that rosettasomes
containing gamma were relatively less stable than those with
alpha and/or beta subunits. A protein sequence alignment of
40 the alpha, beta, gamma subunits of S. shibatae (see Figure),
also provides useful information for positioning mutations on
the chaperonin polypeptides. FIGS. 16A and 16B provide the
DNA and amino-acid sequences of isolated S. shibatae TF55-
Y
45 The isolated chaperonin polypeptide subunits from a given
organism can assemble into different types of nanotemplates
and other higher order structures (Kagawa et al., 2003
Molecular Microbiology 48:143-156). The isolated S. shiba-
tae TF55 alpha subunit (SEQ ID NO: 39) alone forms discrete
5o homo-oligomeric rosettasomes with the characteristic nine-
fold ring member symmetry, and arrays of rosettasomes. The
isolated S. shibatae TF55 beta subunit (SEQ ID NO: 1) forms
filaments of rosettasomes and bundles of filaments. The iso-
lated S. shibatae TF55 gamma subunit (SEQ ID NO: 38) does
55 not assemble into rosettasomes, but forms amorphous aggre-
gates and non-uniform round objects, which were seen in the
TEM (FIG. 6C). Varying the proportions of the different
subunits from a given organism can also result in the assem-
bly of different higher order structure being formed (Kagawa
60 et al., 2003 Molecular Microbiology 48:143-156). A 1:1:1
mixture of S. shibatae TF55 alpha, beta, and gamma subunits
results in hetero-oligomeric rosettasomes and filaments that
were less bundled than the ones formed from isolated beta
subunits. The 1:1 mixture of S. shibatae TF55 alpha and beta
65 subunits results in filaments that are indistinguishable from




In one embodiment, the higher order structures, such as the
nanotemplates and nanostructures, comprise at least one iso-
lated S. shibatae TF55 gamma subunit. This embodiment of
the invention can comprise mutated or wild-type chaperonin
polypeptides. In a specific embodiment, the higher order
structures, comprise at least one isolated S. shibatae TF55
gamma subunit and wild-type chaperonin polypeptides.
In another embodiment, the nanotemplate forms part of a
coating or a nanofabric. Due to the capability of the chaper-
onins to self-assemble in an ordered arrangement on a fairly
large length scale as compared to their pore diameters, they
can be applied in these areas that could take advantage of the
capability. Additionally, the resulting coating or nanofabric
can be made to include optical, electric, magnetic, catalytic,
or enzymatic moieties as functional units. These are produced
through the selected placement of different nanoscale mate-
rials the apical domain of the chaperonin, e.g., near the pores
of the nanotemplates, or on other binding sites of the chap-
eronin, or in between chaperoning. The inclusion of nanos-
cale material with the nanotemplates is discussed further in
the section on nanostructures.
Changes in the subunit composition that can influence
volume and reactivity of the central cavity of a chaperonin can
also be exploited for various applications of the nanotem-
plates. While not wishing to be limited to a particular theory
or mechanism, it is noted that the N- and C-termini of chap-
eronin subunits are believed to project into and occlude the
central cavity. As such, because these termini can differ
between subunits of a given species (e.g., rosettasome of S.
shibatae), changes in subunit composition of the chaperonin
can be used to impact on the central cavity. Changes in the
volume and binding properties of the central cavity of the
chaperonin can therefore be dictated based on the composi-
tion of the chaperonin, which can be exploited in the forma-
tion of nanostructures which present different types of bind-
ing sites for nanoscale materials. In certain embodiments the
N- and C-termini are deleted.
The assembly of chaperonin polypeptides, for example
HSP60s, into such structures as rings, tubes, filaments, and
sheets (2-D crystals) can be regulated chemically. The assem-
bly can be manipulated by, for example, the proportion of
ATP/Mg2' and/or by manipulating the concentration of these
regions. HSP60-rings, tubes, and filaments can, for example,
function as nano-vessels if they are able to absorb, retain,
protect and release gases or chemical reagents, including
reagents of medical or pharmaceutical interest. On a nano-
scale, the filamentous structures, preferably HSP60 struc-
tures, are hollow and chemicals that are diffused or bound
inside can be bound or released under programmed condi-
tions at targeted locations.
The structures, e.g., rings, tubes, and filaments, can be
induced to form ordered structures on surfaces. Under con-
trolled conditions the chaperonins are observed to form 2-di-
mensional crystals on surfaces and the filament bundles may
be oriented on surfaces. In an alternate embodiment, the
nanotemplate functions as a multi-nanowell assay plate, or a
single-molecule probe for DNA detection and hybridization.
Layers of interwoven chaperonin filaments may form a
nano-fabric. Such fabrics may be induced to form on lipid
layers and may ultimately be used to coat surfaces of mate-
rials. This may be of value in medical transplants in which the
material could be coated with, e.g., an HSP60 (derived from
the host organism) fabric from the host and thereby limit the
immune response against the transplant.
Fabrics or two-dimensional crystals of chaperonins com-
prising HSP60 can form nano-arrays of DNA or RNA by
taking advantage of the intrinsic affinity of HSP60s for
40
nucleic acids. Such arrays would represent an unprecedented
density of DNA probes and thereby greatly amplify the den-
sity of information per unit area. Other kinds of probes based
on other molecules that associate with HSP60 can also be
5 developed.
For characterization, electron microscopy and electron
probing methods (EDAX) can be used for investigating the
contents of nano vessels, the continuity of nano-wires, the
product of template experiments, and the nature of nano-
10 fabrics. Atomic force microscope (AFM) can be used in
imaging and analyzing features of these nanotemplates. The
DNA nano-arrays can be tested by hybridization methods.
The present invention provides methods for forming nano-
structures. The chaperonins offer many advantages over other
15 molecules for the controlled assembly of complex architec-
tures, in their ability to self-assemble. A nanostructure can be
formed from a selective placement process involving self-
assembly, or directed binding, depending on the desired
resulting architectural arrangement. The steps in the forma-
20 tion of a nanostructure can include adding one or more
nanounits comprising (i) at least one nanotemplate, (ii) at
least one wild-type chaperonin, or (iii) a mixture of (i) and (ii)
to a surface, and adding one or more nanounits comprising (i)
at least one nanoparticle, (ii) at least one quantum dot, or (iii)
25 a combination of (i) and (ii) to said surface. Any unbound
nanounits are removed in order to maintain the desired archi-
tecture. Each of the addition steps are repeated as many times
as necessary to result in a nanostructure. Optimal conditions
for assembly (i.e., concentration and proportion of Mg 2l to
so ATP, ADP, AMP-PNP, GTP or ATPyS) are easily determined
by routine experimentation, such as by changing each vari-
able individually and monitoring formation of the appropriate
products. In alternate embodiment, the nanostructures
assemble in the absence of any of Mg2l, ATP, ADP, AMP-
ss PNP, GTP or ATPyS. In yet other embodiments, assembly
may require the presence of K'.
The resulting nanostructures utilize proteins to control the
assembly of structures that may, in certain embodiments,
40 incorporate organic materials or inorganic materials such as
metallic, semiconducting or magnetic nanoparticles
(Bruchez et al., 1998 Science 281: 2013-16; Peng et al., 2000
Nature 404(6773): 59-61; Whaley et al., 2000 Nature 405:
665-68).
45 For the formation of a nanostructure, nanoscale materials
can be combined with the chaperonin polypeptides and/or
chaperonins under suitable conditions (e.g., concentration
and proportion of Mgt', K', ATP, ADP, AMP-PNP, GTP or
ATPyS). The nanoscale material (i.e., the nanoparticle or
50 quantum dot) can be attached to the chaperonin and/or the
polypeptide subunits at specific binding sites prior to assem-
bly of the nanostructure. The nanoscale materials can be
introduced before the formation of the nanotemplates, e.g., by
being directly bound to a subunit, prior to assembly of the
55 various subunits and/or chaperonins into the nanostructures.
In an alternate embodiment, the nanoscale material is
attached to specific binding sites after the nanotemplate is
assembled. In such an embodiment, a nanotemplate is first
formed, with the selected sites for binding of the nanostruc-
60 tures present on pre-determined locations of the nanotem-
plates, and then the nanostructures are introduced.
In another embodiment, the nanoparticles are coated with a
coating that allows specific binding of the nanostructures to
the pre-determined locations on the nanotemplates. FIG. 10A
65 shows a gold particle derivatized with surface-accessible,
thiol-reactive maleimide groups (monomaleimido Nanogold,
Nanoprobes, Inc.). The nanogold quantum dots were
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covalently bound to the mutant beta subunit of S. shibatae
with a cysteine presented as a binding site.
In other embodiments, the nanoscale materials are coated
with an inorganic and/or organic compounds, a polymer, a
protein, a peptide, hormones, antibodies, nucleic acids,
receptors, reactive chemical groups, binding agents and the
like. For example, the nanoscale materials can be coated with
a polyethylene glycol compound containing chemically reac-
tive amine groups.
In yet another embodiment, the nanoscale materials are
coated with biotin or streptavidin. In a specific embodiment,
the nanoscale materials are coated with bovine serum albu-
min (BSA) and biotin, and the streptavidin is located at one or
more binding sites of the nanotemplate. In another example,
amino acids, or small peptides are coated directly on the
surface of the nanoscale materials, or are chemically linked to
polymers or other type of macromolecules.
Examples of nanoscale materials include, but are not lim-
ited to, nanoparticles, such as gold, silver and other metal
nanoparticle or composite nanoparticles of the metals; quan-
tum dots (QD), including CdSe ZnS, CdS, ZnS, CdSe, InP,
InGaAs, CuCl, and InAs quantum dots, silicon nanocrystals
and nanopyramids, silver nanoparticles; or magnetic quan-
tum dots, e.g., nanomagnets, such as CoCu, FeCu, NiFe/Ag,
and CoAg nanomagnets. The nanoscale materials can com-
prise one or more materials, or combinations of materials,
such as transition metals, including gold, silver, zinc, cad-
mium, platinum, palladium, cobalt, mercury or nickel; alkali
or alkaline earth metals, including sodium, potassium, cal-
cium or cesuim; group III elements, including, aluminum,
gallium or indium; group IV elements, including, silicon,
germanium, tin or lead; group V elements, including, phos-
phorous, arsenic, antimony, or bismuth; or group VI ele-
ments, including, sulfur, selenium or tellurium. The listed
materials can be in any given combination. Examples of III-V
compounds include GaAs orAlGaAs. The nanoscale material
could also be a fullerene, a carbon nanotube, or a dielectric,
polymeric, or semiconducting nanoparticle. In an alternate
embodiment, flexible protein joints may be added to rigid
carbon nanotubes to increase the diversity of possible forms
while maintaining the functional features inherent in both
kinds of nano-structures.
The size of the nanoscale material can be about 0.5 mu, 1
mu, about 10 mu, about 50 mu, about 100 mu, about 200 mu,
or about 500 mu, or more. The size of the nanoparticles can
depend on the location of the binding site on the nanotem-
plate. If the binding site is at an apical domain, or within the
internal cavity of the chaperonin, then the size of nanoscale
material may correlate with the pore diameter of the chapero-
nin to which it binds. FIGS. 7C and 7E show that the size of
the nanoscale material that bind at the apical domain of chap-
eronins formed from variants of the beta subunits of S. shi-
batae. FIG. 7C shows an illustration of the 3-mu-pore 2D
crystal (p312) indicating how 5 nm gold binds within the
engineered pores. FIG. 7E shows an illustration of the 9-mu-
pore 2D crystal (p312) indicating how 10 nm gold binds
within the engineered pores. The nanoscale materials may
also be located in interstitial regions of the nanotemplate, i.e.,
between the chaperonins. The nanoscale materials may be
bound to more than one chaperonin, such as when the nanos-
cale material in present in an interstitial site. In another
embodiment, the nanoscale material is located on top of a
region of the nanotemplate, and serve as a type of "mask." In
this embodiment, the nanoscale material can range up to 500
nm in size.
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Morphologies of nanoparticles include, for example, nano-
pillars, nanocrystals, nanorods, nanotubes, nanowires,
nanofilaments, nanofibers and composite metal/dielectric
nanoshells.
5 In a specific embodiment, application of an electric field is
used to disrupt the nanostructure or the template which may
be reformed on addition of other reagents with the removal of
the electric field.
In an alternate embodiment, differing amounts or propor-
io tions of ATP, ADP, AMP-PNP, GTP or ATPyS are used to
disrupt the nanostructure or nanotemplates, or to cause the
nanoscale material to become unbound from the nanostruc-
ture or nanotemplate.
In an embodiment, amino acid tails that do not inhibit their
15 ability to assemble into rings and tubes are attached to the
chaperonin polypeptides, e.g., HSP60s, and that allow the
binding of the nanoscale materials inside the chaperonins
structure, at an apical, equitorial or intermediate domain, or
on other locations of the chaperonin.
20 Mutated chaperonin polypeptides, including HSP60s, can
form nanometer or micron scale tubes and filaments or arrays
containing metals or doped or undoped semiconductors, and
could function as nano-wires, field-effect transistors,
switches, diodes or logic devices. Given that metals can be
25 attached to chaperonin polypeptides, their assembly into
tubes would create a protein coated metal-cored conduit, i.e.,
a wire. By orienting and networking such wires nano-cir-
cuitry can potentially be created, which may be of value in the
computer industry.
30 The nanostructures can also be incorporated into coatings
with optical, electric, magnetic, catalytic, or enzymatic moi-
eties as functional units.
A nanoarray is a nanoscale or microscale ordered arrange-
ment of nanotemplates and/or nanostructures. A nanoarray,
35 therefore comprises an ordered array of nanostructures. A
nanoarray can have any type of long range packing symmetry,
including 2-, 3-, 4-, or 6-fold packing symmetry. The nanoar-
ray can be a one-dimensional structure, a two-dimensional
array, or a three-dimensional array. In a specific embodiment,
40 where the nanoparticles are dielectrics, a three-dimensional
nanoarray can be a photonic bandgap crystal. Optimal con-
ditions for assembly and crystallization of a nanoarray (i.e.,
concentration and proportion of Mgt+ to ATP, ADP, AMP-
PNP, GTP orATPyS) are easily determinedby routine experi-
45 mentation, such as by changing each variable individually
and monitoring formation of the appropriate products.
Assembly and higher order organization of mutant chap-
eronin polypeptides has been previously described (PCT/
US02/35889) and can be used as a basis to select the optimal
50 conditions for assembly and higher order organization using
the modified chaperonin polypeptides of the present inven-
tion. For example, in a previous study (PCT/US02/35889),
two classes of beta mutants of S. shibatae are described
having a single native cysteine residue changed to a nonreac-
55 tive alanine to prevent potential problems with folding and
with assembly of mutant subunits. The cysteine is then placed
at different solvent-exposed sites. The thiols of these cys-
teines provide binding sites for soft metals including gold and
zinc. In one class of beta mutants, the exposed cysteine was
60 placed near the tip of a 28 amino acid loop on the apical
domain of beta, which in the assembled chaperonin protrudes
into the central cavity. FIG. 7A-E shows an example of the
assembly of engineered HSP60s into nanoparticle array tem-
plates of the preferred embodiment. This mutant chaperonin
65 has a ring of reactive thiols with a diameter of approximately
3 nm on both ends (FIG. 7A, left). In the other class of beta





placed the exposed cysteine on the apical domain itself. The 	 QDs were reacted with the chaperonin templates attached to
mutant chaperonin assembled from this subunit has a ring of
	
formvar-coated TEM grids (see Example 6.6) and imaged in
reactive thiols with a diameter of approximately 9 mn and an 	 TEM mode at 60 W. At low magnifications the chaperonin
open pore into its central cavity (FIG. 7A, right). FIG. 7A (top 	 2D crystals were visualized in the TEM using the electron
left) shows a model of a mutated HSP60 beta subunit indicat-  5 density of the gold QDs themselves. FIG. 8A shows a low
ing apical loop cysteine placement by an arrow. The side view 	 magnification TEM image of 10 µm diameter unstained 2D
is consistent with both classes of chaperonin variants 	 crystal of 9 mn chaperonin variant with 10 mn gold QDs
assembled from mutated beta subunits into two symmetri- 	 bound. Contrast is from gold QDs bound to the crystalline
cally stacked nine-fold rings (FIG. 7A, center), while FIG. 7A 	 lattice of the underlying protein template. Drying can cause
(bottom left) shows a top view of beta chaperonin variant io significant cracking and contributes to distortions and sepa-
revealing 3 mn pore ringed by nine cysteines. 	 ration of regions of order within the array. FIG. 8B Higher-
For the previously described mutants (PCT/US02/35889), 	 magnification stained TEM image of side views of 5 mn gold
the TEM image of a negatively stained 2D crystal of the beta 	 QDs tethered at the apical pores of the 3-mu-pore mutant
chaperonin variant with cysteines substituted into the apical 	 chaperonins. At high magnification the chaperonin-gold
pores is shown in FIG. 7B. The two-sided plane group p312 15 interactions were visualized in the TEM by negative-staining
was assigned to the lattice through image analysis of micro- 	 samples with uranyl acetate. FIG. 8B (inset) shows a slab-
graphs of beta chaperonin 2D crystals from S. shibatae (Ko- 	view cutaway diagram of postulated orientation of 5 mn and
eck et al., 1998 Biochim. Biophys. Acta 1429: 40-44). FIG. 	 10 mn gold QDs bound at the apical pores of the two chap-
7A (top right). Result of genetic removal of the 28 residue	 eronin variants. FIG. 8C shows a stained image of 5 mn gold
apical loop of beta and substitution of cysteine at the site 20 QDs bound within the pores of the 3-mu-pore crystalline
fusing the a-carbon backbone. Residue deletion choices were 	 template. Occupied rings show the QDs (dark areas) sur-
made based on the structural data from the model in FIG. 7A 	 rounded and held in place by the outer protein density of the
(left) as indicated by the arrows. FIG. 7B (bottom right)	 chaperonin pores. Empty rings have a brighter, less electron
shows a top view of chaperonin variant with 9 nm pore ringed
	
dense appearance. FIG. 8D shows ordered region of 10 mn
by cysteines. FIG. 7B shows the 2D crystal of 9-mu-pore 25 gold bound to a 9-mu-pore template with similar area cover-
variant detailing apparent increase in pore size by the change 	 age as in FIG. 8C. The protein holding the QDs in place is
in electron density within the negatively stained rings. Both	 more difficult to see due to the larger size of the 10 nm QDs.
samples were imaged at the same condenser defocus setting.	 Individual chaperonins in solution were observed to bind gold
The ordering of the crystal is illustrated by the FFT of the	 QDs on one or both ends. The QDs are presumably held in
image. FIG. 7C shows an illustration of the 3-mu-pore 2D 30 place by multiple dative bonds formed between the gold
crystal (p312) indicating how 5 nm gold binds within the 	 surface and the thiols within the pores (FIG. 813).
engineered pores. FIG. 7E shows an illustration of the 9-mu- 	 In a previous study (see PCT/US02/35889), in control
pore 2D crystal (p312) indicating how 10 nm gold binds	 experiments using chaperonin 2D crystals without exposed
within the engineered pores. 	 cysteines and with or without the amino acid loop deletions,
As shown in a previous study (PCT/US0235889) the beta 35 the gold QDs appeared randomly distributed with no specific
subunit S. shibatae proves to have sufficient structural plas-	 binding to the chaperonin crystals. On the surface of chap-
ticity in its apical domain to accommodate both the amino 	 eronin 2D crystals with cysteines, however, the gold QDs
acid substitutions and deletions can be made without loss of
	
bound specifically onto the pores (FIG. 8C) forming regions
its ability to form chaperonins and 2D crystals. Under reduc- 	 of order on the protein (FIG. 8D) separated from one another
ing conditions both classes of beta mutants formed chaper- 4o by the cracked regions that resulted from drying, indicating
onins that assembled into disk-shaped, hexagonally packed 	 that the engineered chaperonin crystals function as templates
2D crystals up to 20 M in diameter (PCT/US02/35889, and 	 for gold QDs in solution. These chaperonin templates were
FIG. 713, 7D). The order within the crystalline lattices is 	 size selective when attached to substrates and appeared to
illustrated by fast Fourier transformation (FFT) of the TEM 	 bind QDs only on the exposed side. Templates made from
images (FIG. 713, inset) which produced an optical diffracto-  45 beta mutants with cysteines added to the apical loop that
gram expressing the periodicity.	 formed 3 mn rings of reactive thiols ordered 5 nm (±3 mu)
In a previous study (PCT/US02/35889) to determine 	 gold QDs, but did not order 10 nm (±2 nm) or 15 nm (±1 nm)
whether the thi ol -containing 2D crystals of chaperonins acts 	 gold QDs, which bound randomly on the template surface.
as templates to bind and order nanoparticle QDs into arrays, 	 Variations in size distribution of gold QDs are a result of the
commercially available gold nanoparticles (Ted Pella, Inc, 50 manufacturer's method of synthesis. The chaperonin tem-
Redding, Calif.) of different diameters were used (FIG. 8). 	 plates with the loop removed and cysteines on the apical
FIG. 8 shows gold quantum dot binding to engineered chap- 	 domains that formed 9 mn rings of reactive thiols ordered 10
eronins and chaperonin templates. The uniform dispersion of	 nm (±2 nm) gold QDs, but 5 nm (±nm) and 15 nm (±1 nm)
these gold QDs in aqueous solution allows them to bind to	 QDs boundrandomly. This size selectivity is due to the acces-
hydrated chaperonin templates. To increase their likelihood 55 sibility and positioning of cysteine residues within the pores
of binding specifically to the reactive thiol of the cysteines,	 of the templates.
however, the nanoparticles can be passivated with the ligand 	 As shown in a previous study (PCT/US02/35889), the pre-
bis(p-sulfonatophenyl)phenylphosphine (BSPP) (Loweth, C. 	 cision of the center-to-center spacing of gold QDs ordered by
J., Caldwell, W. B., Peng, X., Alivisatos, A. P. & Schultz, P. G. 	 the chaperonin templates was 16 nm (±2 nm, n=200) for both
(1999) DNA-based assembly of gold nanocrystals. Angew. 60 5 and 10 mn gold QD arrays, as determined by TEM. This is
Chem. Int. Ed. 38: 1808-1812). BSPP displaces the citrate 	 consistent withthe center-to-center spacing of the chaperonin
shell formed during synthesis of gold QDs (Novak, J. P., 	 pores in the underlying templates. The edge-to-edge spacing
Nickerson, C., Franzen, S. & Feldheim, D. L. (2001) Purifi- 	 between QDs ranged from 6 to 10 nin for arrays made with 5
cation of molecularly bridged metal nanoparticle arrays by 	 nin (±3 mu) QDs bound to 3-mu-pore chaperonin templates
centrifugation and size exclusion chromatography. Anal. 65 and from 4 to 6 mu for arrays made with 10 mu (±2 nm) QDs
Chem. 73: 5758-5761) and thereby reduces nonspecific bind- 	 bound to 9-mu-pore chaperonin templates. This variation in
ing of the QDs to the protein template. The passivated gold 	 spacing can be attributed to boththe variation in the size of the
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gold QDs and to imperfections in the lattice of the chaperonin
templates resulting from drying, cracking and dislocations
within the arrays. The observed variation in QD spacing could
be decreased with improved routes to QD synthesis having
narrower size distributions. With more monodisperse QDs, 5
the precision of center-to-center spacing in the gold nanoar-
rays should make it possible to tune the physical properties of
the arrays by controlling the interparticle coupling using dif-
ferent sized QDs (Dujardin, et al., 2002 Adv. Mater. 14:
775-788).	 10
The chaperonin nanotemplate arrays can also bind and
order semiconductor QDs to form nanoarrays. Quantum dots
of size 4.5 mn luminescent core-shell (CdSe ZnS QDs)
were used (Dabbousi, B. O. et al. (1997) (CdSe)ZnS core- 15
shell quantum dots: Synthesis and characterization of a size
series of highly luminescent nanocrystallites. J. Phys. Chem.
B 101: 9463-9475). These QDs were reacted with 3-mu-pore
chaperonin templates attached to glass or formvar substrates.
Semiconductor QDs have low solubility in aqueous solutions. 20
A QD suspension in trioctylphosphine/trioctylphosphine
oxide (TOP/TOPO) diluted with butanol was reacted with
dried chaperonin templates. Under these conditions the QDs
bound to the cysteine-containing chaperonin templates (see
PCT/US02/35889, and FIG. 9), but not appreciably to chap- 25
eronin 2D crystals without exposed cyteines (FIGS. 12 and
13). This is consistent with observations that Zn in the outer
ZnS shell of CdSe ZnS QDs binds solvent-exposed thiols
(Chan, W. C. & Nie, S. (1998) Quantum dotbioconjugates for
ultrasensitive nonisotopic detection. Science 281: 2016- 30
2018).
FIGS. 9A-D show the semiconductor QD nanoarray of a
previously described mutant chaperonin polypeptide (PCT/
US02/35889). FIG. 9A shows differential interference con-
trast (DIC) light micrograph of an 8 µm crystalline disc of 35
3-mu-pore template with 4.5 nm luminescent CdSe ZnS
QDs bound. The differential interference contrast (DIC)
image of the QD-bound template (FIG. 9A) and the corre-
sponding fluorescent image reveal that QDs bound to cysteine
thiol retain their luminescent properties (Bruchez, M., Jr., 40
Moronne, M., Gin, P., Weiss, S. & Alivisatos, A. P. (1998)
Semiconductor nanocrystals as fluorescent biological labels.
Science 281: 2013-2016). FIG. 9B shows both dry and rehy-
drated discs fluoresced indicating the QDs bound to the sur-
face of the template. Selectivity for cysteine is confirmed 45
using 2D crystals of beta variant without added cysteines
which showed minimal QD binding (supporting informa-
tion), while FIG. 9C shows low magnification TEM of an
unstained array of CdSe ZnS QDs. Image contrast is due to
the bound semiconductor QDs. The mottled appearance of 50
both the QD luminescence and the electron density of low
magnification TEM images indicate that the QDs are
unevenly distributed on the chaperonin templates. FIG. 9D
shows higher-magnification image of same crystal revealing
an ordered region of QDs bound to the protein lattice. At 55
higher magnification of unstained samples, regions of
ordered QDs are visible. These regions are separated by unoc-
cupied regions where QDs did not bind to the protein tem-
plate. This difference could be due to drying or to solvent
effects of the butanol, both of which may alter the structure of 60
the chaperonin template and the accessibility of the thiols.
Water-soluble (silica-capped) CdSe ZnS (Gerion, D. et al.,
2001, "Synthesis and properties of biocompatible water-
soluble silica-coated semiconductor nanocrystals," J. Phys.
Chem. B 105: 8861-8871) QDs containing exposed thiol 65
groups can bind more uniformly to hydrated chaperonin tem-
plates. The thiols on these QDs, however, can cause them to
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aggregate, which can result in the formation of defective
arrays, in which case, it is preferable that the thiols be
removed.
Nanoscale materials can be maneuvered into nanoarrays
and nanostructures by first tethering them to chaperonin sub-
units and then ordered as the subunits assemble into chaper-
onins and 2D crystals (nanoarrays) or other nanostructures.
As an example, commercially available 1.4 mn gold QDs
derivatized with surface-accessible, thiol-reactive maleimide
groups can be used (monomaleimido Nanogold, Nanoprobes,
Inc., Yaphank, N.Y.). FIGS.1 OA-D show an embodiment of a
nanogold nanoarray comprising a previously described
mutant chaperonin polypeptide (PCT/US02/35889). FIG.
10A shows a covalent attachment of 1.4 nm monomaleimido
Nanogold to subunits of loop-minus beta variant of the beta
subunit of S. shibatae through Michael addition of cysteine
thiol to QD surface maleimide groups. FIG. 10A (right)
shows possible arrangement of nine 1.4 nm covalently
attached Nanogold QDs viewed at one end of a ring
assembled from the derivatized subunit. FIG. 10B shows low
magnification TEM image of a 2D crystalline array lightly
stained with methylamine vanadate. The dark circular feature
(arrow) demarks the analyzed area corresponding to the
dashed-line spectrum in FIG. 10D and is the result of poly-
merization of mobile hydrocarbon which is attracted to the
beam periphery. FIG. 10C shows higher-magnification
brightfield EF-TEM image of the array revealing the ordered
pattern of electron density that extends across the crystalline
template. FIG. 10D shows XEDS spectra of bare carbon film
(solid line) and Nanogold array (dashed line) from the probe
outlined in FIG. 10B. Characteristic X-ray peaks from gold
(Au Ma-2 keV and An La-9.7 keV) confirm the presence of
Nanogold within the array and the relative absence of An on
the support film.
These Nanogold QDs were covalently bound to the mutant
beta subunit with cysteine inserted in place of the 28 amino
acid loop in the apical domain (see PCT/US02/35889, and
FIGS. 10A-D). Subunits, with Nanogold attached, assembled
into chaperonins in the presence of ATP/Mg 21 (FIG. 10A);
these chaperonins form 2D crystals (FIGS. 10B and 10C).
The binding of the Nanogold QDs and localization within the
pores of the chaperonin crystals was confirmed by analytical
TEM (FIGS. 10 and 11A-11C). FIGS. 11A-11C show an
HAADF STEM imaging of Nanogold array. FIGS. 11A-11C
show the diameter of the features contributing to the array
periodicity is consistent with multiple QDs localized within
each ring. The diameter of electron density observed within
the chaperonin rings forming the array (FIGS. 11A-11C) is
approximately 8 to 12 times that observed for a single 1.4 mn
Nanogold QD (FIGS. 11A-11C). FIGS. 11A-11C show the
periodicity from the Nanogold QDs localized within the rings
extends across the entire crystal.
In a previous study (PCT/US02/35889) ordered hexago-
nally spaced inclusions within the crystalline template were
observed and determined to contain gold by imaging methy-
lamine vanadate stained Nanogold samples in brightfield
Energy Filtering (EFTEM) mode and by using X-ray Energy
Dispersive Spectroscopy (XEDS) (FIG. lOB-D). Oxygen
plasma-treated carbon support films were used because they
are more stable in an electron beam than formvar. Because the
protein templates do not adhere to plasma-treated carbon as
well as to formvar, samples were stained with methylamine
vanadate to enable identification of their location on the sub-
strate. The XEDS spectrum of the Nanogold array reveals
distinct peaks due to gold that are well separated from vana-
dium and copper peaks from the stain and carbon/copper





High Angle Annular Dark Field (HAADF) Scanning/ 	 together into functional nanodevices, for example by using
Transmission Electron Microscopy (STEM) was also used in 	 genetics, as alternate binding sites may be engineered at
a previous study (PCT/US02/35889) to image the gold local- 	 different locations on the chaperonin.
ized and ordered within the Nanogold arrays (FIGS. 11A-C). 	 The possibility to induce asymmetry within the arrays by
Comparisons of bare Nanogold to Nanogold ordered into an 5 engineering alternate facets of the protein crystal is exploited
array revealed that multiple Nanogold QDs were localized	 in forming the nanodevices of the present invention. A nan-
within the pores of the crystallized chaperonins (FIGS. 11A 	 odevice comprises at least one nanotemplate, at least one
and 1113). The HAADF image of the Nanogold crystal also 	 nanostructure, at least one nanoarray or some combination
confirms the presence of gold within the chaperonin pores	 thereof. A nanodevice can, for example, be an electronic,
because contrast in HAADF imaging mode is atomic number io semiconductor, mechanical, nanoelectromechanical, mag-
dependent, and nearly independent of focus or thickness. An 	 netic, photonic, optical, optoelectronic or biomedical device
HAADF comparison of the diameter of bare Nanogold par-	 formed from at least one nanostructure, at least one nanoar-
ticles on carbon to the diameter of the gold nanoparticles 	 ray, and/or at least one nanotemplate.
contained within the central pores of the chaperonins that 	 In a specific embodiment, the nanostructures are organized
template the Nanogold into arrays reveals that the central 15 into a nanodevice that functions with the chaperonins still
diameters are approximately eight to twelve times that of the 	 present. In an alternate embodiment, the chaperonins are
diameter of a single Nanogold QD. This observation is con- 	 removed before the functioning of the nanodevice. The nan-
sistent with a model which suggests that each ring can contain 	 otemplate and nanostructure provide an organizational basis
up to nine Nanogold QDs (one per subunit). A lower magni- 	 for attached molecules, nanoparticles and quantum dots. The
fication HAADF image of a similar area of an array reveals 20 attached nano scale materials can be equally spaced at, e.g., 15
the ordering of the gold extends throughout the template 	 run intervals, or selectively place at pre-determined sites.
(FIG. 11C). High resolution XEDS mapping attempts of the 	 Taking advantage of the fact that enzymes (such as proteases)
gold within the array were unsuccessful as the crystals were 	 can be used to specifically remove the chaperonin, the nan-
destroyed with the electron dose needed for such measure- 	 otemplates can serve to leave behind pure material accurately
ments. EELS (Electron Energy Loss Spectroscopy) mapping 25 placed on a surface at nano-scale resolution.
using the An O shell was correspondingly unsuccessful 	 The steps in the formation of a nanodevice are similar to
because the V M shell edge lies in close proximity to the An 	 those for forming a nanostructure, except that the building
O shell and thus masks the gold signal. FIG. 12 shows a	 blocks are nanotemplates, nanostructures, and/or nanoarrays.
control experiment showing DIC (left) and fluorescent (right) 	 The steps can include adding one or more nanotemplates,
images of non-cys-mutated chaperonin crystals after incuba- 30 nanostructures, nanoarrays, or some combination thereof to a
tion with CdSe ZnS QDs.	 surface, and then removing any unbound nanotemplates,
The luminescence intensity of the fluorescent image is 	 nanostructures, or nanoarrays. The steps are repeated any
barely visible indicating minimal QD binding. FIG. 13 shows	 desired number of times, with the choice of material intro-
an Energy Filtered TEM thickness map of a typical 2D pro- 	 duction being changed at each step to build the desired nan-
tein crystal. The intensity in this image is the ratio of the 35 odevice. Other masking techniques, e.g., semiconductor fab-
inelastic signal to the elastic signal and is proportional to the 	 rication can also be combined with the present invention in
ratio of t/X where lambda is the mean free path for inelastic 	 the construction of the nanodevice.
scattering and t is the local mass thickness. Regions of nomi- 	 There is no direct parallel of the present invention in the
nally uniform intensity indicate regions of nominally con- 	 semiconductor manufacturing industry. The use of protein-
stant mass thickness. Increasing intensity indicates increased 4o based templates that self assemble into highly ordered struc-
thickness. At the various regions and at the edges of the 	 tures allow of the engineering of semiconductor materials on
crystal one can observe clear transitions indicating that the 	 a size regime much smaller than that currently attainable.
crystal is composed of several layers. 	 Further, given the diversity of the chaperonin system (e.g, its
In a previous study (PCT/US02/35889) crystal thickness 	 ability to bind other biomolecules such as lipid and DNA/
measurements (AFM and TEM) suggest that these crystals 45 RNA) the compositions and devices of the invention can also
can be multilayered (supporting information), and are	 be utilized in a biomedical, e.g., biomedical device, context.
observed as crystals ranging from 1 to 10 layers (approxi- 	 The invention further provides methods to selectively
mately 20 to 200 mu). The assembly of QDs into arrays by 	 deposit nanoparticles or quantum dots in an ordered array
first covalently attaching them to subunits may create more 	 onto inorganic substrates. DNA manipulation and genetic
defect-tolerant arrays because each chaperonin is composed 50 engineering of the genes that code for chaperonins can be
of 18 subunits and therefore there are 18 chances for each site	 used to generate specificity in molecular recognition at
in the array to contain at least one QD. Likewise, the regions 	 defined sites within the protein. For example, by introducing
of QD ordering within arrays assembled this way appear to 	 cysteine residues into the protein, it can specifically bind
span the dimensions of the crystalline template and with 	 colloidal gold molecules through dative bonding between the
fewer defects than previously observed. These types of arrays 55 sulfhydryl (SIT) moiety of Cys and AuO. This allows for the
may find use in applications that demand longer range order- 	 organization of gold nanoparticles into ordered arrays onto
ing than the 5 and 10 run gold and semiconductor nanoparticle 	 substrates. After organizing the gold onto the surface, the
binding protocols allow.	 protein can be removed using a reactive ion cold plasma,
The present invention provides a hybrid bio/inorganic 	 leaving the patterned gold in place on a clean surface (FIG.
approach to nanophase materials organization where the 60 14), thereby producing a nanodevice of the invention. The
functionality of proteins can be rationally engineered. Using	 HSP60s bound with proteins or peptides are capable of
structural information and recombinant biotechnology tech- 	 releasing the bound proteins or peptides in the presence of
niques, genetically engineered chaperonins can be made to 	 adenosine triphosphate (ATP) or acidic conditions (Udono
function both as nanotemplates and as vehicles for controlled 	 and Srivastava, 1993 J. Exp. Med. 178:1391-1396).
nanoscale organization of preformed QDs into ordered 65	 With advances in microbial genetics, for example using
nanoarrays, e.g., arrays of nanomagnets. These nanotem- 	 phage and cell surface display to identify inorganic binding
plates, nanostructures, and nanoarrays can be "wired"	 peptide sequences (Whaley et al., Nature 405: 665-668), the
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usefulness of this system extends beyond soft metals to other
materials by, for example, the addition of sequences back into
the loop region that was removed.
Examples of additional, non-limiting applications of the
nanodevices include field emitters, sensors, optoelectronic
and all-optical switches, lenses, probes, lasers, nanoelectro-
mechanical systems (NEMS), circuitry and nanoelectronics,
nanomachines (e.g., by attaching nanomotors), neural net-
works (nanoelectrodes for connections), nanocomputers,
quantum computers, high-density magnetic memory or stor-
age media, photonic crystals, nanocrystal antennas, multi-
nanowell assay plates, nanocatalysts (e.g., palladium), nan-
opores for single-molecule DNA sequencing, amplifiers for
telecommunications (approximately 7 mn PbSe and PbS
quantum dots have a tunable gap near 1500 mu). Applications
include, for example, memory or storage devices (e.g., hard-
disk drive read heads, magnetic RAM), magnetic field sen-
sors, magnetic logic devices, logic gates, and switches.
Further applications can also include, for example, biochip
applications. Quantum dots in a biochip, for example, can
each account for at least one or several data bits. The position
of a single electron in a quantum dot can attain several states,
so that a quantum dot can represent a byte of data. In an
alternate embodiment, a quantum dot can be used in more
than one computational instruction at a time.
Other applications of quantum dots include nanomachines,
neural networks, and high-density memory or storage media.
In an alternate embodiment, the nanodevice, nanotemplate
or nanoarray functions as a single-molecule probe for DNA
detection, hybridization, and sequencing.
Polymer microspheres with uniformly embedded poly-
mers have applications as, for example, active fluorescent
building blocks in flat panel displays and luminescent labels
in biological detection. This application is achieved by form-
ing a nanodevice comprising a nanoarray of embedded poly-
mer nanoparticles
Still further applications relate to molecular motors, e.g.,
molecular motors in a biomedical context.
The following examples are presented to illustrate the
present invention and to assist one of ordinary skill in making
and using the same. The methodology and results may vary
depending on the intended goal of treatment and the proce-
dures employed. The examples are not intended in any way to
otherwise limit the scope of the invention.
Example 1
The following provides a description of methods used to
produce DNA sequences encoding the modified chaperonin
polypeptides comprising relocated N-terminal and C-termi-
nal ends, and encoding fusion proteins which are modified
chaperonin polypeptide comprising relocate N- and C-termi-
nal ends where the carboxy-terminal end is joined with a
sequence encoding yellow fluorescent protein.
Materials and Methods
DNA Constructs
Genes encoding the permuted chaperonin proteins were
created using a two-step polymerase chain reaction (PCR)
method in which fragments of DNA before and after the
permutation site are amplified with the flexible linked added
to the beginning and end of the gene. The starting template
DNA sequence encoding a TF5 5 beta subunit from Sulfolobus
shibatae is shown in FIG. 28A. In the second step, the two
fragments are annealed together at the flexible linker and the
resulting template DNA was amplified by PCR. The DNA
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encoding the permuted protein was then cloned into an E. coli
expression vector (pETI9b, Novagen) at the Nco I and Xho I
restrictions sites.
The resulting DNA sequences encoding the five different
5 circular permutated TF55 polypeptides at positions 153, 267,
316, 480, or 499 are shown in FIGS. 22-26, respectively.
Models of the five different circular permutated TF55
polypeptides in folded and assembled conformations are
shown in FIGS. 17A-E.
10 
Protein Expression
The expression vectors described above were transformed
into E. coli BL21 DE3 cells containing a second vector that
supplements rare tRNAs (BL21 DE3 CodonPlus RIL, Strat-
15 agene). This second vector was used because E. coli codon
usage differs from Sulfolobus. Some tRNAs that are common
in Sulfolobus (and therefore in Sulfolobus genes) are rare in E.
coli. These cells were then culture in Luria Broth with 100
micrograms/liter ampicillin and 34 micrograms/liter
20 chloramphenicol. IPTG was added to a final concentration of
1 mM when the culture reached an optical density of 0.4-0.8
at 600 mu. After four hours the cells were harvested by
centrifugation. The resulting pellet was weighed, resus-
pended in 25 ml HEPES, 1 mM EDTA, pH 7.5 and stored at
25 minus 80 degrees C.
Protein Purification
Cells were removed from storage at minus 80 degrees C.
and thawed. Protease inhibitor cocktail (Sigma-Aldrich) was
added during thawing at 0.25 ml per gram of wet pellet
30 weight. When thawed, the cell suspension was placed on ice
and sonicated 3 times for 2 minutes each with a one minute
pause between sonications (Branson Sonifier 450, 60% duty
cycle, output 6). The cell lysate was placed in a water bath at
70 degrees C. water bath for 30 minutes to precipitate heat-
35 labile proteins. After heating, the lysate was cooled on ice for
10 minutes and then centrifuged at 17,000 g, at 4 degrees C.,
for 30 minutes. The supernatant was decanted and 2.5% (v/v)
of a 5% (w/v) stock solution of polyethyleneimine (Sigma-
Aldrich) at pH 7.8 was added to precipitate nucleic acids.
40 After 10 minutes nice, the solution was again centrifuged at
17,000 g, at 4 degrees C., for 30 minutes. The supernatant
from this step was filtered through a 0.45 micrometer pore
membrane and diluted to 50 ml with 25 mM HEPES, 1 mM
EDTA, pH 7.5. This protein solution was loaded onto a
45 MonoQ 10/10 anion exchange column (Amersham Bio-
sciences) and eluted by a linear gradient from 1 to 400 mM
NaCl in 25 mM HEPES, 1 mM EDTA, pH 7.5. Peak fractions
were confirmed by denaturing polyacrylamide gel electro-
phoresis, pooled and concentrated using Centriprep YM30
50 centrifugal concentrators (Millipore). Buffer was exchanged
in the centrifugal concentrator with at least 10 volumes of 25
mM HEPES,1 mM EDTA, pH 7.5. Protein concentration was
determined by measuring absorbance at 280 nm using an
estimated extinction coefficient of 56,820 M-i cm-'.
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Inclusion Body Preparation.
Cells were removed from storage at -80 degrees C.
Reagents were added to a concentration of 25 mM HEPES,
100 mM NaCl, 0.5% TritonX-100 and 0.25 ml Protease
60 Inhibitor Cocktail (Sigma-Aldrich) per gram wet pellet
weight before thawing. Cells were lysed by sonication, 3
times for 2 minutes each with a 3 minute pause (Branson
Sonifier 450,40% duty cycle, output 5). Reagents were added
to the cell lysate to a concentration of 10 mM MgSO4, 1
65 mg/ml Lysozyme (Sigma-Aldrich) and 1 microliter/10 ml
Benzonase (Sigma-Aldrich) and incubated at room tempera-
ture for 20 minutes before centrifugation at 6000xG and 4
US 7,795,388 B2
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degrees C. for 15 min. The pellet was resuspended in 30 ml
Buffer R (50 mM Tris-HC1 pH 8.0, 100 mM NaCl, 5 mM
EDTA, 0.5% Triton X-100), then sonicated for 1 minute at
previous settings. Reagents for 10 mM MgSO4, 1 mg/ml
Lysozyme and 1 microliterl/10 ml Benzonase were added, the 5
lysate was incubated at room temperature for 20 minutes,
then centrifuged at 6000xG, 4 degrees C., 10 min. The pellet
was resuspended in 30 ml Buffer R, sonicated for 1 min and
centrifuged 10 min. This last step was repeated (resuspended,
sonicated, centrifuged). Next, the pellet was resuspended in io
30 ml 25 mM HEPES pH 8.0, 100 mM NaCl, 5 mM EDTA,
0.1 NaN3, and centrifuged for 1 min at 6000xG, 4 degrees C.
(This pellet was stored at —80° C. overnight).
The pellet was solubilized in 500 microliter 100 mM Tris-
HCl pH 7.5, 50 mM Glycine, then denatured in a solution of 15
10 M Urea pH 7.5, 100 mM Tris, 50 mM Glycine to a final
concentration of 8.5 M Urea. The protein was refolded by
adding dropwise into 100 ml 50 mM Tris-HCl, 35 mM KCl,
2 mM MgC12, 1 mM Beta mercaptoethanol pH 7.5.
This protein solution was purified by ion exchange chro- 20
matography as in the circular permutants.
Polyacrylamide Gel Electrophoresis
The purity of the proteins was evaluated using denaturing
polyacrylamide gel electrophoresis (GeneMate 8-16%
Express Gels, ISC BioExpress). The ability of each of the
circular permutations to form double rings was assessed by
non-denaturing 4-40% gradient polyacrylamide gel (FIG. 18)
as previously described (7 K Trent, et al., 1991 Nature 354:
490-493).
Formation of Crystals and Filaments
Crystal or filaments were formed from the circular permu-
tant proteins by placing them in solution at concentrations of
1 to 5 mg/ml in 25 mM HEPES at pH7.5 with 1 mM ATP and
25 mM MgCl2. The samples were stored at room temperature
for 1 to 3 days before examination for higher order structure
by light and electron microscopy.
Results
Transmission Electron Microscopy
Samples were prepared for the electron microscope by
drop casting on carbon-coated formvar substrates (Ladd) and
stained with 1% uranyl acetate. Samples were visualized
using a Leo 912AB electron microscope in bright field TEM
mode at 65 kV with a tungsten filament electron source.
Samples of the five different circular permutated chapero-
nin polypeptides (without the joined EYFP sequence) were
analyzed at 1 hour or 24 hours after addition of 1 mMATP and
25 mM Mg2l (FIG. 19A-J). All five circular permuted chap-
eronins analyzed formed double rings having the same struc-
ture as wild-type chaperonin double rings, with two rings of
nine subunits each (FIG. 19A-E). The circular permutated
chaperonin polypeptides 153, 267 and 316 formed predomi-
nantly crystalline structures. The circular permutated chap-
eronin polypeptides 480 and 499 formed predominantly fila-
mentous structures. For permutants at positions 480 and 499,
heating the sample to 70 degrees C. for 30 minutes immedi-
ately after addition of ATP and Mg 2l produced longer fila-
ments. This same heating regime did not improve crystalli-
zation of permutants 153, 267 or 316.
The circular permutant EYFP fusion proteins —267 and
—480 were analyzed via TEM. The 480 fusion protein
assemble into chaperonin double rings having the same or
similar form as wild-type chaperonins (FIG. 20B), and the




The circular permutant fusion proteins (267 and 480) were
analyzed using Leica filter cube I3 (excitation 470 mu, emis-
sion 515 mu). The chaperonin-EYFP fusion proteins (circular
permutants 267 and 480) exhibit fluorescence similar excita-
tion and emission spectra of EYFP (FIG. 20A). Additionally,
fluorescence microscopy shows the 267 circular permutant
fusion protein organizes into a crystalline structure (FIG.
20C).
Discussion
We present a general method for modifying protein tem-
plates using circular permutation so that additional peptide
sequences canbe added in a wide variety of specific locations.
Circular permutation is a reordering of the polypeptide chain
such that the original N- and C-terminal ends are joined and
new end termini are created elsewhere in the protein. New
protein sequences can be joined to the relocated termini with-
out perturbing the protein structure and with minimal limita-
tion on the size and conformation of the added sequence. We
have used circular permutation to modify a chaperonin
HSP60 protein template (TF55 beta subunit), by relocating
the terminal ends at five different locations distributed across
the surface of the protein complex.
Chaperonins are composed of 14, 16 or 18 subunits known
as heat shock protein 60 (HSP60) (FU Hartl and M Hayer-
Hard 2002 Science 295:1852-1858), where 60 refers to their
molecular mass of approximately 60 kilodaltons. In the pres-
ence of ATP and Mg ', these subunits assemble into a two-
stacked ring structure. The modified chaperonin polypeptides
of the present invention were based on an HSP60 from the
hyperthermophilic archeon Sulfolobus shibatae, which lives
in geothermal hot springs and thrives at pH 2 and tempera-
tures up to 85 degrees C. Sulfolobus shibatae produces three
related HSP60 proteins, designated alpha, beta and gamma.
These three HSP60 proteins assemble in various stoichiom-
etries, into octadecameric complexes with nine subunits per
ring. These double ring structures are symmetric around a
nine-fold axis and across a perpendicular two-fold axis. The
surface adjacent to the interface between the rings is known as
the equatorial surface and the surface of the ring most distant
from the equator is the apical surface. Overall, the double
rings are approximately 17 nm in diameter and 18 mn in
length, and have a central pore. The Sulfolobus shibatae chap-
eronins are known to form higher order structures such as
filaments (7 D Trent, et al., 1997 Proc Natl Acad Sci USA
94:5383-5388) and two-dimensional crystals (7 P Koeck, et
al., 1998 Biochim Biophys Acta 1429:40-44; M 7 Ellis, et al.,
1998 7 Struct Biol 123:30-36). The filaments are based on
interactions between the apical surfaces on one double ring
with the apical surfaces of two adjacent double rings. The two
dimensional crystals are based on interactions between the
equatorial surface of one double ring with equatorial surfaces
of six adjacent double rings. Bundled filaments have also
been observed and are believed to contain both types of inter-
actions.
We selected the HSP60 beta subunit (TF55, beta subunit)
for our research because it forms homo-oligomeric rings that
also assemble into filaments and two-dimensional crystals.
We previously reported attaching nanoparticles to the chap-
eronin double rings using thiol chemistry provided by a single
cysteine residue substituted into the HSP60 protein sequence
(PCT/US02/35889). We report here creating a chaperonin
circular permutant by joining a second peptide sequences
having arbitrary length and topology (yellow fluorescent pro-
tein) onto the chaperonin protein sequence. The second pep-
tide sequence is fused to the C-terminal end which is relo-
cated from the central pore to a position on the exterior of the
chaperonin polypeptide.
Circular permutant proteins have been reported using other
proteins. Published studies of circular permutations in other












amino and carboxyl termini are near in space, many new
locations for the termini are viable (P T Beernink, et al., 2001
Protein Sci 10:528-537; U Heinemann and M Hahn 1995
Prog Biophys Mol Biol 64:121-143; M Iwakura, et al., 2000
Nat Struct Biol 7:580-585). In one study, dihydrofolate 5
reductase was permuted at each of the 158 possible positions,
resulting in 85 permutants that are competent to fold (M
Iwakura, et al., 2000 Nat Struct Biol 7:580-585).
We selected five sites for circular permutation that are
distributed across the exterior surface of the double ring. io
These sites met the following criteria: (a) they are not buried;
(b) they are not near the subunit interfaces; and (c) they are not
part of regular secondary structure (alpha helices and beta
sheets). In five different circular permutants, the new end
termini are relocated after residues 153, 267, 316, 480 and 15
499 in the native TF55 beta subunit from Sulfolobus shibatae.
The original end termini are linked by a flexible peptide
sequence (GGSGGT). Models of the permuted proteins are
shown in FIG. 17.
The circular permuted proteins were expressed at high 20
levels in E. coli and were readily purified to better than 95%
purity as determined by SDS-PAGE. The circular permuted
proteins assemble into double rings with efficiency similar to
wild-type protein, as demonstrated by non-denaturing gel
electrophoresis (FIG. 18). Examination by transmission elec- 25
tron microscopy (TEM) indicates that the circular permuted
chaperonin double rings have the same form as wild-type
chaperonin double rings, with two rings of nine subunits each
(FIG. 19A-E).
We expected circular permutation to affect the assembly of 30
the resulting chaperonins into higher order structures. Spe-
cifically, perturbation of the peptide chain and addition of the
new amino and carboxyl termini at different positions on the
surface of the chaperonin double rings was expected to affect
their propensity to form filamentous structures versus two- 35
dimensional crystals. Changes to the apical surface of the
chaperonin should destabilize the interactions necessary to
form filaments, resulting in samples containing two-dimen-
sional crystals with little or no filamentous material. On the
other hand, changes on the equatorial surface of the chapero- 40
nin should destabilize interactions that are necessary to form
two-dimensional crystals resulting inpredominantly filamen-
tous structures.
Examination of the assembled circular permutants using
transmission electron microscopy confirms that permutations 45
at positions 153, 267 or 316 results in predominantly crystal-
line samples. Conversely, permutations at positions 480 or
499 produce predominantly filamentous structures (FIGS.
19F-J). For permutants at positions 480 and 499, heating the
sample to 70 degrees C. for 30 minutes immediately after 50
addition of ATP and Mgt+ produced longer filaments. This
same heating regime did not improve crystallization of per-
mutants 153, 267 or 316.
SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 91
<210> SEQ ID NO 1
<211> LENGTH: 552
<212> TYPE: PRT
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: TF55 beta subunit
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The fusion proteins were created by joining the circular
permutant 267 and 480 with a sequence encoding the yellow
fluorescent protein.Yellow fluorescent protein (EYFP) is a 28
kDa protein with a fluorescent excitation maximum at 512 mn
and emission maximum at 529 mu. The fluorescent chro-
mophore produced by EYFP is a result of cyclization and
oxidation reactions, which require proper folding of the
EYFP. The chaperonin-EYFP fusion proteins (circular per-
mutants 267 and 480) exhibit fluorescence excitation and
emission spectra typical of EYFP (FIG. 20A). This result
indicates the EYFP assumed its correct structure to facilitate
the reactions that produce the chromophore. Furthermore, the
480 fusion protein assemble into chaperonin double rings
having the same or similar form as wild-type chaperonins
(FIG. 20B), and the 267 fusion protein organizes into a crys-
talline structure (FIGS. 20C and D). These results indicate
that fused EYFP is free in both fusion proteins to assume its
most favorable conformation, and does not interfere with
formation of double rings. Rings composed of the 267 fusion
permutants readily form two-dimensional crystals of the
same form as the 267 permutants lacking the fused EYFP. By
contrast, the 480 fusion permutants do not form filaments
under the same conditions as the 480 permutants lacking the
fused EYFP. For example, filament formation by the 480 and
499 permutants (lacking EYFP) is improved upon heating to
70 degrees C. However, heating does not improve filament
formation of the 480 fusion permutant because the heat
unfolds the EYFP.
The chaperonin circular permutants described above are
competent to form the double-ring structures typical of wild-
type chaperonin proteins. We also fused a fluorescent protein
(EYFP) to two representative permutants (267 and 480), and
demonstrate that the fluorescent protein folds into its active
structure and does not interfere with assembly of chaperonin
double-rings.
The yellow fluorescent protein is a convenient reporter
molecule. Other peptide sequences can also be used to pro-
vide desirable properties to the chaperonin circular permu-
tants. For example, peptide sequences having catalytic,
chemical reactivity, or binding specificity for inorganic mate-
rials are known. The peptide sequences can be a linear, con-
strained loop, or a fully structured protein. Some of these
sequences have been discovered through studies of natural
biomineralization (D E Morse, et al., 1993 Mat Res Soc Symp
Proc 292:59-67; M L Paine and M L Snead 1997 7 Bone
Miner Res 12:221-227; N Kroger, et al., 1999 Science 286:
1129-1132; 7 M Slocik, et al., 2002 Nanoletters 2:169-173),
while others have been isolated from large combinatorial
libraries using phage display or bacterial cell-surface display
(M Sarikaya, et al., 2003 Nat Mater 2:577-585). These
sequences serve as an interface between the highly versatile
structural properties of proteins, and the optical an electronic







Met Ala Thr Ala Thr Val Ala Thr Thr Pro Glu Gly Ile Pro Val Ile
1	 5	 10	 15
Ile Leu Lys Glu Gly Ser Ser Arg Thr Tyr Gly Lys Glu Ala Leu Arg
20	 25	 30
Ala Asn Ile Ala Ala Val Lys Ala Ile Glu Glu Ala Leu Lys Ser Thr
35	 40	 45
Tyr Gly Pro Arg Gly Met Asp Lys Met Phe Val Asp Ser Leu Gly Asp
50	 55	 60
Ile Thr Ile Thr Asn Asp Gly Ala Thr Ile Leu Asp Lys Met Asp Leu
65	 70	 75	 80
Gin His Pro Thr Gly Lys Leu Leu Val Gin Ile Ala Lys Gly Gin Asp
85	 90	 95
Glu Glu Thr Ala Asp Gly Thr Lys Thr Ala Val Ile Leu Ala Gly Glu
100	 105	 110
Leu Ala Lys Lys Ala Glu Asp Leu Leu Tyr Lys Glu Ile His Pro Thr
115	 120	 125
Ile Ile Val Ser Gly Tyr Lys Lys Ala Glu Glu Ile Ala Leu Lys Thr
130	 135	 140
Ile Gin Asp Ile Ala Gin Pro Val Ser Ile Asn Asp Thr Asp Val Leu
145	 150	 155	 160
Arg Lys Val Ala Leu Thr Ser Leu Gly Ser Lys Ala Val Ala Gly Ala
165	 170	 175
Arg Glu Tyr Leu Ala Asp Leu Val Val Lys Ala Val Ala Gin Val Ala
180	 185	 190
Glu Leu Arg Gly Asp Lys Trp Tyr Val Asp Leu Asp Asn Val Gin Ile
195	 200	 205
Val Lys Lys His Gly Gly Ser Ile Asn Asp Thr Gin Leu Val Tyr Gly
210	 215	 220
Ile Val Val Asp Lys Glu Val Val His Pro Gly Met Pro Lys Arg Ile
225	 230	 235	 240
Glu Asn Ala Lys Ile Ala Leu Leu Asp Ala Ser Leu Glu Val Glu Lys
245	 250	 255
Pro Glu Leu Asp Ala Glu Ile Arg Ile Asn Asp Pro Thr Gin Met His
260	 265	 270
Lys Phe Leu Glu Glu Glu Glu Asn Ile Leu Lys Glu Lys Val Asp Lys
275	 280	 285
Ile Ala Ala Thr Gly Ala Asn Val Val Ile Cys Gin Lys Gly Ile Asp
290	 295	 300
Glu Val Ala Gin His Tyr Leu Ala Lys Lys Gly Ile Leu Ala Val Arg
305	 310	 315	 320
Arg Ala Lys Lys Ser Asp Leu Glu Lys Leu Ala Arg Ala Thr Gly Gly
325	 330	 335
Arg Val Ile Ser Asn Ile Asp Glu Leu Thr Ser Gin Asp Leu Gly Tyr
340	 345	 350
Ala Ala Leu Val Glu Glu Arg Lys Val Gly Glu Asp Lys Met Val Phe
355	 360	 365
Val Glu Gly Ala Lys Asn Pro Lys Ser Val Ser Ile Leu Ile Arg Gly
370	 375	 380
Gly Leu Glu Arg Val Val Asp Glu Thr Glu Arg Ala Leu Arg Asp Ala
385	 390	 395	 400







Gly Gly Ala Val Glu Ile Glu Ile Ala Lys Arg Leu Arg Lys Tyr Ala
420	 425	 430
Pro Gin Val Gly Gly Lys Glu Gin Leu Ala Ile Glu Ala Tyr Ala Asn
435	 440	 445
Ala Ile Glu Gly Leu Ile Met Ile Leu Ala Glu Asn Ala Gly Leu Asp
450	 455	 460
Pro Ile Asp Lys Leu Met Gin Leu Arg Ser Leu His Glu Asn Glu Thr
465	 470	 475	 480
Asn Lys Trp Tyr Gly Leu Asn Leu Phe Thr Gly Asn Pro Glu Asp Met
485	 490	 495
Trp Lys Leu Gly Val Ile Glu Pro Ala Leu Val Lys Met Asn Ala Ile
500	 505	 510
Lys Ala Ala Thr Glu Ala Val Thr Leu Val Leu Arg Ile Asp Asp Ile
515	 520	 525
Val Ala Ala Gly Lys Lys Gly Gly Ser Glu Pro Gly Gly Lys Lys Glu
530	 535	 540
Lys Glu Glu Lys Ser Ser Glu Asp
545	 550
<210> SEQ ID NO 2
<211> LENGTH: 548
<212> TYPE: PRT
<213> ORGANISM: Escherichia coli
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: GroEL
<400> SEQUENCE: 2
Met Ala Ala Lys Asp Val Lys Phe Gly Asn Asp Ala Arg Val Lys Met
1	 5	 10	 15
Leu Arg Gly Val Asn Val Leu Ala Asp Ala Val Lys Val Thr Leu Gly
20	 25	 30
Pro Lys Gly Arg Asn Val Val Leu Asp Lys Ser Phe Gly Ala Pro Thr
35	 40	 45
Ile Thr Lys Asp Gly Val Ser Val Ala Arg Glu Ile Glu Leu Glu Asp
50	 55	 60
Lys Phe Glu Asn Met Gly Ala Gin Met Val Lys Glu Val Ala Ser Lys
65	 70	 75	 80
Ala Asn Asp Ala Ala Gly Asp Gly Thr Thr Thr Ala Thr Val Leu Ala
85	 90	 95
Gin Ala Ile Ile Thr Glu Gly Leu Lys Ala Val Ala Ala Gly Met Asn
100	 105	 110
Pro Met Asp Leu Lys Arg Gly Ile Asp Lys Ala Val Thr Ala Ala Val
115	 120	 125
Glu Glu Leu Lys Ala Leu Ser Val Pro Cys Ser Asp Ser Lys Ala Ile
130	 135	 140
Ala Gin Val Gly Thr Ile Ser Ala Asn Ser Asp Glu Thr Val Gly Lys
145	 150	 155	 160
Leu Ile Ala Glu Ala Met Asp Lys Val Gly Lys Glu Gly Val Ile Thr
165	 170	 175
Val Glu Asp Gly Thr Gly Leu Gin Asp Glu Leu Asp Val Val Glu Gly
180	 185	 190





Glu Thr Gly Ala Val Glu Leu Glu Ser Pro Phe Ile Leu Leu Ala Asp
210	 215	 220
Lys Lys Ile Ser Asn Ile Arg Glu Met Leu Pro Val Leu Glu Ala Val
225	 230	 235	 240
Ala Lys Ala Gly Lys Pro Leu Leu Ile Ile Ala Glu Asp Val Glu Gly
245	 250	 255
Glu Ala Leu Ala Thr Ala Val Val Asn Thr Ile Arg Gly Ile Val Lys
260	 265	 270
Val Ala Ala Val Lys Ala Pro Gly Phe Gly Asp Arg Arg Lys Ala Met
275	 280	 285
Leu Gin Asp Ile Ala Thr Leu Thr Gly Gly Thr Val Ile Ser Glu Glu
290	 295	 300
Ile Gly Met Glu Leu Glu Lys Ala Thr Leu Glu Asp Leu Gly Gin Ala
305	 310	 315	 320
Lys Arg Val Val Ile Asn Lys Asp Thr Thr Thr Ile Ile Asp Gly Val
325	 330	 335
Gly Glu Glu Ala Ala Ile Gin Gly Arg Val Ala Gin Ile Arg Gin Gin
340	 345	 350
Ile Glu Glu Ala Thr Ser Asp Tyr Asp Arg Glu Lys Leu Gin Glu Arg
355	 360	 365
Val Ala Lys Leu Ala Gly Gly Val Ala Val Ile Lys Val Gly Ala Ala
370	 375	 380
Thr Glu Val Glu Met Lys Glu Lys Lys Ala Arg Val Glu Asp Ala Leu
385	 390	 395	 400
His Ala Thr Arg Ala Ala Val Glu Glu Gly Val Val Ala Gly Gly Gly
405	 410	 415
Val Ala Leu Ile Arg Val Ala Ser Lys Leu Ala Asp Leu Arg Gly Gin
420	 425	 430
Asn Glu Asp Gin Asn Val Gly Ile Lys Val Ala Leu Arg Ala Met Glu
435	 440	 445
Ala Pro Leu Arg Gin Ile Val Leu Asn Cys Gly Glu Glu Pro Ser Val
450	 455	 460
Val Ala Asn Thr Val Lys Gly Gly Asp Gly Asn Tyr Gly Tyr Asn Ala
465	 470	 475	 480
Ala Thr Glu Glu Tyr Gly Asn Met Ile Asp Met Gly Ile Leu Asp Pro
485	 490	 495
Thr Lys Val Thr Arg Ser Ala Leu Gin Tyr Ala Ala Ser Val Ala Gly
500	 505	 510
Leu Met Ile Thr Thr Glu Cys Met Val Thr Asp Leu Pro Lys Asn Asp
515	 520	 525
Ala Ala Asp Leu Gly Ala Ala Gly Gly Met Gly Gly Met Gly Gly Met
530	 535	 540
Gly Gly Met Met
545
<210> SEQ ID NO 3
<211> LENGTH: 543
<212> TYPE: PRT
<213> ORGANISM: Thermoplasma acidophilum
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: beta subunit
<400> SEQUENCE: 3
Met Ile Ala Gly Gin Pro Ile Phe Ile Leu Lys Glu Gly Thr Lys Arg




Glu Ser Gly Lys Asp Ala Met Lys Glu Asn Ile Glu Ala Ala Ile Ala
20	 25	 30
Ile Ser Asn Ser Val Arg Ser Ser Leu Gly Pro Arg Gly Met Asp Lys
35	 40	 45
Met Leu Val Asp Ser Leu Gly Asp Ile Val Ile Thr Asn Asp Gly Val
50	 55	 60
Thr Ile Leu Lys Glu Met Asp Val Glu His Pro Ala Ala Lys Met Met
65	 70	 75	 80
Val Glu Val Ser Lys Thr Gln Asp Ser Phe Val Gly Asp Gly Thr Thr
85	 90	 95
Thr Ala Val Ile Ile Ala Gly Gly Leu Leu Gln Gln Ala Gln Gly Leu
100	 105	 110
Ile Asn Gln Asn Val His Pro Thr Val Ile Ser Glu Gly Tyr Arg Met
115	 120	 125
Ala Ser Glu Glu Ala Lys Arg Val Ile Asp Glu Ile Ser Thr Lys Ile
130	 135	 140
Gly Ala Asp Glu Lys Ala Leu Leu Leu Lys Met Ala Gln Thr Ser Leu
145	 150	 155	 160
Asn Ser Lys Ser Ala Ser Val Ala Lys Asp Lys Leu Ala Glu Ile Ser
165	 170	 175
Tyr Glu Ala Val Lys Ser Val Ala Glu Leu Arg Asp Gly Lys Tyr Tyr
180	 185	 190
Val Asp Phe Asp Asn Ile Gln Val Val Lys Lys Gln Gly Gly Ala Ile
195	 200	 205
Asp Asp Thr Gln Leu Ile Asn Gly Ile Ile Val Asp Lys Glu Lys Val
210	 215	 220
His Pro Gly Met Pro Asp Val Val Lys Asp Ala Lys Ile Ala Leu Leu
225	 230	 235	 240
Asp Ala Pro Leu Glu Ile Lys Lys Pro Glu Phe Asp Thr Asn Leu Arg
245	 250	 255
Ile Glu Asp Pro Ser Met Ile Gln Lys Phe Leu Ala Gln Glu Glu Asn
260	 265	 270
Met Leu Arg Glu Met Val Asp Lys Ile Lys Ser Val Gly Ala Asn Val
275	 280	 285
Val Ile Thr Gln Lys Gly Ile Asp Asp Met Ala Gln His Tyr Leu Ser
290	 295	 300
Arg Ala Gly Ile Tyr Ala Val Arg Arg Val Lys Lys Ser Asp Met Asp
305	 310	 315	 320
Lys Leu Ala Lys Ala Thr Gly Ala Ser Ile Val Ser Thr Ile Asp Glu
325	 330	 335
Ile Ser Ser Ser Asp Leu Gly Thr Ala Glu Arg Val Glu Gln Val Lys
340	 345	 350
Val Gly Glu Asp Tyr Met Thr Phe Val Thr Gly Cys Lys Asn Pro Lys
355	 360	 365
Ala Val Ser Ile Leu Val Arg Gly Glu Thr Glu His Val Val Asp Glu
370	 375	 380
Met Glu Arg Ser Ile Thr Asp Ser Leu His Val Val Ala Ser Ala Leu
385	 390	 395	 400
Glu Asp Gly Ala Tyr Ala Ala Gly Gly Gly Ala Thr Ala Ala Glu Ile
405	 410	 415







Leu Ala Ile Glu Lys Phe Ala Asp Ala Ile Glu Glu Ile Pro Arg Ala
435	 440	 445
Leu Ala Glu Asn Ala Gly Leu Asp Pro Ile Asp Ile Leu Leu Lys Leu
450	 455	 460
Arg Ala Glu His Ala Lys Gly Asn Lys Thr Tyr Gly Ile Asn Val Phe
465	 470	 475	 480
Thr Gly Glu Ile Glu Asp Met Val Lys Asn Gly Val Ile Glu Pro Ile
485	 490	 495
Arg Val Gly Lys Gin Ala Ile Glu Ser Ala Thr Glu Ala Ala Ile Met
500	 505	 510
Ile Leu Arg Ile Asp Asp Val Ile Ala Thr Lys Ser Ser Ser Ser Ser
515	 520	 525
Ser Asn Pro Pro Lys Ser Gly Ser Ser Ser Glu Ser Ser Glu Asp
530	 535	 540
<210> SEQ ID NO 4
<211> LENGTH: 544
<212> TYPE: PRT
<213> ORGANISM: Cyanobacterial synechococcus
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: Cyanobacterial HSP60
<400> SEQUENCE: 4
Met Ala Lys Arg Ile Ile Tyr Asn Glu Asn Ala Arg Arg Ala Leu Glu
1	 5	 10	 15
Lys Gly Ile Asp Ile Leu Ala Glu Ala Val Ala Val Thr Leu Gly Pro
20	 25	 30
Lys Gly Arg Asn Val Val Leu Glu Lys Lys Phe Gly Ala Pro Gin Ile
35	 40	 45
Ile Asn Asp Gly Val Thr Ile Ala Lys Glu Ile Glu Leu Glu Asp His
50	 55	 60
Ile Glu Asn Thr Gly Val Ala Leu Ile Arg Gin Ala Ala Ser Lys Thr
65	 70	 75	 80
Asn Asp Ala Ala Gly Asp Gly Thr Thr Thr Ala Thr Val Leu Ala His
85	 90	 95
Ala Val Val Lys Glu Gly Leu Arg Asn Val Ala Ala Gly Ala Asn Ala
100	 105	 110
Ile Leu Leu Lys Arg Gly Ile Asp Lys Ala Thr Asn Phe Leu Val Glu
115	 120	 125
Gin Ile Lys Ser His Ala Arg Pro Val Glu Asp Ser Lys Ser Ile Ala
130	 135	 140
Gin Val Gly Ala Ile Ser Ala Gly Asn Asp Phe Glu Val Gly Gin Met
145	 150	 155	 160
Ile Ala Asp Ala Met Asp Lys Val Gly Lys Glu Gly Val Ile Ser Leu
165	 170	 175
Glu Glu Gly Lys Ser Met Thr Thr Glu Leu Glu Val Thr Glu Gly Met
180	 185	 190
Arg Phe Asp Lys Gly Tyr Ile Ser Pro Tyr Phe Ala Thr Asp Thr Glu
195	 200	 205
Arg Met Glu Ala Val Phe Asp Glu Pro Phe Ile Leu Ile Thr Asp Lys
210	 215	 220
Lys Ile Gly Leu Val Gin Asp Leu Val Pro Val Leu Glu Gin Val Ala
225	 230	 235	 240







Ala Leu Ala Thr Leu Val Val Asn Arg Leu Arg Gly Val Leu Asn Val
260	 265	 270
Ala Ala Val Lys Ala Pro Gly Phe Gly Asp Arg Arg Lys Ala Met Leu
275	 280	 285
Glu Asp Ile Ala Val Leu Thr Gly Gly Gin Leu Ile Thr Glu Asp Ala
290	 295	 300
Ala Arg Lys Leu Asp Thr Thr Lys Leu Asp Gin Leu Gly Lys Ala Arg
305	 310	 315	 320
Arg Ile Thr Ile Thr Lys Asp Asn Thr Thr Ile Val Ala Glu Gly Asn
325	 330	 335
Glu Ala Ala Val Lys Ala Arg Val Asp Gin Ile Arg Arg Gin Ile Glu
340	 345	 350
Glu Thr Glu Ser Ser Tyr Asp Lys Glu Lys Leu Gin Glu Arg Leu Ala
355	 360	 365
Lys Leu Ser Gly Gly Val Ala Val Val Lys Val Gly Ala Ala Thr Glu
370	 375	 380
Thr Glu Met Lys Asp Arg Lys Leu Arg Leu Glu Asp Ala Ile Asn Ala
385	 390	 395	 400
Thr Lys Ala Ala Val Glu Glu Gly Ile Val Pro Gly Gly Gly Thr Thr
405	 410	 415
Leu Ala His Leu Ala Pro Gin Leu Glu Glu Trp Ala Thr Ala Asn Leu
420	 425	 430
Ser Gly Glu Glu Leu Thr Gly Ala Gin Ile Val Ala Arg Ala Leu Thr
435	 440	 445
Ala Arg Leu Lys Arg Ile Ala Glu Asn Ala Gly Leu Asn Gly Ala Val
450	 455	 460
Ile Ser Glu Arg Val Lys Glu Leu Pro Phe Asp Glu Gly Tyr Asp Ala
465	 470	 475	 480
Ser Asn Asn Gin Phe Val Asn Met Phe Thr Ala Gly Ile Val Asp Pro
485	 490	 495
Ala Lys Val Thr Arg Ser Ala Leu Gin Asn Ala Ala Ser Ile Ala Ala
500	 505	 510
Met Val Leu Thr Thr Glu Cys Ile Val Val Asp Lys Pro Glu Pro Lys
515	 520	 525
Glu Lys Ala Pro Ala Gly Ala Gly Gly Gly Met Gly Asp Phe Asp Tyr
530	 535	 540
<210> SEQ ID NO 5
<211> LENGTH: 535
<212> TYPE: PRT
<213> ORGANISM: Methanosarcina acetivorans
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: acetivoran HSP60-4
<400> SEQUENCE: 5
Met Ala Ser Glu Leu Lys Thr Pro Gly Asn Thr Ser Pro Glu Ser Gin
1	 5	 10	 15
Asp Gly Met Ala Lys Leu Ala Arg Thr Ile Arg Asp Lys Ile Leu Ile
20	 25	 30
Asp Glu Pro Val Lys Glu Glu Glu Leu Ile Asp Gin Leu Glu Arg Ala
35	 40	 45
Ala Ile Glu Ile Asp Glu Leu Leu Gly Ser Ser Leu Gly Pro Lys Gly
50	 55	 60






65	 70	 75	 80
Asp Gly Lys Val Ile Leu Lys Glu Ile Asp Val Leu His Pro Ile Val
85	 90	 95
Thr Ser Leu Lys Lys Leu Ala Glu Ser Met Asp Lys Ala Cys Gly Asp
100	 105	 110
Gly Thr Lys Thr Ala Val Ile Phe Ala Ser Asn Leu Ile Lys Asn Ala
115	 120	 125
Val Arg Leu Ile Arg Ala Gly Val His Pro Thr Ile Ile Ile Glu Gly
130	 135	 140
Tyr Glu Leu Ala Met Gln Lys Thr Tyr Glu Met Leu Gln Tyr Ser Ile
145	 150	 155	 160
Arg Gln Ala Ser Glu Glu Asp Ile Arg Thr Thr Ile Met Cys Ser Ala
165	 170	 175
Thr Gly Lys Gly Ile Glu Arg Gln Gln Ala Gln Ala Val Thr Glu Ile
180	 185	 190
Ala Leu Lys Val Ile Ser His Leu Ser Glu Lys Gln Ala Gly Arg Ile
195	 200	 205
Asp Leu Asn Arg Asn Val Lys Ile Leu Lys Lys Lys Gly Gly Pro Glu
210	 215	 220
Ile Val Ala Ile Glu Gly Leu Ile Met Asp Glu Asn Pro Ala Arg Glu
225	 230	 235	 240
Asp Met Pro Lys Ser Tyr Gln Asn Pro Ala Val Leu Ile Thr Asn Tyr
245	 250	 255
Asp Leu Lys Ile Lys Ser Gly Tyr Leu Asn Pro Gln His Asn Phe Lys
260	 265	 270
Met Asp Ser Val Gln Thr Ala Leu Leu Phe Glu Glu Arg Lys Lys Gln
275	 280	 285
Leu Cys Gly Glu Ile Ala Arg Lys Ile Ile Asp Ser Gly Ala Asn Val
290	 295	 300
Leu Phe Ser Glu Gly Asp Ile Asp Pro Tyr Ile Glu Thr Leu Leu Arg
305	 310	 315	 320
Asp Ser Asn Ile Leu Ala Phe Lys Lys Leu Lys Met Lys Asp Leu Glu
325	 330	 335
Lys Leu Ala Glu Ala Thr Gly Thr Thr Leu Met Ala Gln Pro Asp Glu
340	 345	 350
Ile Arg Pro Cys Asp Leu Gly Arg Ala Gly Ser Ile Lys Leu Glu Lys
355	 360	 365
Lys Asn Gly Glu Asn Phe Val Phe Ile Thr Val Lys Asp Lys Ala Ile
370	 375	 380
Ala Thr Ile Leu Ile Arg Glu Pro Val Lys Tyr Gly Leu Asp Lys Val
385	 390	 395	 400
Glu Glu Ala Val Asp Asp Ala Leu Asn Asn Ala Ala Phe Leu Arg Lys
405	 410	 415
Asn Arg Glu Ile Val Asn Gly Gly Gly Ala Ile Glu Phe Glu Leu Ala
420	 425	 430
His Met Val Arg Leu Phe Ala Ala Thr Gln Thr Gly Lys Arg Gln Leu
435	 440	 445
Ala Val Gln Ala Tyr Ala Glu Ala Leu Glu Lys Ile Pro Val Ile Leu
450	 455	 460
Ala Arg Asn Ile Gly Met Asn Glu Ile Asp Ala Met Ala Gln Met Arg
465	 470	 475	 480





Val Thr Asp Arg Gly Pro Glu Val Tyr Asp Ser Ala Thr Val Lys Lys
500	 505	 510
Leu Ala Ile Ile Ala Gly Thr Glu Thr Ala Lys Lys Val Leu Arg Ile
515	 520	 525
Asp Glu Ile Val Pro Lys Lys
530	 535
<210> SEQ ID NO 6
<211> LENGTH: 540
<212> TYPE: PRT
<213> ORGANISM: Methanosarcina tuberculosis
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: tuberculosis HSP65
<400> SEQUENCE: 6
Met Ala Lys Thr Ile Ala Tyr Asp Glu Glu Ala Arg Arg Gly Leu Glu
1	 5	 10	 15
Arg Gly Leu Asn Ala Leu Ala Asp Ala Val Lys Val Thr Leu Gly Pro
20	 25	 30
Lys Gly Arg Asn Val Val Leu Glu Lys Lys Trp Gly Ala Pro Thr Ile
35	 40	 45
Thr Asn Asp Gly Val Ser Ile Ala Lys Glu Ile Glu Leu Glu Asp Pro
50	 55	 60
Tyr Glu Lys Ile Gly Ala Glu Leu Val Lys Glu Val Ala Lys Lys Thr
65	 70	 75	 80
Asp Asp Val Ala Gly Asp Gly Thr Thr Thr Ala Thr Val Leu Ala Gin
85	 90	 95
Ala Leu Val Arg Glu Gly Leu Arg Asn Val Ala Ala Gly Ala Asn Pro
100	 105	 110
Leu Gly Leu Lys Arg Gly Ile Glu Lys Ala Val Glu Lys Val Thr Glu
115	 120	 125
Thr Leu Leu Lys Gly Ala Lys Glu Val Glu Thr Lys Glu Gin Ile Ala
130	 135	 140
Ala Thr Ala Ala Ile Ser Ala Gly Asp Gin Ser Ile Gly Asp Leu Ile
145	 150	 155	 160
Ala Glu Ala Met Asp Lys Val Gly Asn Glu Gly Val Ile Thr Val Glu
165	 170	 175
Glu Ser Asn Thr Phe Gly Leu Gin Leu Glu Leu Thr Glu Gly Met Arg
180	 185	 190
Phe Asp Lys Gly Tyr Ile Ser Gly Tyr Phe Val Thr Asp Pro Glu Arg
195	 200	 205
Gin Glu Ala Val Leu Glu Asp Pro Tyr Ile Leu Leu Val Ser Ser Lys
210	 215	 220
Val Ser Thr Val Lys Asp Leu Leu Pro Leu Leu Glu Lys Val Ile Gly
225	 230	 235	 240
Ala Gly Lys Pro Leu Leu Ile Ile Ala Glu Asp Val Glu Gly Glu Ala
245	 250	 255
Leu Ser Thr Leu Val Val Asn Lys Ile Arg Gly Thr Phe Lys Ser Val
260	 265	 270
Ala Val Lys Ala Pro Gly Phe Gly Asp Arg Arg Lys Ala Met Leu Gin
275	 280	 285
Asp Met Ala Ile Leu Thr Gly Gly Gin Val Ile Ser Glu Glu Val Gly
290	 295	 300






305	 310	 315	 320
Val Val Val Thr Lys Asp Glu Thr Thr Ile Val Glu Gly Ala Gly Asp
325	 330	 335
Thr Asp Ala Ile Ala Gly Arg Val Ala Gin Ile Arg Gin Glu Ile Glu
340	 345	 350
Asn Ser Asp Ser Asp Tyr Asp Arg Glu Lys Leu Gin Glu Arg Leu Ala
355	 360	 365
Lys Leu Ala Gly Gly Val Ala Val Ile Lys Ala Gly Ala Ala Thr Glu
370	 375	 380
Val Glu Leu Lys Glu Arg Lys His Arg Ile Glu Asp Ala Val Arg Asn
385	 390	 395	 400
Ala Lys Ala Ala Val Glu Glu Gly Ile Val Ala Gly Gly Gly Val Thr
405	 410	 415
Leu Leu Gin Ala Ala Pro Thr Leu Asp Glu Leu Lys Leu Glu Gly Asp
420	 425	 430
Glu Ala Thr Gly Ala Asn Ile Val Lys Val Ala Leu Glu Ala Pro Leu
435	 440	 445
Lys Gin Ile Ala Phe Asn Ser Gly Leu Glu Pro Gly Val Val Ala Glu
450	 455	 460
Lys Val Arg Asn Leu Pro Ala Gly His Gly Leu Asn Ala Gin Thr Gly
465	 470	 475	 480
Val Tyr Glu Asp Leu Leu Ala Ala Gly Val Ala Asp Pro Val Lys Val
485	 490	 495
Thr Arg Ser Ala Leu Gin Asn Ala Ala Ser Ile Ala Gly Leu Phe Leu
500	 505	 510
Thr Thr Glu Ala Val Val Ala Asp Lys Pro Glu Lys Glu Lys Ala Ser
515	 520	 525
Val Pro Gly Gly Gly Asp Met Gly Gly Met Asp Phe
530	 535	 540
<210> SEQ ID NO 7
<211> LENGTH: 554
<212> TYPE: PRT
<213> ORGANISM: Aeropyrum pernix
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: Alpha subunit
<400> SEQUENCE: 7
Met Ala Ala Thr Gly Tyr Pro Val Leu Ile Leu Lys Glu Gly Thr Gin
1	 5	 10	 15
Arg Thr Tyr Gly Arg Glu Ala Leu Arg Ala Asn Ile Leu Ala Ala Arg
20	 25	 30
Val Leu Ala Glu Met Leu Lys Ser Ser Leu Gly Pro Arg Gly Leu Asp
35	 40	 45
Lys Met Leu Val Asp Ala Phe Gly Asp Ile Thr Val Thr Asn Asp Gly
50	 55	 60
Ala Thr Ile Val Lys Glu Met Glu Ile Gin His Pro Ala Ala Lys Leu
65	 70	 75	 80
Leu Val Glu Val Ala Lys Ala Gin Asp Ala Glu Val Gly Asp Gly Thr
85	 90	 95
Thr Ser Val Val Val Leu Ala Gly Ala Leu Leu Glu Lys Ala Glu Lys
100	 105	 110







Lys Ala Met Glu Glu Ala Leu Arg Leu Val Asp Glu Ala Ala Val Pro
130	 135	 140
Val Glu Val Glu Asp Asp Ser Val Leu Arg Arg Ile Ala Glu Thr Thr
145	 150	 155	 160
Leu Ala Ser Lys Phe Val Gly Thr Gly Pro Glu Arg Asp Lys Ile Ile
165	 170	 175
Ser Met Val Ile Asp Ala Ile Arg Thr Val Ala Glu Lys Arg Pro Asp
180	 185	 190
Gly Gly Tyr Glu Val Asp Leu Asp Tyr Val Lys Ile Glu Lys Lys Lys
195	 200	 205
Gly Gly Ser Leu Leu Asp Ser Lys Leu Val Arg Gly Ile Val Leu Asp
210	 215	 220
Lys Glu Val Val His Pro Ala Met Pro Lys Arg Val Glu Asn Ala Lys
225	 230	 235	 240
Ile Leu Val Leu Asp Ala Pro Leu Glu Val Gln Lys Pro Glu Leu Thr
245	 250	 255
Thr Lys Ile Arg Val Thr Asp Ile Glu Lys Leu Glu Ser Phe Leu Glu
260	 265	 270
Glu Glu Thr Arg Met Leu Arg Asp Met Val Glu Lys Ile Ala Ala Thr
275	 280	 285
Gly Ala Asn Val Val Ile Thr Gln Lys Gly Ile Asp Glu Val Ala Gln
290	 295	 300
His Phe Leu Ala Lys Lys Gly Ile Leu Ala Val Arg Arg Val Lys Arg
305	 310	 315	 320
Ser Asp Ile Glu Lys Val Ala Lys Ala Thr Gly Ala Lys Ile Val Thr
325	 330	 335
Ser Leu Arg Asp Leu Lys Pro Glu Tyr Leu Gly Tyr Ala Glu Leu Val
340	 345	 350
Glu Glu Arg Lys Val Gly Glu Asp Lys Met Val Phe Ile Glu Gly Ala
355	 360	 365
Lys Asn Pro Lys Ser Val Thr Ile Leu Leu Arg Gly Ala Asn Asp Met
370	 375	 380
Leu Leu Asp Glu Ala Glu Arg Asn Ile Lys Asp Ala Leu His Gly Leu
385	 390	 395	 400
Arg Asn Ile Leu Arg Glu Pro Lys Ile Val Gly Gly Gly Gly Ala Val
405	 410	 415
Glu Val Glu Leu Ala Leu Lys Leu Lys Glu Phe Ala Arg Thr Val Gly
420	 425	 430
Gly Lys Gln Gln Leu Ala Ile Glu Ala Tyr Ala Glu Ala Leu Glu Thr
435	 440	 445
Ile Pro Thr Val Leu Ala Glu Ser Ala Gly Met Asp Ala Leu Glu Ala
450	 455	 460
Leu Leu Lys Leu Arg Ser Leu His Ser Gln Gly Tyr Lys Phe Ala Gly
465	 470	 475	 480
Val Asn Val Leu Glu Gly Lys Ile Glu Glu Asp Met Thr Lys Ile Asn
485	 490	 495
Val Tyr Glu Pro Val Leu Val Lys Lys Gln Val Ile Lys Ser Ala Ser
500	 505	 510
Glu Ala Ala Ile Ser Ile Leu Lys Ile Asp Asp Val Ile Ala Ala Ala
515	 520	 525
Pro Pro Lys Lys Lys Glu Lys Lys Gly Lys Thr Gly Glu Glu Glu Glu
530	 535	 540







<210> SEQ ID NO 8
<211> LENGTH: 542
<212> TYPE: PRT
<213> ORGANISM: Aeropyrum mazei
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: Alpha subunit
<400> SEQUENCE: 8
Met Ala Ala Gin Pro Ile Phe Ile Leu Arg Glu Gly Ser Lys Arg Thr
1	 5	 10	 15
His Gly Ser Asp Ala Gin His Asn Asn Ile Met Ala Ala Lys Ala Val
20	 25	 30
Ala Glu Ala Val Arg Thr Thr Leu Gly Pro Lys Gly Met Asp Lys Met
35	 40	 45
Leu Val Asp Ala Met Gly Asp Val Val Ile Thr Asn Asp Gly Ala Thr
50	 55	 60
Ile Leu Lys Glu Met Asp Ile Glu His Pro Gly Ala Lys Met Ile Val
65	 70	 75	 80
Glu Val Ala Lys Thr Gin Asp Ala Glu Val Gly Asp Gly Thr Thr Thr
85	 90	 95
Ala Ala Val Leu Ala Gly Glu Leu Leu Thr Lys Ala Glu Asp Leu Leu
100	 105	 110
Glu Ser Gly Val His Pro Thr Val Ile Ala Ser Gly Tyr Arg Leu Ala
115	 120	 125
Ala Ile Gin Ala Val Lys Ile Leu Asp Thr Ile Thr Ile Ser Ala Ser
130	 135	 140
Pro Glu Asp Thr Glu Thr Leu Glu Lys Ile Ala Gly Thr Ala Ile Thr
145	 150	 155	 160
Gly Lys Gly Ala Glu Ser His Lys Ala His Leu Ser Asn Leu Ala Val
165	 170	 175
Arg Ala Ile Lys Ser Ile Val Glu Lys Asp Glu Asn Gly Lys Ile Thr
180	 185	 190
Val Asp Ile Glu Asp Val Lys Thr Glu Lys Arg Pro Gly Gly Ser Ile
195	 200	 205
Lys Asp Ser Glu Ile Val Glu Gly Val Ile Val Asp Lys Glu Arg Val
210	 215	 220
His Thr Gly Met Pro Glu Val Val Lys Asp Ala Lys Val Leu Leu Leu
225	 230	 235	 240
Ser Val Pro Ile Glu Leu Lys Lys Thr Glu Thr Lys Ala Glu Ile Lys
245	 250	 255
Ile Thr Thr Pro Asp Gin Met Gin Leu Phe Leu Asp Gin Glu Glu Ala
260	 265	 270
Met Leu Arg Glu Ile Val Asp Lys Val Ile Asp Thr Gly Ala Asn Val
275	 280	 285
Val Phe Cys Gin Lys Gly Ile Asp Asp Leu Ala Gin Tyr Tyr Leu Thr
290	 295	 300
Lys Ala Gly Ile Phe Ala Met Arg Arg Val Lys Lys Ser Asp Met Asp
305	 310	 315	 320
Lys Leu Ser Arg Ala Thr Gly Gly Arg Ile Ile Thr Asn Leu Asp Glu
325	 330	 335







Val Thr Gly Ser Arg Met Thr Phe Val Thr Gly Cys Lys Asp Ser Lys
355	 360	 365
Thr Thr Ser Ile Leu Leu Arg Gly Gly Thr Glu His Val Val Asp Gly
370	 375	 380
Leu Glu Arg Ala Leu Glu Asp Ala Leu Arg Val Val Gly Val Ala Leu
385	 390	 395	 400
Glu Asp Gin Lys Ile Val Val Gly Gly Gly Ser Pro Glu Ile Glu Leu
405	 410	 415
Ser Leu Arg Leu Lys Glu Tyr Ala Ala Thr Leu Lys Gly Arg Glu Gin
420	 425	 430
Leu Ala Val Thr Lys Phe Ala Glu Ser Leu Glu Val Ile Pro Gin Thr
435	 440	 445
Leu Ala Glu Asn Ala Gly Leu Asp Pro Ile Asp Met Leu Val Glu Met
450	 455	 460
Arg Ser Gin His Glu Lys Gly Asn Lys Arg Ala Gly Leu Asn Val Tyr
465	 470	 475	 480
Lys Gly Lys Ile Glu Asp Met Phe Glu Asn Asn Val Val Glu Pro Leu
485	 490	 495
Arg Ile Lys Thr Gin Ala Ile Asn Ala Ala Thr Glu Ala Ala Ile Met
500	 505	 510
Val Leu Arg Ile Asp Asp Val Ile Ala Ser Thr Gly Gly Gly Arg Ala
515	 520	 525
Ala Pro Gly Gly Met Pro Gly Gly Asp Met Glu Asp Met Met
530	 535	 540
<210> SEQ ID NO 9
<211> LENGTH: 577
<212> TYPE: PRT
<213> ORGANISM: Arabodopsis thaliana
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: Mitochondrial thaliana HSP60
<400> SEQUENCE: 9
Met Tyr Arg Phe Ala Ser Asn Leu Ala Ser Lys Ala Arg Ile Ala Gin
1	 5	 10	 15
Asn Ala Arg Gin Val Ser Ser Arg Met Ser Trp Ser Arg Asn Tyr Ala
20	 25	 30
Ala Lys Glu Ile Lys Phe Gly Val Glu Ala Arg Ala Leu Met Leu Lys
35	 40	 45
Gly Val Glu Asp Leu Ala Asp Ala Val Lys Val Thr Met Gly Pro Lys
50	 55	 60
Gly Arg Asn Val Val Ile Glu Gin Ser Trp Gly Ala Pro Lys Val Thr
65	 70	 75	 80
Lys Asp Gly Val Thr Val Ala Lys Ser Ile Glu Phe Lys Asp Lys Ile
85	 90	 95
Lys Asn Val Gly Ala Ser Leu Val Lys Gin Val Ala Asn Ala Thr Asn
100	 105	 110
Asp Val Ala Gly Asp Gly Thr Thr Cys Ala Thr Val Leu Thr Arg Ala
115	 120	 125
Ile Phe Ala Glu Gly Cys Lys Ser Val Ala Ala Gly Met Asn Ala Met
130	 135	 140
Asp Leu Arg Arg Gly Ile Ser Met Ala Val Asp Ala Val Val Thr Asn
145	 150	 155	 160





Val Gly Thr Ile Ser Ala Asn Gly Glu Arg Glu Ile Gly Glu Leu Ile
180	 185	 190
Ala Lys Ala Met Glu Lys Val Gly Lys Glu Gly Val Ile Thr Ile Gln
195	 200	 205
Asp Gly Lys Thr Leu Phe Asn Glu Leu Glu Val Val Glu Gly Met Lys
210	 215	 220
Leu Asp Arg Gly Tyr Thr Ser Pro Tyr Phe Ile Thr Asn Gln Lys Thr
225	 230	 235	 240
Gln Lys Cys Glu Leu Asp Asp Pro Leu Ile Leu Ile His Glu Lys Lys
245	 250	 255
Ile Ser Ser Ile Asn Ser Ile Val Lys Val Leu Glu Leu Ala Leu Lys
260	 265	 270
Arg Gln Arg Pro Leu Leu Ile Val Ser Glu Asp Val Glu Ser Asp Ala
275	 280	 285
Leu Ala Thr Leu Ile Leu Asn Lys Leu Arg Ala Gly Ile Lys Val Cys
290	 295	 300
Ala Ile Lys Ala Pro Gly Phe Gly Glu Asn Arg Lys Ala Asn Leu Gln
305	 310	 315	 320
Asp Leu Ala Ala Leu Thr Gly Gly Glu Val Ile Thr Asp Glu Leu Gly
325	 330	 335
Met Asn Leu Glu Lys Val Asp Leu Ser Met Leu Gly Thr Cys Lys Lys
340	 345	 350
Val Thr Val Ser Lys Asp Asp Thr Val Ile Leu Asp Gly Ala Gly Asp
355	 360	 365
Lys Lys Gly Ile Glu Glu Arg Cys Glu Gln Ile Arg Ser Ala Ile Glu
370	 375	 380
Leu Ser Thr Ser Asp Tyr Asp Lys Glu Lys Leu Gln Glu Arg Leu Ala
385	 390	 395	 400
Lys Leu Ser Gly Gly Val Ala Val Leu Lys Ile Gly Gly Ala Ser Glu
405	 410	 415
Ala Glu Val Gly Glu Lys Lys Asp Arg Val Thr Asp Ala Leu Asn Ala
420	 425	 430
Thr Lys Ala Ala Val Glu Glu Gly Ile Leu Pro Gly Gly Gly Val Ala
435	 440	 445
Leu Leu Tyr Ala Ala Arg Glu Leu Glu Lys Leu Pro Thr Ala Asn Phe
450	 455	 460
Asp Gln Lys Ile Gly Val Gln Ile Ile Gln Asn Ala Leu Lys Thr Pro
465	 470	 475	 480
Val Tyr Thr Ile Ala Ser Asn Ala Gly Val Glu Gly Ala Val Ile Val
485	 490	 495
Gly Lys Leu Leu Glu Gln Asp Asn Pro Asp Leu Gly Tyr Asp Ala Ala
500	 505	 510
Lys Gly Glu Tyr Val Asp Met Val Lys Ala Gly Ile Ile Asp Pro Leu
515	 520	 525
Lys Val Ile Arg Thr Ala Leu Val Asp Ala Ala Ser Val Ser Ser Leu
530	 535	 540
Leu Thr Thr Thr Glu Ala Val Val Val Asp Leu Pro Lys Asp Glu Ser
545	 550	 555	 560






<210> SEQ ID NO 10
<211> LENGTH: 559
<212> TYPE: PRT
<213> ORGANISM: Saccharomyces sp
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: TCP1 alpha subunit
<400> SEQUENCE: 10
Met Ser Gin Leu Phe Asn Asn Ser Arg Ser Asp Thr Leu Phe Leu Gly
1	 5	 10	 15
Gly Glu Lys Ile Ser Gly Asp Asp Ile Arg Asn Gin Asn Val Leu Ala
20	 25	 30
Thr Met Ala Val Ala Asn Val Val Lys Ser Ser Leu Gly Pro Val Gly
35	 40	 45
Leu Asp Lys Met Leu Val Asp Asp Ile Gly Asp Phe Thr Val Thr Asn
50	 55	 60
Asp Gly Ala Thr Ile Leu Ser Leu Leu Asp Val Gin His Pro Ala Gly
65	 70	 75	 80
Lys Ile Leu Val Glu Leu Ala Gin Gin Gin Asp Arg Glu Ile Gly Asp
85	 90	 95
Gly Thr Thr Ser Val Val Ile Ile Ala Ser Glu Leu Leu Lys Arg Ala
100	 105	 110
Asn Glu Leu Val Lys Asn Lys Ile His Pro Thr Thr Ile Ile Thr Gly
115	 120	 125
Phe Arg Val Ala Leu Arg Glu Ala Ile Arg Phe Ile Asn Glu Val Leu
130	 135	 140
Ser Thr Ser Val Asp Thr Leu Gly Lys Glu Thr Leu Ile Asn Ile Ala
145	 150	 155	 160
Lys Thr Ser Met Ser Ser Lys Ile Ile Gly Ala Asp Ser Asp Phe Phe
165	 170	 175
Ser Asn Met Val Val Asp Ala Leu Leu Ala Val Lys Thr Gin Asn Ser
180	 185	 190
Lys Gly Glu Ile Lys Tyr Pro Val Lys Ala Val Asn Val Leu Lys Ala
195	 200	 205
His Gly Lys Ser Ala Thr Glu Ser Leu Leu Val Pro Gly Tyr Ala Leu
210	 215	 220
Asn Cys Thr Val Ala Ser Gin Ala Met Pro Lys Arg Ile Ala Gly Gly
225	 230	 235	 240
Asn Val Lys Ile Ala Cys Leu Asp Leu Asn Leu Gin Lys Ala Arg Met
245	 250	 255
Ala Met Gly Val Gin Ile Asn Ile Asp Asp Pro Glu Gin Leu Glu Gin
260	 265	 270
Ile Arg Lys Arg Glu Ala Gly Ile Val Leu Glu Arg Val Lys Lys Ile
275	 280	 285
Ile Asp Ala Gly Ala Gin Val Val Leu Thr Thr Lys Gly Ile Asp Asp
290	 295	 300
Leu Cys Leu Lys Glu Phe Val Glu Ala Lys Ile Met Gly Val Arg Arg
305	 310	 315	 320
Cys Lys Lys Glu Asp Leu Arg Arg Ile Ala Arg Ala Thr Gly Ala Thr
325	 330	 335
Leu Val Ser Ser Met Ser Asn Leu Glu Gly Glu Glu Thr Phe Glu Ser
340	 345	 350







Asp Glu Cys Ile Leu Ile Lys Gly Thr Ser Lys His Ser Ser Ser Ser
370	 375	 380
Ile Ile Leu Arg Gly Ala Asn Asp Tyr Ser Leu Asp Glu Met Glu Arg
385	 390	 395	 400
Ser Leu His Asp Ser Leu Ser Val Val Lys Arg Thr Leu Glu Ser Gly
405	 410	 415
Asn Val Val Pro Gly Gly Gly Cys Val Glu Ala Ala Leu Asn Ile Tyr
420	 425	 430
Leu Asp Asn Phe Ala Thr Thr Val Gly Ser Arg Glu Gin Leu Ala Ile
435	 440	 445
Ala Glu Phe Ala Ala Ala Leu Leu Ile Ile Pro Lys Thr Leu Ala Val
450	 455	 460
Asn Ala Ala Lys Asp Ser Ser Glu Leu Val Ala Lys Leu Arg Ser Tyr
465	 470	 475	 480
His Ala Ala Ser Gin Met Ala Lys Pro Glu Asp Val Lys Arg Arg Ser
485	 490	 495
Tyr Arg Asn Tyr Gly Leu Asp Leu Ile Arg Gly Lys Ile Val Asp Glu
500	 505	 510
Ile His Ala Gly Val Leu Glu Pro Thr Ile Ser Lys Val Lys Ser Leu
515	 520	 525
Lys Ser Ala Leu Glu Ala Cys Val Ala Ile Leu Arg Ile Asp Thr Met
530	 535	 540
Ile Thr Val Asp Pro Glu Pro Pro Lys Glu Asp Pro His Asp His
545	 550	 555
<210> SEQ ID NO 11
<211> LENGTH: 485
<212> TYPE: PRT
<213> ORGANISM: Homo sapien
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: Human mitochondrial HSP60
<400> SEQUENCE: 11
Met Pro Ser Lys Lys Met Pro Gly Lys Ser Asn His Gly Lys Asn Asn
1	 5	 10	 15
Thr Phe Lys Leu Arg Ala Lys Phe Ser Phe Pro Ile Leu Ala Ala Asp
20	 25	 30
Val Pro Ser Ala Phe Leu Tyr Gly Thr Ser His Ser Gly Gin Leu Ser
35	 40	 45
Leu Pro Gly Ala Lys Arg Ser Tyr Gly Gin Leu Pro Pro Ser Leu Ala
50	 55	 60
Leu Gin Asp Lys Tyr Lys Asn Thr Gly Ala Lys Leu Val Gin Asp Val
65	 70	 75	 80
Ala Asn Asn Thr Asn Glu Glu Ala Val Asp Gly Thr Thr Thr Val Thr
85	 90	 95
Ala Leu Ala Arg Ser Ile Ala Lys Glu Gly Phe Glu Lys Ile Ser Lys
100	 105	 110
Gly Ala Asn Pro Val Glu Ile Arg Arg Gly Val Met Leu Ala Val Asp
115	 120	 125
Ala Ile Ile Ala Glu Pro Lys Lys Gin Ser Lys Pro Val Thr Thr Pro
130	 135	 140
Glu Glu Ile Ala Arg Val Ala Thr Ile Ser Ala Asn Gly Asp Lys Glu
145	 150	 155	 160







Ile Ile Thr Val Asn Asn Gly Lys Ser Gin Lys Cys Glu Phe Gin Asp
180	 185	 190
Ala Tyr Val Leu Leu Ser Glu Lys Lys Ile Ser Ser Val Gin Ser Ile
195	 200	 205
Ala Pro Ala Leu Glu Ile Ala Asn Ala Tyr Ser Leu Val Ile Ile Ala
210	 215	 220
Glu Asp Val Asn Gly Glu Ala Leu Ser Thr Leu Val Leu Asn Arg Leu
225	 230	 235	 240
Lys Val Gly Leu Gin Val Val Ala Val Lys Asp Pro Gly Phe Gly Asp
245	 250	 255
Asn Arg Asn Asn Gin Leu Lys Asp Met Ala Ile Ala Thr Gly Gly Ala
260	 265	 270
Val Phe Ala Glu Glu Gly Leu Thr Leu Asn Leu Glu Asp Val Gin Pro
275	 280	 285
His Asp Leu Gly Lys Val Gly Glu Val Ile Val Thr Lys Asp Asp Ala
290	 295	 300
Met Leu Leu Lys Gly Lys Asp Gly Val Ala Val Leu Lys Val Gly Gly
305	 310	 315	 320
Thr Ser Asp Ala Glu Val Asn Glu Lys Gin Asp Arg Val Thr Asp Ala
325	 330	 335
Leu Asn Ala Thr Arg Ala Ala Val Glu Glu Gly Ile Val Leu Arg Gly
340	 345	 350
Gly Arg Ala Leu Leu Arg Cys Ile Pro Ala Leu Asp Ser Leu Thr Pro
355	 360	 365
Val Asn Glu Asp His Asn Ile Gly Ile Glu Ile Ile Lys Lys Thr Leu
370	 375	 380
Lys Phe Pro Ala Met Thr Ile Ala Lys Asn Ala Gly Val Glu Val Ser
385	 390	 395	 400
Leu Ile Val Glu Lys Ile Met Gin Ser Ser Ser Glu Val Gly Tyr Asp
405	 410	 415
Ala Met Gly Arg Asp Phe Val Asn Met Val Glu Lys Gly Ile Ile Asp
420	 425	 430
Thr Thr Lys Phe Val Arg Thr Ala Leu Leu Asp Ala Ser Gly Val Ala
435	 440	 445
Ser Leu Leu Thr Thr Ala Glu Val Leu Val Thr Glu Ile Pro Lys Glu
450	 455	 460
Glu Lys Asp Pro Gly Met Gly Ala Met Asp Gly Met Gly Gly Gly Met
465	 470	 475	 480
Gly Gly Gly Met Phe
485
<210> SEQ ID NO 12
<211> LENGTH: 573
<212> TYPE: PRT
<213> ORGANISM: Mus sp
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: Mouse mitochondrial HSP60
<400> SEQUENCE: 12
Met Leu Arg Leu Pro Thr Val Leu Arg Gin Met Arg Pro Val Ser Arg
1	 5	 10	 15
Ala Leu Ala Pro His Leu Thr Arg Ala Tyr Ala Lys Asp Val Lys Phe
20	 25	 30







Asp Ala Val Ala Val Thr Met Gly Pro Lys Gly Arg Thr Val Ile Ile
50	 55	 60
Glu Gln Ser Trp Gly Ser Pro Lys Val Thr Lys Asp Gly Val Thr Val
65	 70	 75	 80
Ala Lys Ser Ile Asp Leu Lys Asp Lys Tyr Lys Asn Ile Gly Ala Lys
85	 90	 95
Leu Val Gln Asp Val Ala Asn Asn Thr Asn Glu Glu Ala Gly Asp Gly
100	 105	 110
Thr Thr Thr Ser Thr Val Leu Ala Arg Ser Ile Ala Lys Glu Gly Phe
115	 120	 125
Glu Lys Ile Ser Lys Gly Ala Asn Pro Val Glu Ile Arg Arg Gly Val
130	 135	 140
Met Leu Ala Val Asp Ala Val Ile Ala Glu Leu Lys Lys Gln Ser Lys
145	 150	 155	 160
Pro Val Thr Thr Pro Glu Glu Ile Ala Gln Val Ala Thr Ile Ser Ala
165	 170	 175
Asn Gly Asp Lys Asp Ile Gly Asn Ile Ile Ser Asp Ala Met Lys Lys
180	 185	 190
Val Gly Arg Lys Gly Val Ile Thr Val Lys Asp Gly Lys Thr Leu Asn
195	 200	 205
Asp Glu Leu Glu Ile Ile Glu Gly Met Lys Phe Asp Arg Gly Tyr Ile
210	 215	 220
Ser Pro Tyr Phe Ile Asn Thr Ser Lys Gly Gln Lys Cys Glu Phe Gln
225	 230	 235	 240
Asp Ala Tyr Val Leu Leu Ser Glu Lys Lys Ile Ser Ser Val Gln Ser
245	 250	 255
Ile Val Pro Thr Leu Glu Ile Ala Asn Ala His Arg Lys Pro Leu Val
260	 265	 270
Ile Ile Ala Glu Asp Val Asp Gly Glu Ala Leu Ser Thr Met Val Leu
275	 280	 285
Asn Arg Leu Lys Val Gly Leu Gln Val Val Ala Val Lys Ala Pro Gly
290	 295	 300
Phe Gly Asp Asn Arg Lys Asn Gln Leu Lys Asp Met Ala Ile Ala Thr
305	 310	 315	 320
Gly Gly Ala Val Phe Gly Glu Glu Gly Leu Asn Leu Asn Leu Glu Asp
325	 330	 335
Val Gln Ala His Asp Leu Gly Lys Val Gly Glu Val Ile Val Thr Lys
340	 345	 350
Asp Asp Ala Met Leu Leu Lys Gly Lys Gly Asp Lys Ala His Ile Glu
355	 360	 365
Lys Arg Ile Gln Glu Ile Thr Glu Gln Leu Asp Ile Thr Thr Ser Glu
370	 375	 380
Tyr Glu Lys Glu Lys Leu Asn Glu Arg Leu Ala Lys Leu Ser Asp Gly
385	 390	 395	 400
Val Ala Val Leu Lys Val Gly Gly Thr Ser Asp Val Glu Val Asn Glu
405	 410	 415
Lys Lys Asp Arg Val Thr Asp Ala Leu Asn Ala Thr Arg Ala Ala Val
420	 425	 430
Glu Glu Gly Ile Val Leu Gly Gly Gly Cys Ala Leu Leu Arg Cys Ile
435	 440	 445







Ile Glu Ile Ile Lys Arg Ala Leu Lys Ile Pro Ala Met Thr Ile Ala
465	 470	 475	 480
Lys Asn Ala Gly Val Glu Gly Ser Leu Ile Val Glu Lys Ile Leu Gin
485	 490	 495
Ser Ser Ser Glu Val Gly Tyr Asp Ala Arg Leu Gly Asp Phe Val Asn
500	 505	 510
Met Val Glu Lys Gly Ile Ile Asp Pro Thr Lys Val Val Arg Thr Ala
515	 520	 525
Leu Leu Asp Ala Ala Gly Val Ala Ser Leu Leu Thr Thr Ala Glu Ala
530	 535	 540
Val Val Thr Glu Ile Pro Lys Glu Glu Lys Asp Pro Gly Met Gly Ala
545	 550	 555	 560
Met Gly Gly Met Gly Gly Gly Met Gly Gly Ser Met Leu
565	 570
<210> SEQ ID NO 13
<211> LENGTH: 556
<212> TYPE: PRT
<213> ORGANISM: Homo sapien
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: Human TCP1
<400> SEQUENCE: 13
Met Glu Gly Pro Leu Ser Val Phe Gly Asp Arg Ser Thr Gly Glu Thr
1	 5	 10	 15
Ile Arg Ser Gin Asn Val Met Ala Ala Ala Ser Ile Ala Asn Ile Val
20	 25	 30
Lys Ser Ser Leu Gly Pro Val Gly Leu Asp Lys Met Leu Val Asp Asp
35	 40	 45
Ile Gly Asp Val Thr Ile Thr Asn Asp Gly Ala Thr Ile Leu Lys Leu
50	 55	 60
Leu Glu Val Glu His Pro Ala Ala Lys Val Leu Cys Glu Leu Ala Asp
65	 70	 75	 80
Leu Gin Asp Lys Glu Val Gly Asp Gly Thr Thr Ser Val Val Ile Ile
85	 90	 95
Ala Ala Glu Leu Leu Lys Asn Ala Asp Glu Leu Val Lys Gin Lys Ile
100	 105	 110
His Pro Thr Ser Val Ile Ser Gly Tyr Arg Leu Ala Cys Lys Glu Ala
115	 120	 125
Val Arg Tyr Ile Asn Glu Asn Leu Ile Val Asn Thr Asp Glu Leu Gly
130	 135	 140
Arg Asp Cys Leu Ile Asn Ala Ala Lys Thr Ser Met Ser Ser Lys Ile
145	 150	 155	 160
Ile Gly Ile Asn Gly Asp Phe Phe Ala Asn Met Val Val Asp Ala Val
165	 170	 175
Leu Ala Ile Lys Tyr Thr Asp Ile Arg Gly Gin Pro Arg Tyr Pro Val
180	 185	 190
Asn Ser Val Asn Ile Leu Lys Ala His Gly Arg Ser Gin Met Glu Ser
195	 200	 205
Met Leu Ile Ser Gly Tyr Ala Leu Asn Cys Val Val Gly Ser Gin Gly
210	 215	 220
Met Pro Lys Arg Ile Val Asn Ala Lys Ile Ala Cys Leu Asp Phe Ser
225	 230	 235	 240





Pro Glu Lys Leu Asp Gin Ile Arg Gin Arg Glu Ser Asp Ile Thr Lys
260	 265	 270
Glu Arg Ile Gin Lys Ile Leu Ala Thr Gly Ala Asn Val Ile Leu Thr
275	 280	 285
Thr Gly Gly Ile Asp Asp Met Cys Leu Lys Tyr Phe Val Glu Ala Gly
290	 295	 300
Ala Met Ala Val Arg Arg Val Leu Lys Arg Asp Leu Lys Arg Ile Ala
305	 310	 315	 320
Lys Ala Ser Gly Ala Thr Ile Leu Ser Thr Leu Ala Asn Leu Glu Gly
325	 330	 335
Glu Glu Thr Phe Glu Ala Ala Met Leu Gly Gin Ala Glu Glu Val Val
340	 345	 350
Gin Glu Arg Ile Cys Asp Asp Glu Leu Ile Leu Ile Lys Asn Thr Lys
355	 360	 365
Ala Arg Thr Ser Ala Ser Ile Ile Leu Arg Gly Ala Asn Asp Phe Met
370	 375	 380
Cys Asp Glu Met Glu Arg Ser Leu His Asp Ala Leu Cys Val Val Lys
385	 390	 395	 400
Arg Val Leu Glu Ser Lys Ser Val Val Pro Gly Gly Gly Ala Val Glu
405	 410	 415
Ala Ala Leu Ser Ile Tyr Leu Glu Asn Tyr Ala Thr Ser Met Gly Ser
420	 425	 430
Arg Glu Gin Leu Ala Ile Ala Glu Phe Ala Arg Ser Leu Leu Val Ile
435	 440	 445
Pro Asn Thr Leu Ala Val Asn Ala Ala Gin Asp Ser Thr Asp Leu Val
450	 455	 460
Ala Lys Leu Arg Ala Phe His Asn Glu Ala Gin Val Asn Pro Glu Arg
465	 470	 475	 480
Lys Asn Leu Lys Trp Ile Gly Leu Asp Leu Ser Asn Gly Lys Pro Arg
485	 490	 495
Asp Asn Lys Gin Ala Gly Val Phe Glu Pro Thr Ile Val Lys Val Lys
500	 505	 510
Ser Leu Lys Phe Ala Thr Glu Ala Ala Ile Thr Ile Leu Arg Ile Asp
515	 520	 525
Asp Leu Ile Lys Leu His Pro Glu Ser Lys Asp Asp Lys His Gly Ser
530	 535	 540
Tyr Glu Asp Ala Val His Ser Gly Ala Leu Asn Asp
545	 550	 555
<210> SEQ ID NO 14
<211> LENGTH: 556
<212> TYPE: PRT
<213> ORGANISM: Mus sp
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: Mouse TCP1
<400> SEQUENCE: 14
Met Glu Gly Pro Leu Ser Val Phe Gly Asp Arg Ser Thr Gly Glu Ala
1	 5	 10	 15
Val Arg Ser Gin Asn Val Met Ala Ala Ala Ser Ile Ala Asn Ile Val
20	 25	 30







Ile Gly Asp Val Thr Ile Thr Asn Asp Gly Ala Thr Ile Leu Lys Leu
50	 55	 60
Leu Glu Val Glu His Pro Ala Ala Lys Val Leu Cys Glu Leu Ala Asp
65	 70	 75	 80
Leu Gln Asp Lys Glu Val Gly Asp Gly Thr Thr Ser Val Val Ile Ile
85	 90	 95
Ala Ala Glu Leu Leu Lys Asn Ala Asp Glu Leu Val Lys Gln Lys Ile
100	 105	 110
His Pro Thr Ser Val Ile Ser Gly Tyr Arg Leu Ala Cys Lys Glu Ala
115	 120	 125
Val Arg Tyr Ile Asn Glu Asn Leu Ile Ile Asn Thr Asp Glu Leu Gly
130	 135	 140
Arg Asp Cys Leu Ile Asn Ala Ala Lys Thr Ser Met Ser Ser Lys Ile
145	 150	 155	 160
Ile Gly Ile Asn Gly Asp Tyr Phe Ala Asn Met Val Val Asp Ala Val
165	 170	 175
Leu Ala Val Lys Tyr Thr Asp Ala Arg Gly Gln Pro Arg Tyr Pro Val
180	 185	 190
Asn Ser Val Asn Ile Leu Lys Ala His Gly Arg Ser Gln Ile Glu Ser
195	 200	 205
Met Leu Ile Asn Gly Tyr Ala Leu Asn Cys Val Val Gly Ser Gln Gly
210	 215	 220
Met Pro Lys Arg Ile Val Asn Ala Lys Ile Ala Cys Leu Asp Phe Ser
225	 230	 235	 240
Leu Gln Lys Thr Lys Met Lys Leu Gly Val Gln Val Val Ile Thr Asp
245	 250	 255
Pro Glu Lys Leu Asp Gln Ile Arg Gln Arg Glu Ser Asp Ile Thr Lys
260	 265	 270
Glu Arg Ile Gln Lys Ile Leu Ala Thr Gly Ala Asn Val Ile Leu Thr
275	 280	 285
Thr Gly Gly Ile Asp Asp Met Tyr Leu Lys Tyr Phe Val Glu Ala Gly
290	 295	 300
Ala Met Ala Val Arg Arg Val Leu Lys Arg Asp Leu Lys His Val Ala
305	 310	 315	 320
Lys Ala Ser Gly Ala Ser Ile Leu Ser Thr Leu Ala Asn Leu Glu Gly
325	 330	 335
Glu Glu Thr Phe Glu Val Thr Met Leu Gly Gln Ala Glu Glu Val Val
340	 345	 350
Gln Glu Arg Ile Cys Asp Asp Glu Leu Ile Leu Ile Lys Asn Thr Lys
355	 360	 365
Ala Arg Thr Ser Ala Ser Ile Ile Leu Arg Gly Ala Asn Asp Phe Met
370	 375	 380
Cys Asp Glu Met Glu Arg Ser Leu His Asp Ala Leu Cys Val Val Lys
385	 390	 395	 400
Arg Val Leu Glu Leu Lys Ser Val Val Pro Gly Gly Gly Ala Val Glu
405	 410	 415
Ala Ala Leu Ser Ile Tyr Leu Glu Asn Tyr Ala Thr Ser Met Gly Ser
420	 425	 430
Arg Glu Gln Leu Ala Ile Ala Glu Phe Ala Arg Ser Leu Leu Val Ile
435	 440	 445
Pro Asn Thr Leu Ala Val Asn Ala Ala Gln Asp Ser Thr Asp Leu Val
450	 455	 460






465	 470	 475	 480
Lys Asn Leu Lys Trp Ile Gly Leu Asp Leu Val His Gly Lys Pro Arg
485	 490	 495
Asp Asn Lys Gin Ala Gly Val Phe Glu Pro Thr Ile Val Lys Val Lys
500	 505	 510
Ser Leu Lys Phe Ala Thr Glu Ala Ala Ile Thr Ile Leu Arg Ile Asp
515	 520	 525
Asp Leu Ile Lys Leu His Pro Glu Ser Lys Asp Asp Lys His Gly Ser
530	 535	 540
Tyr Glu Asn Ala Val His Ser Gly Ala Leu Asp Asp
545	 550	 555





<223> OTHER INFORMATION: alignment consensus sequence
<400> SEQUENCE: 15
Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx
1	 5	 10	 15
Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Pro Ile Glx Ile Glx Glu
20	 25	 30
Ala Glx Glx Arg Glx Phe Gly Glx Asp Ala Arg Glx Glx Asn Ile Glx
35	 40	 45
Ala Ala Glx Ala Leu Ala Glu Ala Val Lys Ser Thr Leu Gly Pro Lys
50	 55	 60
Gly Leu Asp Lys Met Leu Val Asp Ser Trp Gly Asp Ile Thr Ile Thr
65	 70	 75	 80
Asn Asp Gly Glx Thr Ile Leu Lys Glu Ile Glu Leu Glu His Pro Glx
85	 90	 95
Glx Glx Glx Gly Ala Lys Leu Leu Glx Glu Val Ala Glx Glx Gin Asp
100	 105	 110
Asp Glu Glx Gly Asp Gly Thr Thr Thr Ala Val Val Leu Ala Glx Ala
115	 120	 125
Leu Leu Lys Glx Ala Glx Glu Leu Val Glx Glx Gly Ile His Pro Thr
130	 135	 140
Glx Glx Ile Glx Gly Tyr Glx Leu Ala Val Glu Glx Ala Val Arg Glx
145	 150	 155	 160
Ile Glx Glx Glx Ala Glx Glx Glx Glx Glx Val Glx Glx Glx Glu Glx
165	 170	 175
Ile Glx Gin Val Ala Glx Thr Ser Ala Glx Ser Lys Glx Glx Glx Gly
180	 185	 190
Glx Glx Glx Ala Asp Ala Met Glx Glx Val Gly Val Glu Ala Val Ile
195	 200	 205
Thr Val Glx Glu Glx Lys Glx Gly Glx Glx Glx Glx Glx Glx Val Glu
210	 215	 220
Glx Val Lys Ile Asp Lys Gly Tyr Gly Glx Ser Glx Glx Asp Ser Glx
225	 230	 235	 240
Leu Ile Glx Gly Glx Glx Glx Glx Glx Val Glx Glu Glx Glx Gly Met
245	 250	 255
Pro Lys Lys Ile Glx Glx Glx Glx Ala Lys Ile Glx Leu Leu Asp Glx
260	 265	 270







Glx Glx Ala Leu Ser Glx Leu Val Leu Asn Arg Glu Arg Glx Ile Leu
290	 295	 300
Lys Glu Val Ala Glx Lys Ile Glx Gly Glx Gly Ala Asn Val Val Glx
305	 310	 315	 320
Glx Lys Gly Ile Asp Asp Leu Glx Glx Glx Glx Glx Leu Ile Glx Glx
325	 330	 335
Glx Glx Glx Glx Leu Ala Leu Arg Arg Val Lys Lys Glx Asp Leu Glx
340	 345	 350
Lys Leu Ala Lys Ala Thr Gly Ala Lys Ile Val Thr Thr Ile Glx Glu
355	 360	 365
Leu Glx Gly Glu Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Leu Gly
370	 375	 380
Glx Ala Glx Glu Val Glx Glx Glx Lys Glx Glx Glx Asp Lys Leu Glx
385	 390	 395	 400
Glx Ile Glx Ala Glx Lys Ala Glx Gly Val Ala Ser Ile Leu Leu Arg
405	 410	 415
Gly Ala Thr Glu Glx Glx Val Asp Glu Glx Glu Arg Ser Leu Glx Asp
420	 425	 430
Ala Leu Glx Val Lys Ala Ala Leu Glu Glx Glu Gly Glx Val Val Gly
435	 440	 445
Gly Gly Gly Ala Leu Glu Glx Leu Ala Glx Leu Leu Glx Glx Glx Tyr
450	 455	 460
Ala Glx Thr Val Glx Gly Arg Glu Gln Leu Ala Ile Glx Glx Phe Ala
465	 470	 475	 480
Glx Ala Leu Glu Glx Ile Pro Glx Thr Leu Ala Glx Asn Ala Gly Leu
485	 490	 495
Asp Glx Glx Asp Ile Val Glx Lys Leu Arg Ser Glx His Glx Glx Glx
500	 505	 510
Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx
515	 520	 525
Gly Leu Asp Leu Glx Glx Glx Glx Glx Gly Glx Asp Met Val Glx Glx
530	 535	 540
Gly Val Ile Asp Pro Glx Lys Val Lys Arg Glx Ala Leu Glx Glx Ala
545	 550	 555	 560
Thr Glu Ala Ala Glx Leu Ile Leu Arg Ile Asp Asp Val Val Glx Glx
565	 570	 575
Glx Pro Glx Glx Glx Glx Asp Glx Glx Glx Glx Ala Glx Glx Glx Glx
580	 585	 590
Glx Glx Glx Met Gly Glx Glx Glx Glx Glx Glx Glx Glx Glx
595	 600	 605





<223> OTHER INFORMATION: metal binding peptide - GaAs or InP
<400> SEQUENCE: 16
Val Thr Ser Pro Asp Ser Thr Thr Gly Ala Met Ala
1	 5	 10








<223> OTHER INFORMATION: metal binding peptide - GaAs or InP
<400> SEQUENCE: 17
Ala Ala Ser Pro Thr Gln Ser Met Ser Gln Ala Pro
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - GaAs or InP
<400> SEQUENCE: 18
Ala Gln Asn Pro Ser Asp Asn Asn Thr His Thr His
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - GaAs or InP
<400> SEQUENCE: 19
Ala Ser Ser Ser Arg Ser His Phe Gly Gln Thr Asp
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - GaAs or InP
<400> SEQUENCE: 20
Trp Ala His Ala Pro Gln Leu Ala Ser Ser Ser Thr
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - GaAs or InP
<400> SEQUENCE: 21
Ala Arg Tyr Asp Leu Ser Ile Pro Ser Ser Glu Ser
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - GaAs or InP
<400> SEQUENCE: 22
Thr Pro Pro Arg Pro Ile Gln Tyr Asn His Thr Ser
1	 5	 10








<223> OTHER INFORMATION: metal binding peptide - GaAs or InP
<400> SEQUENCE: 23
Ser Ser Leu Gln Leu Pro Glu Asn Ser Phe Pro His
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - GaAs or InP
<400> SEQUENCE: 24
Gly Thr Leu Ala Asn Gln Gln Ile Phe Leu Ser Ser
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - GaAs or InP
<400> SEQUENCE: 25
His Gly Asn Pro Leu Pro Met Thr Pro Phe Pro Gly
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - GaAs or InP
<400> SEQUENCE: 26
Arg Leu Glu Leu Ala Ile Pro Leu Gln Gly Ser Gly
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - ZnS
<400> SEQUENCE: 27
Cys Asn Asn Pro Met His Gln Asn Cys
1	 5





<223> OTHER INFORMATION: metal binding peptide - Ag
<400> SEQUENCE: 28
Ala Tyr Ser Ser Gly Ala Pro Pro Met Pro Pro Phe
1	 5	 10








<223> OTHER INFORMATION: metal binding peptide - Ag
<400> SEQUENCE: 29
Asn Pro Ser Ser Leu Phe Arg Tyr Leu Pro Ser Asp
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - Ag
<400> SEQUENCE: 30
Ser Leu Ala Thr Gln Pro Pro Arg Thr Pro Pro Val
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - Au
<400> SEQUENCE: 31
Met His Gly Lys Thr Gln Ala Thr Ser Gly Thr Ile Gln Ser
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - Au
<400> SEQUENCE: 32
Ala Leu Val Pro Thr Ala His Arg Leu Asp Gly Asn Met His
1	 5	 10





<223> OTHER INFORMATION: PCR primer - gamma gene
<400> SEQUENCE: 33
atgaacttag agccttccta t 	 21





<223> OTHER INFORMATION: PCR primer - P2 gamma gene
<400> SEQUENCE: 34
ttaactccat aagaaacttg t 	 21










gaaagaacat atggcctatt tattaagaga aggaacacag	 40





<223> OTHER INFORMATION: PCR primer - P2 primer
<400> SEQUENCE: 36
taaagtactc gagaaaacct aaataaaata atcatatctt aac 	 43
<210> SEQ ID NO 37
<211> LENGTH: 1607
<212> TYPE: DNA
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: TF55 gamma subunit
<400> SEQUENCE: 37
atggcctatt tattaagaga aggaacacag agatctactg gaaacgaggt aatactaaac 	 60
aacatagctg tagccaaaat attactggaa atgctaaagt caagcctagg tcctaagggt 	 120
ttagacaaga tgttagttga ggggcaagac attacaataa ctaatgacgg tgcgacaata 	 180
gttaaaaaca tggaagtgca gcatcctact gcaaaattac tcattgaaac cgctaaaact	 240
gttgataccg aggtaggaga tgggacaact tcagtagtcg ttcttgccgg gttactatta 	 300
gaaaaagctg aggatttgct gaatcagaag atccatccaa ctgtcataat agaaggttat 	 360
aggaaggctc taagttcatc attagaattg ttaaaaagta ttgcagataa gattagtcca 	 420
gaagatagga agatagttca cgatctagta tatactactc tatcgagtaa gttcttctca 	 480
acagagcata ctctagagaa gataataaat ctagttattg aagcttcatt ggcggtattg 	 540
gataaaagag atggaaccta tgatctggat attaagaata taaagattgt aaaagtcaat	 600
ggtggggaat ttgatgatag tgagcttgta aatgggatcg ttgtagataa ggagcccacc 	 660
aatgagaata tgccgaaaag ggcggaaaac gttaaggtaa tgttagctga cttcccatta 	 720
aaacttgaaa aaacggaaat tagcatgaag ctgggaataa gtgaccccac tcagataaag 	 780
ggatacttgg atgaacaaac ggcatatgtt aagcaaatgg tggataagat aaaggctatg	 840
ggcgttaaat tgtttattac acaaaaggac attgatgaag tcgcttcata tttaatggga 	 900
aaaagtggga taatagcgtt aaagaacgta aagaggagtg acatagagtt actgagtaga 	 960
gctactggtg cgaaaattgc aagtagcatg aaagacgcta atgagagtga tttaggggaa 	 1020
gctaaattag tggaggttag aaatttagga aagaacaaat acctcttcat tcaatctgat	 1080
aaagctaaag cggtgactgt aatcataaag ggctcgaata acatggtaac tgatgaagca 	 1140
gaaaggagtt taaatgacgc ctttaactcc ataagaaact tgttactaga accctatatt 	 1200
gtggctggtg gtggtgctgt agaggaggag ttggctaaga ggttaaggga gaacgctgga 	 1260
aaagttcccg gaaaggagca attggcattt aatgcatttg cggatgcttt ggaggagtac	 1320
gtttcaatac tatcagaaac tgctggcatg gatcccataa gtgcgttaac cgaaataaga	 1380
cataaacatg caaacgggtt aaagaatgct gggattgaca tagttaaggc tagaatttac 	 1440
gataacatgc ttgagcttaa agtaatcgat tctctaaagg ttaaggaaca agttttaaag	 1500
agcgccacag aagccgctac tgcgatttta aagatcgacg acatgatagc agcagctcct 	 1560




<210> SEQ ID NO 38
<211> LENGTH: 535
<212> TYPE: PRT
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: TF55 gamma subunit
<400> SEQUENCE: 38
Met Ala Tyr Leu Leu Arg Glu Gly Thr Gin Arg Ser Thr Gly Asn Glu
1	 5	 10	 15
Val Ile Leu Asn Asn Ile Ala Val Ala Lys Ile Leu Leu Glu Met Leu
20	 25	 30
Lys Ser Ser Leu Gly Pro Lys Gly Leu Asp Lys Met Leu Val Glu Gly
35	 40	 45
Gin Asp Ile Thr Ile Thr Asn Asp Gly Ala Thr Ile Val Lys Asn Met
50	 55	 60
Glu Val Gin His Pro Thr Ala Lys Leu Leu Ile Glu Thr Ala Lys Thr
65	 70	 75	 80
Val Asp Thr Glu Val Gly Asp Gly Thr Thr Ser Val Val Val Leu Ala
85	 90	 95
Gly Leu Leu Leu Glu Lys Ala Glu Asp Leu Leu Asn Gin Lys Ile His
100	 105	 110
Pro Thr Val Ile Ile Glu Gly Tyr Arg Lys Ala Leu Ser Ser Ser Leu
115	 120	 125
Glu Leu Leu Lys Ser Ile Ala Asp Lys Ile Ser Pro Glu Asp Arg Lys
130	 135	 140
Ile Val His Asp Leu Val Tyr Thr Thr Leu Ser Ser Lys Phe Phe Ser
145	 150	 155	 160
Thr Glu His Thr Leu Glu Lys Ile Ile Asn Leu Val Ile Glu Ala Ser
165	 170	 175
Leu Ala Val Leu Asp Lys Arg Asp Gly Thr Tyr Asp Leu Asp Ile Lys
180	 185	 190
Asn Ile Lys Ile Val Lys Val Asn Gly Gly Glu Phe Asp Asp Ser Glu
195	 200	 205
Leu Val Asn Gly Ile Val Val Asp Lys Glu Pro Thr Asn Glu Asn Met
210	 215	 220
Pro Lys Arg Ala Glu Asn Val Lys Val Met Leu Ala Asp Phe Pro Leu
225	 230	 235	 240
Lys Leu Glu Lys Thr Glu Ile Ser Met Lys Leu Gly Ile Ser Asp Pro
245	 250	 255
Thr Gin Ile Lys Gly Tyr Leu Asp Glu Gin Thr Ala Tyr Val Lys Gin
260	 265	 270
Met Val Asp Lys Ile Lys Ala Met Gly Val Lys Leu Phe Ile Thr Gin
275	 280	 285
Lys Asp Ile Asp Glu Val Ala Ser Tyr Leu Met Gly Lys Ser Gly Ile
290	 295	 300
Ile Ala Leu Lys Asn Val Lys Arg Ser Asp Ile Glu Leu Leu Ser Arg
305	 310	 315	 320
Ala Thr Gly Ala Lys Ile Ala Ser Ser Met Lys Asp Ala Asn Glu Ser
325	 330	 335
Asp Leu Gly Glu Ala Lys Leu Val Glu Val Arg Asn Leu Gly Lys Asn
340	 345	 350





Ile Lys Gly Ser Asn Asn Met Val Thr Asp Glu Ala Glu Arg Ser Leu
370	 375	 380
Asn Asp Ala Phe Asn Ser Ile Arg Asn Leu Leu Leu Glu Pro Tyr Ile
385	 390	 395	 400
Val Ala Gly Gly Gly Ala Val Glu Glu Glu Leu Ala Lys Arg Leu Arg
405	 410	 415
Glu Asn Ala Gly Lys Val Pro Gly Lys Glu Gin Leu Ala Phe Asn Ala
420	 425	 430
Phe Ala Asp Ala Leu Glu Glu Tyr Val Ser Ile Leu Ser Glu Thr Ala
435	 440	 445
Gly Met Asp Pro Ile Ser Ala Leu Thr Glu Ile Arg His Lys His Ala
450	 455	 460
Asn Gly Leu Lys Asn Ala Gly Ile Asp Ile Val Lys Ala Arg Ile Tyr
465	 470	 475	 480
Asp Asn Met Leu Glu Leu Lys Val Ile Asp Ser Leu Lys Val Lys Glu
485	 490	 495
Gin Val Leu Lys Ser Ala Thr Glu Ala Ala Thr Ala Ile Leu Lys Ile
500	 505	 510
Asp Asp Met Ile Ala Ala Ala Pro Ala Lys Gin Gin Pro Gin Pro Gin
515	 520	 525
Gin Pro Asn Pro Tyr Leu Gly
530	 535
<210> SEQ ID NO 39
<211> LENGTH: 560
<212> TYPE: PRT
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: TF55 alpha subunit
<400> SEQUENCE: 39
Met Ala Ser Pro Val Leu Leu Leu Lys Glu Gly Thr Ser Arg Thr Thr
1	 5	 10	 15
Gly Arg Asp Ala Leu Arg Asn Asn Ile Leu Ala Ala Lys Thr Leu Ala
20	 25	 30
Glu Met Leu Arg Ser Ser Leu Gly Pro Lys Gly Leu Asp Lys Met Leu
35	 40	 45
Ile Asp Ser Phe Gly Asp Val Thr Ile Thr Asn Asp Gly Ala Thr Ile
50	 55	 60
Val Lys Asp Met Glu Ile Gin His Pro Ala Ala Lys Leu Leu Val Glu
65	 70	 75	 80
Ala Ala Lys Ala Gin Asp Ala Glu Val Gly Asp Gly Thr Thr Ser Ala
85	 90	 95
Val Val Leu Ala Gly Ala Leu Leu Glu Lys Ala Glu Ser Leu Leu Asp
100	 105	 110
Gin Asn Ile His Pro Thr Ile Ile Ile Glu Gly Tyr Lys Lys Ala Tyr
115	 120	 125
Thr Lys Ala Leu Glu Leu Leu Pro Gin Leu Gly Thr Arg Ile Asp Ile
130	 135	 140
Arg Asp Leu Asn Ser Ser Val Ala Arg Asp Thr Leu Arg Lys Ile Ala
145	 150	 155	 160





Lys Ile Ile Asp Met Val Ile Asp Ala Ile Val Asn Val Ala Glu Pro
180	 185	 190
Leu Pro Asn Gly Gly Tyr Asn Val Ser Leu Asp Leu Ile Lys Ile Asp
195	 200	 205
Lys Lys Lys Gly Gly Ser Ile Glu Asp Ser Val Leu Val Lys Gly Leu
210	 215	 220
Val Leu Asp Lys Glu Val Val His Pro Gly Met Pro Arg Arg Val Thr
225	 230	 235	 240
Lys Ala Lys Ile Ala Val Leu Asp Ala Ala Leu Glu Val Glu Lys Pro
245	 250	 255
Glu Ile Ser Ala Lys Ile Ser Ile Thr Ser Pro Glu Gln Ile Lys Ala
260	 265	 270
Phe Leu Asp Glu Glu Ser Lys Tyr Leu Lys Asp Met Val Asp Lys Leu
275	 280	 285
Ala Ser Ile Gly Ala Asn Val Val Ile Cys Gln Lys Gly Ile Asp Asp
290	 295	 300
Ile Ala Gln His Phe Leu Ala Lys Lys Gly Ile Leu Ala Val Arg Arg
305	 310	 315	 320
Val Lys Arg Ser Asp Ile Glu Lys Leu Glu Lys Ala Leu Gly Ala Arg
325	 330	 335
Ile Ile Ser Ser Ile Lys Asp Ala Thr Pro Asp Asp Leu Gly Tyr Ala
340	 345	 350
Glu Leu Val Glu Glu Arg Arg Val Gly Asn Asp Lys Met Val Phe Ile
355	 360	 365
Glu Gly Ala Lys Asn Leu Lys Ala Val Asn Ile Leu Leu Arg Gly Ser
370	 375	 380
Asn Asp Met Ala Leu Asp Glu Ala Glu Arg Ser Ile Asn Asp Ala Leu
385	 390	 395	 400
His Ala Leu Arg Asn Ile Leu Leu Glu Pro Val Ile Leu Pro Gly Gly
405	 410	 415
Gly Ala Ile Glu Leu Glu Leu Ala Met Lys Leu Arg Glu Tyr Ala Arg
420	 425	 430
Ser Val Gly Gly Lys Glu Gln Leu Ala Ile Glu Ala Phe Ala Asp Ala
435	 440	 445
Leu Glu Glu Ile Pro Thr Ile Leu Ala Glu Thr Ala Gly Leu Glu Ala
450	 455	 460
Ile Ser Ala Leu Met Asp Leu Arg Ala Arg His Ala Lys Gly Leu Thr
465	 470	 475	 480
Asn Thr Gly Val Asp Val Ile Gly Gly Lys Ile Val Asp Asp Val Tyr
485	 490	 495
Ala Leu Asn Ile Ile Glu Pro Ile Arg Val Lys Ala Gln Val Leu Lys
500	 505	 510
Ser Ala Thr Glu Ala Ala Thr Ala Ile Leu Lys Ile Asp Asp Leu Ile
515	 520	 525
Ala Ala Ala Pro Leu Lys Ser Glu Lys Lys Gly Gly Glu Gly Ser Lys
530	 535	 540
Glu Glu Ser Gly Gly Glu Gly Gly Ala Gly Thr Pro Ser Leu Gly Asp
545	 550	 555	 560










Ser Lys Thr Ser Leu Gly Gin Ser Gly Ala Ser Leu Gin Gly Ser Glu
1	 5	 10	 15
Lys Leu Thr Asn Gly
20





<223> OTHER INFORMATION: metal binding peptide - Au
<400> SEQUENCE: 41
Gin Ala Thr Ser Glu Lys Leu Val Arg Gly Met Glu Gly Ala Ser Leu
1	 5	 10	 15
His Pro Ala Lys Thr
20





<223> OTHER INFORMATION: metal binding peptide - Pt
<400> SEQUENCE: 42
Asp Arg Thr Ser Thr Trp Arg
1	 5





<223> OTHER INFORMATION: metal binding peptide - Pt
<400> SEQUENCE: 43
Gin Ser Val Thr Ser Thr Lys
1	 5





<223> OTHER INFORMATION: metal binding peptide - Pt
<400> SEQUENCE: 44
Ser Ser Ser His Leu Asn Lys
1	 5





<223> OTHER INFORMATION: metal binding peptide - Pd
<400> SEQUENCE: 45
Ser Val Thr Gin Asn Lys Tyr
1	 5








<223> OTHER INFORMATION: metal binding peptide - Pd
<400> SEQUENCE: 46
Ser Pro His Pro Gly Pro Tyr
1	 5





<223> OTHER INFORMATION: metal binding peptide - Pd
<400> SEQUENCE: 47
His Ala Pro Thr Pro Met Leu
1	 5





<223> OTHER INFORMATION: metal binding peptide - SiO2
<400> SEQUENCE: 48
Met Ser Pro His Pro His Pro Arg His His His Thr
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - SiO2
<400> SEQUENCE: 49
Arg Gly Arg Arg Arg Arg Leu Ser Cys Arg Leu Leu
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - SiO2
<400> SEQUENCE: 50
Lys Pro Ser His His His His His Thr Gly Ala Asn
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - zeolites
<400> SEQUENCE: 51
Val Lys Thr Gin Ala Thr Ser Arg Glu Glu Pro Pro Arg Leu Pro Ser
1	 5	 10	 15










<223> OTHER INFORMATION: metal binding peptide - zeolites
<400> SEQUENCE: 52
Met Asp His Gly Lys Tyr Arg Gin Lys Gin Ala Thr Pro Gly
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - ZnO
<400> SEQUENCE: 53
Asn Thr Arg Met Thr Ala Arg Gin His Arg Ser Ala Asn His Lys Ser
1	 5	 10	 15
Thr Gin Arg Ala
20





<223> OTHER INFORMATION: metal binding peptide ZnO
<400> SEQUENCE: 54
Tyr Asp Ser Arg Ser Met Arg Pro His
1	 5





<223> OTHER INFORMATION: metal binding peptide - CaCO3
<400> SEQUENCE: 55
His Thr Gin Asn Met Arg Met Tyr Glu Pro Trp Phe
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - CaCO3
<400> SEQUENCE: 56
Asp Val Phe Ser Ser Phe Asn Leu Lys His Met Arg
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - Cr2O3
<400> SEQUENCE: 57










<223> OTHER INFORMATION: metal binding peptide - Cr2O3
<400> SEQUENCE: 58
Arg Ile Arg His Arg Leu Val Gly Gln
1	 5





<223> OTHER INFORMATION: metal binding peptide - Fe2O3
<400> SEQUENCE: 59
Arg Arg Thr Val Lys His His Val Asn
1	 5





<223> OTHER INFORMATION: metal binding peptide - GaAs
<400> SEQUENCE: 60
Ala Gln Asn Pro Ser Asp Asn Asn Thr Thr His
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - GaAs
<400> SEQUENCE: 61
Arg Leu Glu Leu Ala Ile Pro Leu Gln Gly Ser Gly
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - GaAs
<400> SEQUENCE: 62
Thr Pro Pro Arg Pro Ile Gln Tyr Asn His Thr Ser
1	 5	 10





<223> OTHER INFORMATION: metal binding peptide - ZnS
<400> SEQUENCE: 63










<223> OTHER INFORMATION: flexible peptide linker
<400> SEQUENCE: 64
Gly Gly Ser Gly Gly Thr
1	 5





<223> OTHER INFORMATION: flexible linker
<400> SEQUENCE: 65
ggtggttctg gtggtacc	 18
<210> SEQ ID NO 66
<211> LENGTH: 1575
<212> TYPE: DNA
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: chaperonin permutant 153
<400> SEQUENCE: 66
atggcaataa atgatactga cgtacttagg aaagtagcat taacatcctt aggcagtaag 	 60
gcagtagcag gcgcacgaga gtatttagct gaccttgtgg ttaaagcagt ggcacaagta 	 120
gcagaattaa gaggagataa gtggtatgtt gatctagata atgtacaaat agttaaaaaa 	 180
catggtggta gcattaatga tactcaatta gtatacggca tagtagttga taaggaagtt 	 240
gtacatccgg gcatgccaaa gaggattgaa aatgctaaga tagccctttt agacgcttca 	 300
ttagaagttg agaaacccga attggatgca gaaataagaa ttaacgatcc aacacagatg 	 360
cacaaattct tggaagaaga agaaaacata ttgaaagaaa aagtagataa gattgcagct 	 420
actggtgcta acgttgtaat agcgcagaaa ggtatcgatg aagttgcaca acactattta 	 480
gctaagaaag gtatattagc tgttaggaga gccaagaaga gtgatttaga gaaattagct 	 540
agagctaccg gaggtagagt catatcaaat attgatgaat taacttcaca agatctaggt 	 600
tatgccgcat tagtggaaga gagaaaagta ggtgaagaca agatcgtatt cgtagaaggt 	 660
gcaaagaatc caaaatcagt tagtatacta ataagaggag gattagagag agtagtagat 	 720
gagactgaaa gagctcttag ggacgcttta ggtacagtgg cagatgtaat aagggatggt 	 780
agagcagtag ctggtggtgg agctgttgag atagagatag ctaagagatt aagaaagtat 	 840
gccccacaag ttggtggtaa agagcaatta gcaattgaag catatgctaa tgcaatagag 	 900
ggtctcatta tgatattggc ggaaaacgca ggattagatc ctatagacaa attaatgcaa 	 960
ttaagaagtc ttcacgagaa tgagaccaat aaatggtatg gacttaattt atttactgga 	 1020
aatccagagg atatgtggaa attaggtgtt attgaaccgg cactagtgaa aatgaatgca 	 1080
attaaggctg caacagaagc agtaacatta gtgttaagaa tagatgatat tgtaggtggt 	 1140
tctggtggta ccatacctgt aataatttta aaagagggat caagtagaac atatggaaaa 	 1200




tatggtccac gtggaatgga taagattctt gttgatagct taggagatat tacaataaca 	 1320
aatgatggag ccactattct tgataaaatg gatttacaac acccaacagg taagctttta 	 1380
gttcagatag ctaaaggaca agacgaggaa acagctgatg gcactaaaac tgctgtaatt 	 1440
cttgctggag aattagctaa aaaagcagaa gatcttttat ataaggagat tcacccaaca 	 1500
ataattgtaa gcggatataa gaaggcagaa gaaattgcat taaagaccat ccaagatata 	 1560
gcacaaccgg tcagc	 1575
<210> SEQ ID NO 67
<211> LENGTH: 525
<212> TYPE: PRT
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: chaperonin permutant 153
<400> SEQUENCE: 67
Met Ala Ile Asn Asp Thr Asp Val Leu Arg Lys Val Ala Leu Thr Ser
1	 5	 10	 15
Leu Gly Ser Lys Ala Val Ala Gly Ala Arg Glu Tyr Leu Ala Asp Leu
20	 25	 30
Val Val Lys Ala Val Ala Gin Val Ala Glu Leu Arg Gly Asp Lys Trp
35	 40	 45
Tyr Val Asp Leu Asp Asn Val Gin Ile Val Lys Lys His Gly Gly Ser
50	 55	 60
Ile Asn Asp Thr Gin Leu Val Tyr Gly Ile Val Val Asp Lys Glu Val
65	 70	 75	 80
Val His Pro Gly Met Pro Lys Arg Ile Glu Asn Ala Lys Ile Ala Leu
85	 90	 95
Leu Asp Ala Ser Leu Glu Val Glu Lys Pro Glu Leu Asp Ala Glu Ile
100	 105	 110
Arg Ile Asn Asp Pro Thr Gin Met His Lys Phe Leu Glu Glu Glu Glu
115	 120	 125
Asn Ile Leu Lys Glu Lys Val Asp Lys Ile Ala Ala Thr Gly Ala Asn
130	 135	 140
Val Val Ile Ala Gin Lys Gly Ile Asp Glu Val Ala Gin His Tyr Leu
145	 150	 155	 160
Ala Lys Lys Gly Ile Leu Ala Val Arg Arg Ala Lys Lys Ser Asp Leu
165	 170	 175
Glu Lys Leu Ala Arg Ala Thr Gly Gly Arg Val Ile Ser Asn Ile Asp
180	 185	 190
Glu Leu Thr Ser Gin Asp Leu Gly Tyr Ala Ala Leu Val Glu Glu Arg
195	 200	 205
Lys Val Gly Glu Asp Lys Ile Val Phe Val Glu Gly Ala Lys Asn Pro
210	 215	 220
Lys Ser Val Ser Ile Leu Ile Arg Gly Gly Leu Glu Arg Val Val Asp
225	 230	 235	 240
Glu Thr Glu Arg Ala Leu Arg Asp Ala Leu Gly Thr Val Ala Asp Val
245	 250	 255
Ile Arg Asp Gly Arg Ala Val Ala Gly Gly Gly Ala Val Glu Ile Glu
260	 265	 270
Ile Ala Lys Arg Leu Arg Lys Tyr Ala Pro Gin Val Gly Gly Lys Glu
275	 280	 285





Ile Leu Ala Glu Asn Ala Gly Leu Asp Pro Ile Asp Lys Leu Met Gln
305	 310	 315	 320
Leu Arg Ser Leu His Glu Asn Glu Thr Asn Lys Trp Tyr Gly Leu Asn
325	 330	 335
Leu Phe Thr Gly Asn Pro Glu Asp Met Trp Lys Leu Gly Val Ile Glu
340	 345	 350
Pro Ala Leu Val Lys Met Asn Ala Ile Lys Ala Ala Thr Glu Ala Val
355	 360	 365
Thr Leu Val Leu Arg Ile Asp Asp Ile Val Gly Gly Ser Gly Gly Thr
370	 375	 380
Ile Pro Val Ile Ile Leu Lys Glu Gly Ser Ser Arg Thr Tyr Gly Lys
385	 390	 395	 400
Glu Ala Leu Arg Ala Asn Ile Ala Ala Val Lys Ala Ile Glu Glu Ala
405	 410	 415
Leu Lys Ser Thr Tyr Gly Pro Arg Gly Met Asp Lys Ile Leu Val Asp
420	 425	 430
Ser Leu Gly Asp Ile Thr Ile Thr Asn Asp Gly Ala Thr Ile Leu Asp
435	 440	 445
Lys Met Asp Leu Gln His Pro Thr Gly Lys Leu Leu Val Gln Ile Ala
450	 455	 460
Lys Gly Gln Asp Glu Glu Thr Ala Asp Gly Thr Lys Thr Ala Val Ile
465	 470	 475	 480
Leu Ala Gly Glu Leu Ala Lys Lys Ala Glu Asp Leu Leu Tyr Lys Glu
485	 490	 495
Ile His Pro Thr Ile Ile Val Ser Gly Tyr Lys Lys Ala Glu Glu Ile
500	 505	 510
Ala Leu Lys Thr Ile Gln Asp Ile Ala Gln Pro Val Ser
515	 520	 525
<210> SEQ ID NO 68
<211> LENGTH:	 1575
<212> TYPE: DNA
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: chaperonin permutant 267
<400> SEQUENCE:	 68
atggcagatc caacacagat gcacaaattc ttggaagaag aagaaaacat attgaaagaa 60
aaagtagata agattgcagc tactggtgct aacgttgtaa tagcgcagaa aggtatcgat 120
gaagttgcac aacactattt agctaagaaa ggtatattag ctgttaggag agccaagaag 180
agtgatttag agaaattagc tagagctacc ggaggtagag tcatatcaaa tattgatgaa 240
ttaacttcac aagatctagg ttatgccgca ttagtggaag agagaaaagt aggtgaagac 300
aagatcgtat tcgtagaagg tgcaaagaat ccaaaatcag ttagtatact aataagagga 360
ggattagaga gagtagtaga tgagactgaa agagctctta gggacgcttt aggtacagtg 420
gcagatgtaa taagggatgg tagagcagta gctggtggtg gagctgttga gatagagata 480
gctaagagat taagaaagta tgccccacaa gttggtggta aagagcaatt agcaattgaa 540
gcatatgcta atgcaataga gggtctcatt atgatattgg cggaaaacgc aggattagat 600
cctatagaca aattaatgca attaagaagt cttcacgaga atgagaccaa taaatggtat 660
ggacttaatt tatttactgg aaatccagag gatatgtgga aattaggtgt tattgaaccg 720






atagatgata ttgtaggtgg ttctggtggt accatacctg taataatttt aaaagaggga 	 840
tcaagtagaa catatggaaa agaagcttta agggctaata ttgctgcagt gaaagcaatt 	 900
gaagaggcat taaaaagcac ctatggtcca cgtggaatgg ataagattct tgttgatagc 	 960
ttaggagata ttacaataac aaatgatgga gccactattc ttgataaaat ggatttacaa 	 1020
cacccaacag gtaagctttt agttcagata gctaaaggac aagacgagga aacagctgat 	 1080
ggcactaaaa ctgctgtaat tcttgctgga gaattagcta aaaaagcaga agatctttta 	 1140
tataaggaga ttcacccaac aataattgta agcggatata agaaggcaga agaaattgca 	 1200
ttaaagacca tccaagatat agcacaaccg gtcagcataa atgatactga cgtacttagg 	 1260
aaagtagcat taacatcctt aggcagtaag gcagtagcag gcgcacgaga gtatttagct 	 1320
gaccttgtgg ttaaagcagt ggcacaagta gcagaattaa gaggagataa gtggtatgtt 	 1380
gatctagata atgtacaaat agttaaaaaa catggtggta gcattaatga tactcaatta 	 1440
gtatacggca tagtagttga taaggaagtt gtacatccgg gcatgccaaa gaggattgaa 	 1500
aatgctaaga tagccctttt agacgcttca ttagaagttg agaaacccga attggatgca 	 1560
gaaataagaa ttaac	 1575
<210> SEQ ID NO 69
<211> LENGTH: 525
<212> TYPE: PRT
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: chaperonin permutant 267
<400> SEQUENCE: 69
Met Ala Asp Pro Thr Gin Met His Lys Phe Leu Glu Glu Glu Glu Asn
1	 5	 10	 15
Ile Leu Lys Glu Lys Val Asp Lys Ile Ala Ala Thr Gly Ala Asn Val
20	 25	 30
Val Ile Ala Gin Lys Gly Ile Asp Glu Val Ala Gin His Tyr Leu Ala
35	 40	 45
Lys Lys Gly Ile Leu Ala Val Arg Arg Ala Lys Lys Ser Asp Leu Glu
50	 55	 60
Lys Leu Ala Arg Ala Thr Gly Gly Arg Val Ile Ser Asn Ile Asp Glu
65	 70	 75	 80
Leu Thr Ser Gin Asp Leu Gly Tyr Ala Ala Leu Val Glu Glu Arg Lys
85	 90	 95
Val Gly Glu Asp Lys Ile Val Phe Val Glu Gly Ala Lys Asn Pro Lys
100	 105	 110
Ser Val Ser Ile Leu Ile Arg Gly Gly Leu Glu Arg Val Val Asp Glu
115	 120	 125
Thr Glu Arg Ala Leu Arg Asp Ala Leu Gly Thr Val Ala Asp Val Ile
130	 135	 140
Arg Asp Gly Arg Ala Val Ala Gly Gly Gly Ala Val Glu Ile Glu Ile
145	 150	 155	 160
Ala Lys Arg Leu Arg Lys Tyr Ala Pro Gin Val Gly Gly Lys Glu Gin
165	 170	 175
Leu Ala Ile Glu Ala Tyr Ala Asn Ala Ile Glu Gly Leu Ile Met Ile
180	 185	 190





Arg Ser Leu His Glu Asn Glu Thr Asn Lys Trp Tyr Gly Leu Asn Leu
210	 215	 220
Phe Thr Gly Asn Pro Glu Asp Met Trp Lys Leu Gly Val Ile Glu Pro
225	 230	 235	 240
Ala Leu Val Lys Met Asn Ala Ile Lys Ala Ala Thr Glu Ala Val Thr
245	 250	 255
Leu Val Leu Arg Ile Asp Asp Ile Val Gly Gly Ser Gly Gly Thr Ile
260	 265	 270
Pro Val Ile Ile Leu Lys Glu Gly Ser Ser Arg Thr Tyr Gly Lys Glu
275	 280	 285
Ala Leu Arg Ala Asn Ile Ala Ala Val Lys Ala Ile Glu Glu Ala Leu
290	 295	 300
Lys Ser Thr Tyr Gly Pro Arg Gly Met Asp Lys Ile Leu Val Asp Ser
305	 310	 315	 320
Leu Gly Asp Ile Thr Ile Thr Asn Asp Gly Ala Thr Ile Leu Asp Lys
325	 330	 335
Met Asp Leu Gln His Pro Thr Gly Lys Leu Leu Val Gln Ile Ala Lys
340	 345	 350
Gly Gln Asp Glu Glu Thr Ala Asp Gly Thr Lys Thr Ala Val Ile Leu
355	 360	 365
Ala Gly Glu Leu Ala Lys Lys Ala Glu Asp Leu Leu Tyr Lys Glu Ile
370	 375	 380
His Pro Thr Ile Ile Val Ser Gly Tyr Lys Lys Ala Glu Glu Ile Ala
385	 390	 395	 400
Leu Lys Thr Ile Gln Asp Ile Ala Gln Pro Val Ser Ile Asn Asp Thr
405	 410	 415
Asp Val Leu Arg Lys Val Ala Leu Thr Ser Leu Gly Ser Lys Ala Val
420	 425	 430
Ala Gly Ala Arg Glu Tyr Leu Ala Asp Leu Val Val Lys Ala Val Ala
435	 440	 445
Gln Val Ala Glu Leu Arg Gly Asp Lys Trp Tyr Val Asp Leu Asp Asn
450	 455	 460
Val Gln Ile Val Lys Lys His Gly Gly Ser Ile Asn Asp Thr Gln Leu
465	 470	 475	 480
Val Tyr Gly Ile Val Val Asp Lys Glu Val Val His Pro Gly Met Pro
485	 490	 495
Lys Arg Ile Glu Asn Ala Lys Ile Ala Leu Leu Asp Ala Ser Leu Glu
500	 505	 510
Val Glu Lys Pro Glu Leu Asp Ala Glu Ile Arg Ile Asn
515	 520	 525
<210> SEQ ID NO 70
<211> LENGTH: 1575
<212> TYPE: DNA
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: chaperonin permutant 316
<400> SEQUENCE: 70
atggcaatat tagctgttag gagagccaag aagagtgatt tagagaaatt agctagagct 	 60
accggaggta gagtcatatc aaatattgat gaattaactt cacaagatct aggttatgcc 120
gcattagtgg aagagagaaa agtaggtgaa gacaagatcg tattcgtaga aggtgcaaag 180




gaaagagctc ttagggacgc tttaggtaca gtggcagatg taataaggga tggtagagca 	 300
gtagctggtg gtggagctgt tgagatagag atagctaaga gattaagaaa gtatgcccca 	 360
caagttggtg gtaaagagca attagcaatt gaagcatatg ctaatgcaat agagggtctc 	 420
attatgatat tggcggaaaa cgcaggatta gatcctatag acaaattaat gcaattaaga 	 480
agtcttcacg agaatgagac caataaatgg tatggactta atttatttac tggaaatcca 	 540
gaggatatgt ggaaattagg tgttattgaa ccggcactag tgaaaatgaa tgcaattaag 	 600
gctgcaacag aagcagtaac attagtgtta agaatagatg atattgtagg tggttctggt 	 660
ggtaccatac ctgtaataat tttaaaagag ggatcaagta gaacatatgg aaaagaagct 	 720
ttaagggcta atattgctgc agtgaaagca attgaagagg cattaaaaag cacctatggt 	 780
ccacgtggaa tggataagat tcttgttgat agcttaggag atattacaat aacaaatgat 	 840
ggagccacta ttcttgataa aatggattta caacacccaa caggtaagct tttagttcag 	 900
atagctaaag gacaagacga ggaaacagct gatggcacta aaactgctgt aattcttgct 	 960
ggagaattag ctaaaaaagc agaagatctt ttatataagg agattcaccc aacaataatt 	 1020
gtaagcggat ataagaaggc agaagaaatt gcattaaaga ccatccaaga tatagcacaa 	 1080
ccggtcagca taaatgatac tgacgtactt aggaaagtag cattaacatc cttaggcagt 	 1140
aaggcagtag caggcgcacg agagtattta gctgaccttg tggttaaagc agtggcacaa 	 1200
gtagcagaat taagaggaga taagtggtat gttgatctag ataatgtaca aatagttaaa 	 1260
aaacatggtg gtagcattaa tgatactcaa ttagtatacg gcatagtagt tgataaggaa 	 1320
gttgtacatc cgggcatgcc aaagaggatt gaaaatgcta agatagccct tttagacgct 	 1380
tcattagaag ttgagaaacc cgaattggat gcagaaataa gaattaacga tccaacacag 	 1440
atgcacaaat tcttggaaga agaagaaaac atattgaaag aaaaagtaga taagattgca 	 1500
gctactggtg ctaacgttgt aatagcgcag aaaggtatcg atgaagttgc acaacactat 	 1560
ttagctaaga aaggt	 1575
<210> SEQ ID NO 71
<211> LENGTH: 525
<212> TYPE: PRT
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: chaperonin permutant 316
<400> SEQUENCE: 71
Met Ala Ile Leu Ala Val Arg Arg Ala Lys Lys Ser Asp Leu Glu Lys
1	 5	 10	 15
Leu Ala Arg Ala Thr Gly Gly Arg Val Ile Ser Asn Ile Asp Glu Leu
20	 25	 30
Thr Ser Gin Asp Leu Gly Tyr Ala Ala Leu Val Glu Glu Arg Lys Val
35	 40	 45
Gly Glu Asp Lys Ile Val Phe Val Glu Gly Ala Lys Asn Pro Lys Ser
50	 55	 60
Val Ser Ile Leu Ile Arg Gly Gly Leu Glu Arg Val Val Asp Glu Thr
65	 70	 75	 80
Glu Arg Ala Leu Arg Asp Ala Leu Gly Thr Val Ala Asp Val Ile Arg
85	 90	 95
Asp Gly Arg Ala Val Ala Gly Gly Gly Ala Val Glu Ile Glu Ile Ala
100	 105	 110







Ala Ile Glu Ala Tyr Ala Asn Ala Ile Glu Gly Leu Ile Met Ile Leu
130	 135	 140
Ala Glu Asn Ala Gly Leu Asp Pro Ile Asp Lys Leu Met Gln Leu Arg
145	 150	 155	 160
Ser Leu His Glu Asn Glu Thr Asn Lys Trp Tyr Gly Leu Asn Leu Phe
165	 170	 175
Thr Gly Asn Pro Glu Asp Met Trp Lys Leu Gly Val Ile Glu Pro Ala
180	 185	 190
Leu Val Lys Met Asn Ala Ile Lys Ala Ala Thr Glu Ala Val Thr Leu
195	 200	 205
Val Leu Arg Ile Asp Asp Ile Val Gly Gly Ser Gly Gly Thr Ile Pro
210	 215	 220
Val Ile Ile Leu Lys Glu Gly Ser Ser Arg Thr Tyr Gly Lys Glu Ala
225	 230	 235	 240
Leu Arg Ala Asn Ile Ala Ala Val Lys Ala Ile Glu Glu Ala Leu Lys
245	 250	 255
Ser Thr Tyr Gly Pro Arg Gly Met Asp Lys Ile Leu Val Asp Ser Leu
260	 265	 270
Gly Asp Ile Thr Ile Thr Asn Asp Gly Ala Thr Ile Leu Asp Lys Met
275	 280	 285
Asp Leu Gln His Pro Thr Gly Lys Leu Leu Val Gln Ile Ala Lys Gly
290	 295	 300
Gln Asp Glu Glu Thr Ala Asp Gly Thr Lys Thr Ala Val Ile Leu Ala
305	 310	 315	 320
Gly Glu Leu Ala Lys Lys Ala Glu Asp Leu Leu Tyr Lys Glu Ile His
325	 330	 335
Pro Thr Ile Ile Val Ser Gly Tyr Lys Lys Ala Glu Glu Ile Ala Leu
340	 345	 350
Lys Thr Ile Gln Asp Ile Ala Gln Pro Val Ser Ile Asn Asp Thr Asp
355	 360	 365
Val Leu Arg Lys Val Ala Leu Thr Ser Leu Gly Ser Lys Ala Val Ala
370	 375	 380
Gly Ala Arg Glu Tyr Leu Ala Asp Leu Val Val Lys Ala Val Ala Gln
385	 390	 395	 400
Val Ala Glu Leu Arg Gly Asp Lys Trp Tyr Val Asp Leu Asp Asn Val
405	 410	 415
Gln Ile Val Lys Lys His Gly Gly Ser Ile Asn Asp Thr Gln Leu Val
420	 425	 430
Tyr Gly Ile Val Val Asp Lys Glu Val Val His Pro Gly Met Pro Lys
435	 440	 445
Arg Ile Glu Asn Ala Lys Ile Ala Leu Leu Asp Ala Ser Leu Glu Val
450	 455	 460
Glu Lys Pro Glu Leu Asp Ala Glu Ile Arg Ile Asn Asp Pro Thr Gln
465	 470	 475	 480
Met His Lys Phe Leu Glu Glu Glu Glu Asn Ile Leu Lys Glu Lys Val
485	 490	 495
Asp Lys Ile Ala Ala Thr Gly Ala Asn Val Val Ile Ala Gln Lys Gly
500	 505	 510
Ile Asp Glu Val Ala Gln His Tyr Leu Ala Lys Lys Gly
515	 520	 525






<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: chaperonin permutant 480
<400> SEQUENCE: 72
atggcaaata aatggtatgg acttaattta tttactggaa atccagagga tatgtggaaa 	 60
ttaggtgtta ttgaaccggc actagtgaaa atgaatgcaa ttaaggctgc aacagaagca 	 120
gtaacattag tgttaagaat agatgatatt gtaggtggtt ctggtggtac catacctgta 	 180
ataattttaa aagagggatc aagtagaaca tatggaaaag aagctttaag ggctaatatt 	 240
gctgcagtga aagcaattga agaggcatta aaaagcacct atggtccacg tggaatggat 	 300
aagattcttg ttgatagctt aggagatatt acaataacaa atgatggagc cactattctt 	 360
gataaaatgg atttacaaca cccaacaggt aagcttttag ttcagatagc taaaggacaa 	 420
gacgaggaaa cagctgatgg cactaaaact gctgtaattc ttgctggaga attagctaaa 	 480
aaagcagaag atcttttata taaggagatt cacccaacaa taattgtaag cggatataag 	 540
aaggcagaag aaattgcatt aaagaccatc caagatatag cacaaccggt cagcataaat 	 600
gatactgacg tacttaggaa agtagcatta acatccttag gcagtaaggc agtagcaggc 	 660
gcacgagagt atttagctga ccttgtggtt aaagcagtgg cacaagtagc agaattaaga 	 720
ggagataagt ggtatgttga tctagataat gtacaaatag ttaaaaaaca tggtggtagc 	 780
attaatgata ctcaattagt atacggcata gtagttgata aggaagttgt acatccgggc 	 840
atgccaaaga ggattgaaaa tgctaagata gcccttttag acgcttcatt agaagttgag 	 900
aaacccgaat tggatgcaga aataagaatt aacgatccaa cacagatgca caaattcttg 	 960
gaagaagaag aaaacatatt gaaagaaaaa gtagataaga ttgcagctac tggtgctaac 	 1020
gttgtaatag cgcagaaagg tatcgatgaa gttgcacaac actatttagc taagaaaggt 	 1080
atattagctg ttaggagagc caagaagagt gatttagaga aattagctag agctaccgga 	 1140
ggtagagtca tatcaaatat tgatgaatta acttcacaag atctaggtta tgccgcatta 	 1200
gtggaagaga gaaaagtagg tgaagacaag atcgtattcg tagaaggtgc aaagaatcca 	 1260
aaatcagtta gtatactaat aagaggagga ttagagagag tagtagatga gactgaaaga 	 1320
gctcttaggg acgctttagg tacagtggca gatgtaataa gggatggtag agcagtagct 	 1380
ggtggtggag ctgttgagat agagatagct aagagattaa gaaagtatgc cccacaagtt 	 1440
ggtggtaaag agcaattagc aattgaagca tatgctaatg caatagaggg tctcattatg 	 1500
atattggcgg aaaacgcagg attagatcct atagacaaat taatgcaatt aagaagtctt 	 1560
cacgagaatg agacc	 1575
<210> SEQ ID NO 73
<211> LENGTH: 525
<212> TYPE: PRT
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: chaperonin permutant 480
<400> SEQUENCE: 73
Met Ala Asn Lys Trp Tyr Gly Leu Asn Leu Phe Thr Gly Asn Pro Glu
1	 5	 10	 15





Ala Ile Lys Ala Ala Thr Glu Ala Val Thr Leu Val Leu Arg Ile Asp
35	 40	 45
Asp Ile Val Gly Gly Ser Gly Gly Thr Ile Pro Val Ile Ile Leu Lys
50	 55	 60
Glu Gly Ser Ser Arg Thr Tyr Gly Lys Glu Ala Leu Arg Ala Asn Ile
65	 70	 75	 80
Ala Ala Val Lys Ala Ile Glu Glu Ala Leu Lys Ser Thr Tyr Gly Pro
85	 90	 95
Arg Gly Met Asp Lys Ile Leu Val Asp Ser Leu Gly Asp Ile Thr Ile
100	 105	 110
Thr Asn Asp Gly Ala Thr Ile Leu Asp Lys Met Asp Leu Gln His Pro
115	 120	 125
Thr Gly Lys Leu Leu Val Gln Ile Ala Lys Gly Gln Asp Glu Glu Thr
130	 135	 140
Ala Asp Gly Thr Lys Thr Ala Val Ile Leu Ala Gly Glu Leu Ala Lys
145	 150	 155	 160
Lys Ala Glu Asp Leu Leu Tyr Lys Glu Ile His Pro Thr Ile Ile Val
165	 170	 175
Ser Gly Tyr Lys Lys Ala Glu Glu Ile Ala Leu Lys Thr Ile Gln Asp
180	 185	 190
Ile Ala Gln Pro Val Ser Ile Asn Asp Thr Asp Val Leu Arg Lys Val
195	 200	 205
Ala Leu Thr Ser Leu Gly Ser Lys Ala Val Ala Gly Ala Arg Glu Tyr
210	 215	 220
Leu Ala Asp Leu Val Val Lys Ala Val Ala Gln Val Ala Glu Leu Arg
225	 230	 235	 240
Gly Asp Lys Trp Tyr Val Asp Leu Asp Asn Val Gln Ile Val Lys Lys
245	 250	 255
His Gly Gly Ser Ile Asn Asp Thr Gln Leu Val Tyr Gly Ile Val Val
260	 265	 270
Asp Lys Glu Val Val His Pro Gly Met Pro Lys Arg Ile Glu Asn Ala
275	 280	 285
Lys Ile Ala Leu Leu Asp Ala Ser Leu Glu Val Glu Lys Pro Glu Leu
290	 295	 300
Asp Ala Glu Ile Arg Ile Asn Asp Pro Thr Gln Met His Lys Phe Leu
305	 310	 315	 320
Glu Glu Glu Glu Asn Ile Leu Lys Glu Lys Val Asp Lys Ile Ala Ala
325	 330	 335
Thr Gly Ala Asn Val Val Ile Ala Gln Lys Gly Ile Asp Glu Val Ala
340	 345	 350
Gln His Tyr Leu Ala Lys Lys Gly Ile Leu Ala Val Arg Arg Ala Lys
355	 360	 365
Lys Ser Asp Leu Glu Lys Leu Ala Arg Ala Thr Gly Gly Arg Val Ile
370	 375	 380
Ser Asn Ile Asp Glu Leu Thr Ser Gln Asp Leu Gly Tyr Ala Ala Leu
385	 390	 395	 400
Val Glu Glu Arg Lys Val Gly Glu Asp Lys Ile Val Phe Val Glu Gly
405	 410	 415
Ala Lys Asn Pro Lys Ser Val Ser Ile Leu Ile Arg Gly Gly Leu Glu
420	 425	 430





Val Ala Asp Val Ile Arg Asp Gly Arg Ala Val Ala Gly Gly Gly Ala
450	 455	 460
Val Glu Ile Glu Ile Ala Lys Arg Leu Arg Lys Tyr Ala Pro Gln Val
465	 470	 475	 480
Gly Gly Lys Glu Gln Leu Ala Ile Glu Ala Tyr Ala Asn Ala Ile Glu
485	 490	 495
Gly Leu Ile Met Ile Leu Ala Glu Asn Ala Gly Leu Asp Pro Ile Asp
500	 505	 510
Lys Leu Met Gln Leu Arg Ser Leu His Glu Asn Glu Thr
515	 520	 525
<210> SEQ ID NO 74
<211> LENGTH: 1575
<212> TYPE: DNA
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: chaperonin permutant 499
<400> SEQUENCE: 74
atggcattag gtgttattga accggcacta gtgaaaatga atgcaattaa ggctgcaaca 	 60
gaagcagtaa cattagtgtt aagaatagat gatattgtag gtggttctgg tggtaccata 	 120
cctgtaataa ttttaaaaga gggatcaagt agaacatatg gaaaagaagc tttaagggct 	 180
aatattgctg cagtgaaagc aattgaagag gcattaaaaa gcacctatgg tccacgtgga 	 240
atggataaga ttcttgttga tagcttagga gatattacaa taacaaatga tggagccact 	 300
attcttgata aaatggattt acaacaccca acaggtaagc ttttagttca gatagctaaa 	 360
ggacaagacg aggaaacagc tgatggcact aaaactgctg taattcttgc tggagaatta 	 420
gctaaaaaag cagaagatct tttatataag gagattcacc caacaataat tgtaagcgga 	 480
tataagaagg cagaagaaat tgcattaaag accatccaag atatagcaca accggtcagc 	 540
ataaatgata ctgacgtact taggaaagta gcattaacat ccttaggcag taaggcagta 	 600
gcaggcgcac gagagtattt agctgacctt gtggttaaag cagtggcaca agtagcagaa 	 660
ttaagaggag ataagtggta tgttgatcta gataatgtac aaatagttaa aaaacatggt 	 720
ggtagcatta atgatactca attagtatac ggcatagtag ttgataagga agttgtacat 	 780
ccgggcatgc caaagaggat tgaaaatgct aagatagccc ttttagacgc ttcattagaa 	 840
gttgagaaac ccgaattgga tgcagaaata agaattaacg atccaacaca gatgcacaaa 	 900
ttcttggaag aagaagaaaa catattgaaa gaaaaagtag ataagattgc agctactggt 	 960
gctaacgttg taatagcgca gaaaggtatc gatgaagttg cacaacacta tttagctaag 	 1020
aaaggtatat tagctgttag gagagccaag aagagtgatt tagagaaatt agctagagct 	 1080
accggaggta gagtcatatc aaatattgat gaattaactt cacaagatct aggttatgcc 	 1140
gcattagtgg aagagagaaa agtaggtgaa gacaagatcg tattcgtaga aggtgcaaag 	 1200
aatccaaaat cagttagtat actaataaga ggaggattag agagagtagt agatgagact 	 1260
gaaagagctc ttagggacgc tttaggtaca gtggcagatg taataaggga tggtagagca 	 1320
gtagctggtg gtggagctgt tgagatagag atagctaaga gattaagaaa gtatgcccca 	 1380
caagttggtg gtaaagagca attagcaatt gaagcatatg ctaatgcaat agagggtctc 	 1440
attatgatat tggcggaaaa cgcaggatta gatcctatag acaaattaat gcaattaaga 	 1500
agtcttcacg agaatgagac caataaatgg tatggactta atttatttac tggaaatcca 	 1560




<210> SEQ ID NO 75
<211> LENGTH: 525
<212> TYPE: PRT
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: chaperonin permutant 499
<400> SEQUENCE: 75
Met Ala Leu Gly Val Ile Glu Pro Ala Leu Val Lys Met Asn Ala Ile
1	 5	 10	 15
Lys Ala Ala Thr Glu Ala Val Thr Leu Val Leu Arg Ile Asp Asp Ile
20	 25	 30
Val Gly Gly Ser Gly Gly Thr Ile Pro Val Ile Ile Leu Lys Glu Gly
35	 40	 45
Ser Ser Arg Thr Tyr Gly Lys Glu Ala Leu Arg Ala Asn Ile Ala Ala
50	 55	 60
Val Lys Ala Ile Glu Glu Ala Leu Lys Ser Thr Tyr Gly Pro Arg Gly
65	 70	 75	 80
Met Asp Lys Ile Leu Val Asp Ser Leu Gly Asp Ile Thr Ile Thr Asn
85	 90	 95
Asp Gly Ala Thr Ile Leu Asp Lys Met Asp Leu Gin His Pro Thr Gly
100	 105	 110
Lys Leu Leu Val Gin Ile Ala Lys Gly Gin Asp Glu Glu Thr Ala Asp
115	 120	 125
Gly Thr Lys Thr Ala Val Ile Leu Ala Gly Glu Leu Ala Lys Lys Ala
130	 135	 140
Glu Asp Leu Leu Tyr Lys Glu Ile His Pro Thr Ile Ile Val Ser Gly
145	 150	 155	 160
Tyr Lys Lys Ala Glu Glu Ile Ala Leu Lys Thr Ile Gin Asp Ile Ala
165	 170	 175
Gin Pro Val Ser Ile Asn Asp Thr Asp Val Leu Arg Lys Val Ala Leu
180	 185	 190
Thr Ser Leu Gly Ser Lys Ala Val Ala Gly Ala Arg Glu Tyr Leu Ala
195	 200	 205
Asp Leu Val Val Lys Ala Val Ala Gin Val Ala Glu Leu Arg Gly Asp
210	 215	 220
Lys Trp Tyr Val Asp Leu Asp Asn Val Gin Ile Val Lys Lys His Gly
225	 230	 235	 240
Gly Ser Ile Asn Asp Thr Gin Leu Val Tyr Gly Ile Val Val Asp Lys
245	 250	 255
Glu Val Val His Pro Gly Met Pro Lys Arg Ile Glu Asn Ala Lys Ile
260	 265	 270
Ala Leu Leu Asp Ala Ser Leu Glu Val Glu Lys Pro Glu Leu Asp Ala
275	 280	 285
Glu Ile Arg Ile Asn Asp Pro Thr Gin Met His Lys Phe Leu Glu Glu
290	 295	 300
Glu Glu Asn Ile Leu Lys Glu Lys Val Asp Lys Ile Ala Ala Thr Gly
305	 310	 315	 320
Ala Asn Val Val Ile Ala Gin Lys Gly Ile Asp Glu Val Ala Gin His
325	 330	 335
Tyr Leu Ala Lys Lys Gly Ile Leu Ala Val Arg Arg Ala Lys Lys Ser
340	 345	 350







Ile Asp Glu Leu Thr Ser Gln Asp Leu Gly Tyr Ala Ala Leu Val Glu
370	 375	 380
Glu Arg Lys Val Gly Glu Asp Lys Ile Val Phe Val Glu Gly Ala Lys
385	 390	 395	 400
Asn Pro Lys Ser Val Ser Ile Leu Ile Arg Gly Gly Leu Glu Arg Val
405	 410	 415
Val Asp Glu Thr Glu Arg Ala Leu Arg Asp Ala Leu Gly Thr Val Ala
420	 425	 430
Asp Val Ile Arg Asp Gly Arg Ala Val Ala Gly Gly Gly Ala Val Glu
435	 440	 445
Ile Glu Ile Ala Lys Arg Leu Arg Lys Tyr Ala Pro Gln Val Gly Gly
450	 455	 460
Lys Glu Gln Leu Ala Ile Glu Ala Tyr Ala Asn Ala Ile Glu Gly Leu
465	 470	 475	 480
Ile Met Ile Leu Ala Glu Asn Ala Gly Leu Asp Pro Ile Asp Lys Leu
485	 490	 495
Met Gln Leu Arg Ser Leu His Glu Asn Glu Thr Asn Lys Trp Tyr Gly
500	 505	 510
Leu Asn Leu Phe Thr Gly Asn Pro Glu Asp Met Trp Lys
515	 520	 525
<210> SEQ ID NO 76
<211> LENGTH: 2349
<212> TYPE: DNA
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: chaperonin permutant 267-EYFP fusion
<400> SEQUENCE: 76
atggcagatc caacacagat gcacaaattc ttggaagaag aagaaaacat attgaaagaa 	 60
aaagtagata agattgcagc tactggtgct aacgttgtaa tagcgcagaa aggtatcgat 	 120
gaagttgcac aacactattt agctaagaaa ggtatattag ctgttaggag agccaagaag 	 180
agtgatttag agaaattagc tagagctacc ggaggtagag tcatatcaaa tattgatgaa 	 240
ttaacttcac aagatctagg ttatgccgca ttagtggaag agagaaaagt aggtgaagac 	 300
aagatcgtat tcgtagaagg tgcaaagaat ccaaaatcag ttagtatact aataagagga 	 360
ggattagaga gagtagtaga tgagactgaa agagctctta gggacgcttt aggtacagtg 	 420
gcagatgtaa taagggatgg tagagcagta gctggtggtg gagctgttga gatagagata 	 480
gctaagagat taagaaagta tgccccacaa gttggtggta aagagcaatt agcaattgaa 	 540
gcatatgcta atgcaataga gggtctcatt atgatattgg cggaaaacgc aggattagat 	 600
cctatagaca aattaatgca attaagaagt cttcacgaga atgagaccaa taaatggtat 	 660
ggacttaatt tatttactgg aaatccagag gatatgtgga aattaggtgt tattgaaccg 	 720
gcactagtga aaatgaatgc aattaaggct gcaacagaag cagtaacatt agtgttaaga 	 780
atagatgata ttgtaggtgg ttctggtggt accatacctg taataatttt aaaagaggga 	 840
tcaagtagaa catatggaaa agaagcttta agggctaata ttgctgcagt gaaagcaatt 	 900
gaagaggcat taaaaagcac ctatggtcca cgtggaatgg ataagattct tgttgatagc 	 960
ttaggagata ttacaataac aaatgatgga gccactattc ttgataaaat ggatttacaa 	 1020






ggcactaaaa ctgctgtaat tcttgctgga gaattagcta aaaaagcaga agatctttta 	 1140
tataaggaga ttcacccaac aataattgta agcggatata agaaggcaga agaaattgca 	 1200
ttaaagacca tccaagatat agcacaaccg gtcagcataa atgatactga cgtacttagg 	 1260
aaagtagcat taacatcctt aggcagtaag gcagtagcag gcgcacgaga gtatttagct 	 1320
gaccttgtgg ttaaagcagt ggcacaagta gcagaattaa gaggagataa gtggtatgtt 	 1380
gatctagata atgtacaaat agttaaaaaa catggtggta gcattaatga tactcaatta 	 1440
gtatacggca tagtagttga taaggaagtt gtacatccgg gcatgccaaa gaggattgaa 	 1500
aatgctaaga tagccctttt agacgcttca ttagaagttg agaaacccga attggatgca 	 1560
gaaataagaa ttaacggcag cggcggatcc ggggtgagca agggcgagga gctgttcacc 	 1620
ggggtggtgc ccatcctggt cgagctggac ggcgacgtaa acggccacaa gttcagcgtg 	 1680
tccggcgagg gcgagggcga tgccacctac ggcaagctga ccctgaagtt catctgcacc 	 1740
accggcaagc tgcccgtgcc ctggcccacc ctcgtgacca ccttcggcta cggcctgcag 	 1800
tgcttcgccc gctaccccga ccacatgaag cagcacgact tcttcaagtc cgccatgccc 	 1860
gaaggctacg tccaggagcg caccatcttc ttcaaggacg acggcaacta caagacccgc 	 1920
gccgaggtga agttcgaggg cgacaccctg gtgaaccgca tcgagctgaa gggcatcgac 	 1980
ttcaaggagg acggcaacat cctggggcac aagctggagt acaacggcgg taccggatct 	 2040
ggaggtgagc tcaacagcca caacgtctat atcatggccg acaagcagaa gaacggcatc 	 2100
aaggtgaact tcaagatccg ccacaacatc gaggacggca gcgtgcagct cgccgaccac 	 2160
taccagcaga acacccccat cggcgacggc cccgtgctgc tgcccgacaa ccactacctg 	 2220
agctaccagt ccgccctgag caaagacccc aacgagaagc gcgatcacat ggtcctgctg 	 2280
gagttcgtga ccgccgccgg gatcactctc ggcatggacg agctgtacaa gcaccaccat 	 2340
caccatcac	 2349
<210> SEQ ID NO 77
<211> LENGTH: 783
<212> TYPE: PRT
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: chaperonin permutant 267-EYFP fusion
<400> SEQUENCE: 77
Met Ala Asp Pro Thr Gin Met His Lys Phe Leu Glu Glu Glu Glu Asn
1	 5	 10	 15
Ile Leu Lys Glu Lys Val Asp Lys Ile Ala Ala Thr Gly Ala Asn Val
20	 25	 30
Val Ile Ala Gin Lys Gly Ile Asp Glu Val Ala Gin His Tyr Leu Ala
35	 40	 45
Lys Lys Gly Ile Leu Ala Val Arg Arg Ala Lys Lys Ser Asp Leu Glu
50	 55	 60
Lys Leu Ala Arg Ala Thr Gly Gly Arg Val Ile Ser Asn Ile Asp Glu
65	 70	 75	 80
Leu Thr Ser Gin Asp Leu Gly Tyr Ala Ala Leu Val Glu Glu Arg Lys
85	 90	 95
Val Gly Glu Asp Lys Ile Val Phe Val Glu Gly Ala Lys Asn Pro Lys
100	 105	 110







Thr Glu Arg Ala Leu Arg Asp Ala Leu Gly Thr Val Ala Asp Val Ile
130	 135	 140
Arg Asp Gly Arg Ala Val Ala Gly Gly Gly Ala Val Glu Ile Glu Ile
145	 150	 155	 160
Ala Lys Arg Leu Arg Lys Tyr Ala Pro Gln Val Gly Gly Lys Glu Gln
165	 170	 175
Leu Ala Ile Glu Ala Tyr Ala Asn Ala Ile Glu Gly Leu Ile Met Ile
180	 185	 190
Leu Ala Glu Asn Ala Gly Leu Asp Pro Ile Asp Lys Leu Met Gln Leu
195	 200	 205
Arg Ser Leu His Glu Asn Glu Thr Asn Lys Trp Tyr Gly Leu Asn Leu
210	 215	 220
Phe Thr Gly Asn Pro Glu Asp Met Trp Lys Leu Gly Val Ile Glu Pro
225	 230	 235	 240
Ala Leu Val Lys Met Asn Ala Ile Lys Ala Ala Thr Glu Ala Val Thr
245	 250	 255
Leu Val Leu Arg Ile Asp Asp Ile Val Gly Gly Ser Gly Gly Thr Ile
260	 265	 270
Pro Val Ile Ile Leu Lys Glu Gly Ser Ser Arg Thr Tyr Gly Lys Glu
275	 280	 285
Ala Leu Arg Ala Asn Ile Ala Ala Val Lys Ala Ile Glu Glu Ala Leu
290	 295	 300
Lys Ser Thr Tyr Gly Pro Arg Gly Met Asp Lys Ile Leu Val Asp Ser
305	 310	 315	 320
Leu Gly Asp Ile Thr Ile Thr Asn Asp Gly Ala Thr Ile Leu Asp Lys
325	 330	 335
Met Asp Leu Gln His Pro Thr Gly Lys Leu Leu Val Gln Ile Ala Lys
340	 345	 350
Gly Gln Asp Glu Glu Thr Ala Asp Gly Thr Lys Thr Ala Val Ile Leu
355	 360	 365
Ala Gly Glu Leu Ala Lys Lys Ala Glu Asp Leu Leu Tyr Lys Glu Ile
370	 375	 380
His Pro Thr Ile Ile Val Ser Gly Tyr Lys Lys Ala Glu Glu Ile Ala
385	 390	 395	 400
Leu Lys Thr Ile Gln Asp Ile Ala Gln Pro Val Ser Ile Asn Asp Thr
405	 410	 415
Asp Val Leu Arg Lys Val Ala Leu Thr Ser Leu Gly Ser Lys Ala Val
420	 425	 430
Ala Gly Ala Arg Glu Tyr Leu Ala Asp Leu Val Val Lys Ala Val Ala
435	 440	 445
Gln Val Ala Glu Leu Arg Gly Asp Lys Trp Tyr Val Asp Leu Asp Asn
450	 455	 460
Val Gln Ile Val Lys Lys His Gly Gly Ser Ile Asn Asp Thr Gln Leu
465	 470	 475	 480
Val Tyr Gly Ile Val Val Asp Lys Glu Val Val His Pro Gly Met Pro
485	 490	 495
Lys Arg Ile Glu Asn Ala Lys Ile Ala Leu Leu Asp Ala Ser Leu Glu
500	 505	 510
Val Glu Lys Pro Glu Leu Asp Ala Glu Ile Arg Ile Asn Gly Ser Gly
515	 520	 525
Gly Ser Gly Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro
530	 535	 540




545	 550	 555	 560
Ser Gly Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys
565	 570	 575
Phe Ile Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val
580	 585	 590
Thr Thr Phe Gly Tyr Gly Leu Gln Cys Phe Ala Arg Tyr Pro Asp His
595	 600	 605
Met Lys Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val
610	 615	 620
Gln Glu Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg
625	 630	 635	 640
Ala Glu Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu
645	 650	 655
Lys Gly Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu
660	 665	 670
Glu Tyr Asn Gly Gly Thr Gly Ser Gly Gly Glu Leu Asn Ser His Asn
675	 680	 685
Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly Ile Lys Val Asn Phe
690	 695	 700
Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val Gln Leu Ala Asp His
705	 710	 715	 720
Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro Val Leu Leu Pro Asp
725	 730	 735
Asn His Tyr Leu Ser Tyr Gln Ser Ala Leu Ser Lys Asp Pro Asn Glu
740	 745	 750
Lys Arg Asp His Met Val Leu Leu Glu Phe Val Thr Ala Ala Gly Ile
755	 760	 765
Thr Leu Gly Met Asp Glu Leu Tyr Lys His His His His His His
770	 775	 780
<210> SEQ ID NO 78
<211> LENGTH:	 2355
<212> TYPE: DNA
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: chaperonin permutant 480 -EYFP fusion
<400> SEQUENCE:	 78
atggcaaata aatggtatgg acttaattta tttactggaa atccagagga tatgtggaaa 60
ttaggtgtta ttgaaccggc actagtgaaa atgaatgcaa ttaaggctgc aacagaagca 120
gtaacattag tgttaagaat agatgatatt gtaggtggtt ctggtggtac catacctgta 180
ataattttaa aagagggatc aagtagaaca tatggaaaag aagctttaag ggctaatatt 240
gctgcagtga aagcaattga agaggcatta aaaagcacct atggtccacg tggaatggat 300
aagattcttg ttgatagctt aggagatatt acaataacaa atgatggagc cactattctt 360
gataaaatgg atttacaaca cccaacaggt aagcttttag ttcagatagc taaaggacaa 420
gacgaggaaa cagctgatgg cactaaaact gctgtaattc ttgctggaga attagctaaa 480
aaagcagaag atcttttata taaggagatt cacccaacaa taattgtaag cggatataag 540
aaggcagaag aaattgcatt aaagaccatc caagatatag cacaaccggt cagcataaat 600
gatactgacg tacttaggaa agtagcatta acatccttag gcagtaaggc agtagcaggc 660




ggagataagt ggtatgttga tctagataat gtacaaatag ttaaaaaaca tggtggtagc 	 780
attaatgata ctcaattagt atacggcata gtagttgata aggaagttgt acatccgggc 	 840
atgccaaaga ggattgaaaa tgctaagata gcccttttag acgcttcatt agaagttgag 	 900
aaacccgaat tggatgcaga aataagaatt aacgatccaa cacagatgca caaattcttg 	 960
gaagaagaag aaaacatatt gaaagaaaaa gtagataaga ttgcagctac tggtgctaac 	 1020
gttgtaatag cgcagaaagg tatcgatgaa gttgcacaac actatttagc taagaaaggt 	 1080
atattagctg ttaggagagc caagaagagt gatttagaga aattagctag agctaccgga 	 1140
ggtagagtca tatcaaatat tgatgaatta acttcacaag atctaggtta tgccgcatta 	 1200
gtggaagaga gaaaagtagg tgaagacaag atcgtattcg tagaaggtgc aaagaatcca 	 1260
aaatcagtta gtatactaat aagaggagga ttagagagag tagtagatga gactgaaaga 	 1320
gctcttaggg acgctttagg tacagtggca gatgtaataa gggatggtag agcagtagct 	 1380
ggtggtggag ctgttgagat agagatagct aagagattaa gaaagtatgc cccacaagtt 	 1440
ggtggtaaag agcaattagc aattgaagca tatgctaatg caatagaggg tctcattatg 	 1500
atattggcgg aaaacgcagg attagatcct atagacaaat taatgcaatt aagaagtctt 	 1560
cacgagaatg agaccggctc tggcggatcc ggatccgggg tgagcaaggg cgaggagctg 	 1620
ttcaccgggg tggtgcccat cctggtcgag ctggacggcg acgtaaacgg ccacaagttc 	 1680
agcgtgtccg gcgagggcga gggcgatgcc acctacggca agctgaccct gaagttcatc 	 1740
tgcaccaccg gcaagctgcc cgtgccctgg cccaccctcg tgaccacctt cggctacggc 	 1800
ctgcagtgct tcgcccgcta ccccgaccac atgaagcagc acgacttctt caagtccgcc 	 1860
atgcccgaag gctacgtcca ggagcgcacc atcttcttca aggacgacgg caactacaag 	 1920
acccgcgccg aggtgaagtt cgagggcgac accctggtga accgcatcga gctgaagggc 	 1980
atcgacttca aggaggacgg caacatcctg gggcacaagc tggagtacaa cggcggtacc 	 2040
ggatctggag gtgagctcaa cagccacaac gtctatatca tggccgacaa gcagaagaac 	 2100
ggcatcaagg tgaacttcaa gatccgccac aacatcgagg acggcagcgt gcagctcgcc 	 2160
gaccactacc agcagaacac ccccatcggc gacggccccg tgctgctgcc cgacaaccac 	 2220
tacctgagct accagtccgc cctgagcaaa gaccccaacg agaagcgcga tcacatggtc 	 2280
ctgctggagt tcgtgaccgc cgccgggatc actctcggca tggacgagct gtacaagcac 	 2340
caccatcacc atcac	 2355
<210> SEQ ID NO 79
<211> LENGTH: 785
<212> TYPE: PRT
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: chaperonin permutant 480-EYFP fusion
<400> SEQUENCE: 79
Met Ala Asn Lys Trp Tyr Gly Leu Asn Leu Phe Thr Gly Asn Pro Glu
1	 5	 10	 15
Asp Met Trp Lys Leu Gly Val Ile Glu Pro Ala Leu Val Lys Met Asn
20	 25	 30
Ala Ile Lys Ala Ala Thr Glu Ala Val Thr Leu Val Leu Arg Ile Asp
35	 40	 45







Glu Gly Ser Ser Arg Thr Tyr Gly Lys Glu Ala Leu Arg Ala Asn Ile
65	 70	 75	 80
Ala Ala Val Lys Ala Ile Glu Glu Ala Leu Lys Ser Thr Tyr Gly Pro
85	 90	 95
Arg Gly Met Asp Lys Ile Leu Val Asp Ser Leu Gly Asp Ile Thr Ile
100	 105	 110
Thr Asn Asp Gly Ala Thr Ile Leu Asp Lys Met Asp Leu Gln His Pro
115	 120	 125
Thr Gly Lys Leu Leu Val Gln Ile Ala Lys Gly Gln Asp Glu Glu Thr
130	 135	 140
Ala Asp Gly Thr Lys Thr Ala Val Ile Leu Ala Gly Glu Leu Ala Lys
145	 150	 155	 160
Lys Ala Glu Asp Leu Leu Tyr Lys Glu Ile His Pro Thr Ile Ile Val
165	 170	 175
Ser Gly Tyr Lys Lys Ala Glu Glu Ile Ala Leu Lys Thr Ile Gln Asp
180	 185	 190
Ile Ala Gln Pro Val Ser Ile Asn Asp Thr Asp Val Leu Arg Lys Val
195	 200	 205
Ala Leu Thr Ser Leu Gly Ser Lys Ala Val Ala Gly Ala Arg Glu Tyr
210	 215	 220
Leu Ala Asp Leu Val Val Lys Ala Val Ala Gln Val Ala Glu Leu Arg
225	 230	 235	 240
Gly Asp Lys Trp Tyr Val Asp Leu Asp Asn Val Gln Ile Val Lys Lys
245	 250	 255
His Gly Gly Ser Ile Asn Asp Thr Gln Leu Val Tyr Gly Ile Val Val
260	 265	 270
Asp Lys Glu Val Val His Pro Gly Met Pro Lys Arg Ile Glu Asn Ala
275	 280	 285
Lys Ile Ala Leu Leu Asp Ala Ser Leu Glu Val Glu Lys Pro Glu Leu
290	 295	 300
Asp Ala Glu Ile Arg Ile Asn Asp Pro Thr Gln Met His Lys Phe Leu
305	 310	 315	 320
Glu Glu Glu Glu Asn Ile Leu Lys Glu Lys Val Asp Lys Ile Ala Ala
325	 330	 335
Thr Gly Ala Asn Val Val Ile Ala Gln Lys Gly Ile Asp Glu Val Ala
340	 345	 350
Gln His Tyr Leu Ala Lys Lys Gly Ile Leu Ala Val Arg Arg Ala Lys
355	 360	 365
Lys Ser Asp Leu Glu Lys Leu Ala Arg Ala Thr Gly Gly Arg Val Ile
370	 375	 380
Ser Asn Ile Asp Glu Leu Thr Ser Gln Asp Leu Gly Tyr Ala Ala Leu
385	 390	 395	 400
Val Glu Glu Arg Lys Val Gly Glu Asp Lys Ile Val Phe Val Glu Gly
405	 410	 415
Ala Lys Asn Pro Lys Ser Val Ser Ile Leu Ile Arg Gly Gly Leu Glu
420	 425	 430
Arg Val Val Asp Glu Thr Glu Arg Ala Leu Arg Asp Ala Leu Gly Thr
435	 440	 445
Val Ala Asp Val Ile Arg Asp Gly Arg Ala Val Ala Gly Gly Gly Ala
450	 455	 460
Val Glu Ile Glu Ile Ala Lys Arg Leu Arg Lys Tyr Ala Pro Gln Val
465	 470	 475	 480





Gly Leu Ile Met Ile Leu Ala Glu Asn Ala Gly Leu Asp Pro Ile Asp
500	 505	 510
Lys Leu Met Gln Leu Arg Ser Leu His Glu Asn Glu Thr Gly Ser Gly
515	 520	 525
Gly Ser Gly Ser Gly Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val
530	 535	 540
Val Pro Ile Leu Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe
545	 550	 555	 560
Ser Val Ser Gly Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr
565	 570	 575
Leu Lys Phe Ile Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr
580	 585	 590
Leu Val Thr Thr Phe Gly Tyr Gly Leu Gln Cys Phe Ala Arg Tyr Pro
595	 600	 605
Asp His Met Lys Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly
610	 615	 620
Tyr Val Gln Glu Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys
625	 630	 635	 640
Thr Arg Ala Glu Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile
645	 650	 655
Glu Leu Lys Gly Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His
660	 665	 670
Lys Leu Glu Tyr Asn Gly Gly Thr Gly Ser Gly Gly Glu Leu Asn Ser
675	 680	 685
His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly Ile Lys Val
690	 695	 700
Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val Gln Leu Ala
705	 710	 715	 720
Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro Val Leu Leu
725	 730	 735
Pro Asp Asn His Tyr Leu Ser Tyr Gln Ser Ala Leu Ser Lys Asp Pro
740	 745	 750
Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val Thr Ala Ala
755	 760	 765




<210> SEQ ID NO 80
<211> LENGTH: 1680
<212> TYPE: DNA
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: TF55 alpha subunit
<400> SEQUENCE: 80
atggcgagcc cggtcttgtt attgaaagag ggaacgagta gaactactgg tagagatgcg 	 60
ttaaggaata atatacttgc tgcaaagaca ctagccgaaa tgttaaggag tagtttaggt 	 120
cctaaaggtc ttgataaaat gttaattgat agtttcggtg acgtaaccat aactaatgat 180
ggtgctacaa tagtaaagga tatggagata cagcatccag cagcaaagct attagtagaa 240




ggtgctctat tggagaaagc tgaaagttta ttggatcaaa atatacatcc aacaataatt	 360
attgaggggt ataagaaggc atataccaag gccttggagt tacttccaca gttaggaact 	 420
aggatcgata taagggattt gaattcttca gttgctaggg atactctaag aaaaatagca 	 480
tttactacac tagcaagtaa gtttattgca gaaggtgctg aattaaataa aataattgac 	 540
atggtaatag acgcaatagt taatgttgca gaacctctac ctaatggtgg gtacaatgtg	 600
agtttagact taataaagat agataagaag aaaggtggaa gtatagagga tagcgtctta	 660
gttaaaggac tagtattaga taaggaggtt gtgcaccctg gaatgcctag aagagtcact 	 720
aaagccaaga tagctgtttt ggatgcagca ttagaggtag aaaagcctga aatctcagct	 780
aagataagta taacatcacc agagcaaatc aaggctttct tagatgagga atccaaatat 	 840
cttaaggaca tggttgataa actagcgtca ataggcgcta acgttgtaat atgccagaaa 	 900
ggtattgatg atatcgcaca gcacttctta gctaagaaag gtatattggc tgtaagaagg	 960
gttaagagga gcgatataga gaaattagag aaggcattag gcgcgagaat aataagcagt 	 1020
attaaagacg ctactcccga tgatttagga tacgccgaat tagttgagga aaggagagtt 	 1080
ggaaatgaca aaatggtatt tatagaaggt gctaagaatc tgaaggccgt gaatatcttg	 1140
ttaagaggtt caaatgatat ggcattagat gaggctgaga ggagtataaa tgatgcattg	 1200
catgctctga ggaacatatt attagagcca gtaatattgc caggtggtgg cgctatcgag 	 1260
ttagaattag cgatgaaatt aagagagtat gctagaagtg taggaggtaa ggagcaatta 	 1320
gctatagaag catttgcaga tgcattagag gagataccta tgattttagc tgaaactgca 	 1380
gggctggagg ctatatctgc actaatggac ttaagagcta gacacgctaa gggattaacc 	 1440
aatactggtg tagatgtaat aggtgggaag atcgtagacg atgtatatgc cttaaacatc 	 1500
attgagccta taagagtaaa ggctcaagtg ttaaagagcg caacagaggc ggctacagca 	 1560
atattaaaga ttgatgacct aatagctgca gctccattaa agagcgagaa gaaaggtgga 	 1620
gaaggaagta aagaagaaag tggtggagaa ggaggagctg gtactccatc tttaggagac	 1680
<210> SEQ ID NO 81
<211> LENGTH:	 1272
<212> TYPE: DNA
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: chaperonin dwarf deletion permutant 267
<400> SEQUENCE:	 81
atggtattcg tagaaggtgc aaagaatcca aaatcagtta gtatactaat aagaggagga 60
ttagagagag tagtagatga gactgaaaga gctcttaggg acgctttagg tacagtggca 120
gatgtaataa gggatggtag agcagtagct ggtggtggag ctgttgagat agagatagct 180
aagagattaa gaaagtatgc cccacaagtt ggtggtaaag agcaattagc aattgaagca 240
tatgctaatg caatagaagg acttatcatg atattggcgg aaaacgcagg attagatcct 300
atagacaaat taatgcaatt aagaagtctt cacgagaatg agaccaataa atggtatgga 360
cttaatttat ttactggaaa tccagaggat atgtggaaat taggtgttat tgaaccggca 420
ctagtgaaaa tgaatgcaat taaggctgca acagaagcag taacattagt gttaagaata 480
gatgatattg taggtggttc tggtggtacc atacctgtaa taattttaaa agagggatca 540
agtagaacat atggaaaaga agctttaagg gctaatattg ctgcagtgaa agcaattgaa 600




ggagatatta caataacaaa tgatggagcc actattcttg ataaaatgga tttacaacac 	 720
ccaacaggta agcttttagt tcagatagct aaaggacaag acgaggaaac agctgatggc 	 780
actaaaactg ctgtaattct tgctggagaa ttagctaaaa aagcagaaga tcttttatat 	 840
aaggagattc acccaacaat aattgtaagc ggatataaga aggcagaaga aattgcatta 	 900
aagaccatcc aagatatagc acaaccggtc agcataaatg atactgacgt acttaggaaa 	 960
gtagcattaa catccttagg cagtaaggca gtagcaggcg cacgagagta tttagctgac 	 1020
cttgtggtta aagcagtggc acaagtagca gaattaagag gagataagtg gtatgttgat 	 1080
ctagataatg tacaaatagt taaaaaacat ggtggtagca ttaatgatac tcaattagta 	 1140
tacggcatag tagttgataa ggaagttgta catccgggca tgccaaagag gattgaaaat 	 1200
gctaagatag cccttttaga cgcttcatta gaagttgaga aacccgaatt ggatgcagaa 	 1260
ataagaatta ac	 1272
<210> SEQ ID NO 82
<211> LENGTH: 424
<212> TYPE: PRT
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: chaperonin dwarf deletion permutant 267
<400> SEQUENCE: 82
Met Val Phe Val Glu Gly Ala Lys Asn Pro Lys Ser Val Ser Ile Leu
1	 5	 10	 15
Ile Arg Gly Gly Leu Glu Arg Val Val Asp Glu Thr Glu Arg Ala Leu
20	 25	 30
Arg Asp Ala Leu Gly Thr Val Ala Asp Val Ile Arg Asp Gly Arg Ala
35	 40	 45
Val Ala Gly Gly Gly Ala Val Glu Ile Glu Ile Ala Lys Arg Leu Arg
50	 55	 60
Lys Tyr Ala Pro Gin Val Gly Gly Lys Glu Gin Leu Ala Ile Glu Ala
65	 70	 75	 80
Tyr Ala Asn Ala Ile Glu Gly Leu Ile Met Ile Leu Ala Glu Asn Ala
85	 90	 95
Gly Leu Asp Pro Ile Asp Lys Leu Met Gin Leu Arg Ser Leu His Glu
100	 105	 110
Asn Glu Thr Asn Lys Trp Tyr Gly Leu Asn Leu Phe Thr Gly Asn Pro
115	 120	 125
Glu Asp Met Trp Lys Leu Gly Val Ile Glu Pro Ala Leu Val Lys Met
130	 135	 140
Asn Ala Ile Lys Ala Ala Thr Glu Ala Val Thr Leu Val Leu Arg Ile
145	 150	 155	 160
Asp Asp Ile Val Gly Gly Ser Gly Gly Thr Ile Pro Val Ile Ile Leu
165	 170	 175
Lys Glu Gly Ser Ser Arg Thr Tyr Gly Lys Glu Ala Leu Arg Ala Asn
180	 185	 190
Ile Ala Ala Val Lys Ala Ile Glu Glu Ala Leu Lys Ser Thr Tyr Gly
195	 200	 205
Pro Arg Gly Met Asp Lys Met Leu Val Asp Ser Leu Gly Asp Ile Thr
210	 215	 220
Ile Thr Asn Asp Gly Ala Thr Ile Leu Asp Lys Met Asp Leu Gin His




Pro Thr Gly Lys Leu Leu Val Gln Ile Ala Lys Gly Gln Asp Glu Glu
245	 250	 255
Thr Ala Asp Gly Thr Lys Thr Ala Val Ile Leu Ala Gly Glu Leu Ala
260	 265	 270
Lys Lys Ala Glu Asp Leu Leu Tyr Lys Glu Ile His Pro Thr Ile Ile
275	 280	 285
Val Ser Gly Tyr Lys Lys Ala Glu Glu Ile Ala Leu Lys Thr Ile Gln
290	 295	 300
Asp Ile Ala Gln Pro Val Ser Ile Asn Asp Thr Asp Val Leu Arg Lys
305	 310	 315	 320
Val Ala Leu Thr Ser Leu Gly Ser Lys Ala Val Ala Gly Ala Arg Glu
325	 330	 335
Tyr Leu Ala Asp Leu Val Val Lys Ala Val Ala Gln Val Ala Glu Leu
340	 345	 350
Arg Gly Asp Lys Trp Tyr Val Asp Leu Asp Asn Val Gln Ile Val Lys
355	 360	 365
Lys His Gly Gly Ser Ile Asn Asp Thr Gln Leu Val Tyr Gly Ile Val
370	 375	 380
Val Asp Lys Glu Val Val His Pro Gly Met Pro Lys Arg Ile Glu Asn
385	 390	 395	 400
Ala Lys Ile Ala Leu Leu Asp Ala Ser Leu Glu Val Glu Lys Pro Glu
405	 410	 415
Leu Asp Ala Glu Ile Arg Ile Asn
420





<223> OTHER INFORMATION: peptide linker 267 EYFP
<400> SEQUENCE: 83
Gly Ser Gly Gly Ser Gly
1	 5





<223> OTHER INFORMATION: peptide linker 267 EYFP
<400> SEQUENCE: 84
Gly Ser Gly Gly Ser Gly Ser Gly
1	 5
<210> SEQ ID NO 85
<211> LENGTH: 1656
<212> TYPE: DNA
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: TF55 beta subunit (HENET)
<400> SEQUENCE: 85
atggcaacag ctacagttgc aactacaccc gaaggtatac ctgtaataat tttaaaagag 60
ggatcaagta gaacatatgg aaaagaagct ttaagggcta atattgctgc agtgaaagca 120




agcttaggag atattacaat aacaaatgat ggagccacta ttcttgataa aatggattta	 240
caacacccaa caggtaagct tttagttcag atagctaaag gacaagacga ggaaacagct 	 300
gatggcacta aaactgctgt aattcttgct ggagaattag ctaaaaaagc agaagatctt 	 360
ttatataagg agattcaccc aacaataatt gtaagcggat ataagaaggc agaagaaatt	 420
gcattaaaga ccatccaaga tatagcacaa ccggtcagca taaatgatac tgacgtactt 	 480
aggaaagtag cattaacatc cttaggcagt aaggcagtag caggcgcacg agagtattta	 540
gctgaccttg tggttaaagc agtggcacaa gtagcagaat taagaggaga taagtggtat 	 600
gttgatctag ataatgtaca aatagttaaa aaacatggtg gtagcattaa tgatactcaa 	 660
ttagtatacg gcatagtagt tgataaggaa gttgtacatc cgggcatgcc aaagaggatt 	 720
gaaaatgcta agatagccct tttagacgct tcattagaag ttgagaaacc cgaattggat 	 780
gcagaaataa gaattaacga tccaacacag atgcacaaat tcttggaaga agaagaaaac	 840
atattgaaag aaaaagtaga taagattgca gctactggtg ctaacgttgt aatatgccag 	 900
aaaggtatcg atgaagttgc acaacactat ttagctaaga aaggtatatt agctgttagg 	 960
agagccaaga agagtgattt agagaaatta gctagagcta ccggaggtag agtcatatca	 1020
aatattgatg aattaacttc acaagatcta ggttatgccg cattagtgga agagagaaaa 	 1080
gtaggagagg ataagatggt attcgtagaa ggtgcaaaga atccaaaatc agttagtata	 1140
ctaataagag gaggattaga gagagtagta gatgagactg aaagagctct tagggacgct	 1200
ttaggtacag tggcagatgt aataagggat ggtagagcag tagctggtgg tggagctgtt 	 1260
gagatagaga tagctaagag attaagaaag tatgccccac aagttggtgg taaagagcaa 	 1320
ttagcaattg aagcatatgc taatgcaata gaaggactta tcatgatatt ggcggaaaac 	 1380
gcaggattag atcctataga caaattaatg caattaagaa gtcttcacga gaatgagacc	 1440
aataaatggt atggacttaa tttatttact ggaaatccag aggatatgtg gaaattaggt	 1500
gttattgaac cggcactagt gaaaatgaat gcaattaagg ctgcaacaga agcagtaaca	 1560
ttagtgttaa gaatagatga tattgtagca gctggaaaga agggtggaag tgagccaggc 	 1620
ggtaagaaag agaaagaaga aaagtcctct gaagac	 1656
<210> SEQ ID NO 86
<211> LENGTH:	 1656
<212> TYPE: DNA
<213> ORGANISM: Sulfolobus shibatae
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: TF55 beta subunit (HDNET)
<400> SEQUENCE:	 86
atggcaacag ctacagttgc aactacaccc gaaggtatac ctgtaataat tttaaaagag 60
ggatcaagta gaacatatgg aaaagaagct ttaagggcta atattgctgc agtgaaagca 120
attgaagagg cattaaaaag cacctatggt ccacgtggaa tggataagat gttcgttgat 180
agcttaggag atattacaat aacaaatgat ggagccacta ttcttgataa aatggattta 240
caacacccaa caggtaagct tttagttcag atagctaaag gacaagacga ggaaacagct 300
gatggcacta aaactgctgt aattcttgct ggagaattag ctaaaaaagc agaagatctt 360
ttatataagg agattcaccc aacaataatt gtaagcggat ataagaaggc agaagaaatt 420
gcattaaaga ccatccaaga tatagcacaa ccggtcagca taaatgatac tgacgtactt 480




gctgaccttg tggttaaagc agtggcacaa gtagcagaat taagaggaga taagtggtat 	 600
gttgatctag ataatgtaca aatagttaaa aaacatggtg gtagcattaa tgatactcaa 	 660
ttagtatacg gcatagtagt tgataaggaa gttgtacatc cgggcatgcc aaagaggatt 	 720
gaaaatgcta agatagccct tttagacgct tcattagaag ttgagaaacc cgaattggat 	 780
gcagaaataa gaattaacga tccaacacag atgcacaaat tcttggaaga agaagaaaac 	 840
atattgaaag aaaaagtaga taagattgca gctactggtg ctaacgttgt aatatgccag 	 900
aaaggtatcg atgaagttgc acaacactat ttagctaaga aaggtatatt agctgttagg 	 960
agagccaaga agagtgattt agagaaatta gctagagcta ccggaggtag agtcatatca 	 1020
aatattgatg aattaacttc acaagatcta ggttatgccg cattagtgga agagagaaaa 	 1080
gtaggagagg ataagatggt attcgtagaa ggtgcaaaga atccaaaatc agttagtata 	 1140
ctaataagag gaggattaga gagagtagta gatgagactg aaagagctct tagggacgct 	 1200
ttaggtacag tggcagatgt aataagggat ggtagagcag tagctggtgg tggagctgtt 	 1260
gagatagaga tagctaagag attaagaaag tatgccccac aagttggtgg taaagagcaa 	 1320
ttagcaattg aagcatatgc taatgcaata gaaggactta tcatgatatt ggcggaaaac 	 1380
gcaggattag atcctataga caaattaatg caattaagaa gtcttcacga caatgagacc 	 1440
aataaatggt atggacttaa tttatttact ggaaatccag aggatatgtg gaaattaggt 	 1500
gttattgaac cggcactagt gaaaatgaat gcaattaagg ctgcaacaga agcagtaaca 	 1560
ttagtgttaa gaatagatga tattgtagca gctggaaaga agggtggaag tgagccaggc 	 1620
ggtaagaaag agaaagaaga aaagtcctct gaagac	 1656
<210> SEQ ID NO 87
<211> LENGTH: 28
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: metal binding peptide - Au
<400> SEQUENCE: 87
Pro Gly Met Lys Ala Ser Lys Ser Met Arg Asn Gin Ala Thr Pro Gly
1	 5	 10	 15
Met Pro Ser Ser Leu Asp Leu Thr Trp Gin Ala Thr
20	 25
<210> SEQ ID NO 88
<211> LENGTH: 28
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: metal binding peptide - Au
<400> SEQUENCE: 88
Pro Gly Met Lys Met Arg Leu Ser Gly Ala Lys Glu Ala Thr Pro Gly
1	 5	 10	 15
Met Ser Thr Thr Val Ala Gly Leu Leu Gin Ala Thr
20	 25
<210> SEQ ID NO 89
<211> LENGTH: 28
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:





Pro Gly Met Ile His Val Gin Lys Thr Ala Val Gin Ala Thr Pro Gly
1	 5	 10	 15
Met Val Asn Leu Thr Ser Pro Val Lys Gin Ala Thr
20	 25
<210> SEQ ID NO 90
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: metal binding peptide - Au
<400> SEQUENCE: 90
Ala Leu Asp Ser Pro Ala Gly Cys Leu Ser Phe Ser Met His
1	 5	 10
<210> SEQ ID NO 91
<211> LENGTH: 246
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: EYFP Yellow Fluroescent Protein
<400> SEQUENCE: 91
Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
1	 5	 10	 15
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20	 25	 30
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys
35	 40	 45
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
50	 55	 60
Gly Tyr Gly Leu Gin Cys Phe Ala Arg Tyr Pro Asp His Met Lys Gin
65	 70	 75	 80
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gin Glu Arg
85	 90	 95
Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100	 105	 110
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115	 120	 125
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
130	 135	 140
Gly Gly Thr Gly Ser Gly Gly Glu Leu Asn Ser His Asn Val Tyr Ile
145	 150	 155	 160
Met Ala Asp Lys Gin Lys Asn Gly Ile Lys Val Asn Phe Lys Ile Arg
165	 170	 175
His Asn Ile Glu Asp Gly Ser Val Gin Leu Ala Asp His Tyr Gin Gin
180	 185	 190
Asn Thr Pro Ile Gly Asp Gly Pro Val Leu Leu Pro Asp Asn His Tyr
195	 200	 205
Leu Ser Tyr Gin Ser Ala Leu Ser Lys Asp Pro Asn Glu Lys Arg Asp
210	 215	 220
His Met Val Leu Leu Glu Phe Val Thr Ala Ala Gly Ile Thr Leu Gly
225	 230	 235	 240





1. A circularly permuted chaperonin peptide molecule,
comprising a new carboxyl-terminal amino acid and a new
amino-terminal amino acid and a reordered chaperonin
polypeptide sequence, wherein the circularly permuted chap-
eronin polypeptide molecule comprises a chaperonin
polypeptide molecule which comprises a native carboxyl-
terminal amino acid and a native amino-terminal amino acid,
wherein the native terminal amino acids are joined directly
together or joined via an intervening linker polypeptide
sequence, and wherein the chaperonin polypeptide molecule,
so joined, is cleaved at a location that differs from the location
of the joined native terminal amino acids so as to generate a
new carboxyl terminal amino acid and a new amino terminal
amino acid and a reordered chaperonin polypeptide
sequence, and wherein the chaperonin polypeptide molecule
comprises a Sulfolobus shibatae thermophilic factor 55
(TF55) beta polypeptide according to any one of SEQ ID
NOS:69, 67, 71, 73, or 75.
2. The circularly permuted chaperonin polypeptide mol-
ecule of claim 1 comprising an intervening linker polypeptide
sequence whichjoins the native carboxyl terminal amino acid
with the native amino terminal amino acid.
3. The circularly permuted chaperonin polypeptide mol-
ecule of claim 2, wherein the intervening linker polypeptide
170
sequence comprises the amino acid sequence Gly-Gly-Ser-
Gly-Gly-Thr according to SEQ ID NO:64.
4. The circularly permuted chaperonin polypeptide mol-
ecule of claim 1, which is a fusion protein, wherein said new
5 carboxyl terminal amino acid or said new amino terminal
amino acid is joined with a second polypeptide.
5. The circularly permuted chaperonin polypeptide mol-
ecule of claim 4, wherein said second polypeptide is a gold-
binding peptide comprising the amino acid sequence SEQ ID
io NO: 31.
6. The circularly permuted chaperonin polypeptide mol-
ecule of claim 4, wherein said second polypeptide is a yellow
fluorescent protein (EYFP) according to SEQ ID NO: 91.
7. The circularly permuted chaperonin polypeptide mol-
15 ecule of claim 1, comprising a Sulfolobus shibatae TF55 beta
polypeptide according to SEQ ID NO: 67.
8. The circularly permuted chaperonin polypeptide mol-
ecule of claim 1, comprising a Sulfolobus shibatae TF55 beta
polypeptide according to SEQ ID NO: 71.
20 9. The circularly permuted chaperonin polypeptide mol-
ecule of claim 1, comprising a Sulfolobus shibatae TF55 beta
polypeptide according to SEQ ID NO: 73.
10. The circularly permuted chaperonin polypeptide mol-
ecule of claim 1, comprising a Sulfolobus shibatae TF55 beta
25 polypeptide according to SEQ ID NO:75.
